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In combating variable pathogens, mammalian immune systems have 
evolved diverse families of ligands and receptors. Epitomizing this strategy 
are the polymorphic major histocompatibility complex class I genes 
(termed HLA class I in humans) that encode ligands for highly variable 
natural killer (NK) cell receptors (in humans, the killer cell 
immunoglobulin-like receptors or KIR). Technological advances are poised 
to allow sequencing of these polymorphic genes, the most variable in the 
human genome, at the highest possible accuracy and resolution. However, 
studies that correlate immunogenetic polymorphisms with functional 
changes are in their infancy and often limited to those variants that 
combine high ligand avidity and high frequency in Caucasians. As a result, 
there is a paucity of information regarding the true scope of functional 
human immunogenetic diversity. This not only restricts our understanding 
of the evolution and function of the human immune system, but also 
underserves non-Caucasian populations with respect to disease association 
studies and therapeutic advances. The work presented in this thesis details 
original research and methodological advances that begin to address these 
functional shortfalls, the goal being to improve our understanding of the 
















The genes that control the response of the human immune system vary 
enormously between people. Understanding the evolution of these genetic 
differences and how they individualize immune responses is central to 
understanding how the immune system works in health and disease. This 
thesis specifically investigates the genes that control the function of natural-
killer cells. These cells act as the body’s first line of defense against viruses 
and other pathogens. They are also able detect cancerous cells and eliminate 
them before they take hold. Because natural-killer cells are so vital to 
maintaining human health, the genes that control them have evolved rapidly 
to match the unique set of pathogens that are present amongst different 
global populations. Thus, populations from around the world all have 
slightly different gene variants that control their natural-killer cells. We have 
studied the extent of this genetic diversity and how specifically it has shaped 
natural-killer cell function in these populations.  Our results have informed 
our understanding of the evolution of these genes, their function and how 
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Killer-cell immunoglobulin-like receptors regulate human NK cell function 
Natural killer (NK) cells are versatile lymphocytes that function in human 
immunity and reproduction [1, 2]. First described in 1975, NK cells were 
initially identified as a distinct sub-population of lymphocytes by their 
capacity to lyse tumor cells without prior sensitization [3-6]. As such, they 
are functionally distinct from the B and T-lymphocyte cells that derive 
from the same lymphoid progenitor lineage but function in the adaptive 
immune response. NK cells are now accepted to play an important role in 
innate and adaptive immune responses that govern infection, autoimmunity, 
tumor immune-surveillance and placental formation [7, 8].  
 
NK cells are cytotoxic cells that release perforin when in close proximity to 
a cell slated for killing. Perforin forms pores in the cell membrane of the 
target cell, creating a channel through which intracellular granzymes can 
enter, inducing apoptosis [9, 10]. NK cells are also responsible for 
production of immunoregulatory cytokines including interferon-γ, tumor 
necrosis factor, granulocyte macrophage colony stimulating factor and IL-
10 [11, 12]. Uterine NK cells form a distinct subset of lymphocytes that are 
potent cytokine secretors but have reduced cytotoxic function. These 
specialized cells form the dominant leucocyte in the uterus during early 
pregnancy and mediate the formation of the placenta through interaction 
with fetal trophoblast cells [13].  
 
NK cells are controlled by a wide array of activating and inhibitory cell-
surface receptors that distinguish healthy cells from diseased cells to allow 
targeted effector function. A common mechanism by which this occurs 
involves inhibitory NK cell receptors that engage MHC class I or MHC 
class I-like molecules [14]. By their level of expression and diverse 
repertoire of peptides, MHC class I molecules provide NK cell receptors 
with a sensitive read-out of cellular health.  
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Humans have two broad, complimentary types of germline-encoded 
inhibitory NK cell receptor that recognize human MHC (HLA) class I 
molecules. Recognition of HLA-E by CD94:NKG2A involves both a 
highly conserved ligand and a highly conserved receptor, and is thus a 
constant feature of human immune systems [15]. At the opposite end of the 
spectrum are the extraordinarily diverse interactions between polymorphic 
HLA-A, -B and –C molecules and the family of variable killer-cell 
immunoglobulin-like receptors (KIR). The interactions between KIR and 
HLA class I direct NK cells to kill virus-infected cells and tumor cells; they 
also induce the secretion of cytokines that activate other leucocytes or 
guide fetal trophoblast cells to invade the uterus during early pregnancy [2, 
16]. In human populations, both KIR and HLA class I are highly 
polymorphic. Their combinatorial diversity contributes to the resistance 
and susceptibility of individuals to a range of infections [17-19], 
autoimmune diseases [20-22] and pregnancy disorders [23, 24], as well as 
to the success or failure of hematopoietic stem cell transplantation [25, 26].  
 
NK cells require education to become functional 
Unlike CD8+ T-cells, which respond to foreign peptides bound to HLA 
class I, NK cells attack cells that lack HLA class I [27]. During their 
maturation in the bone marrow, NK cells undergo an education process that 
ensures they are tolerant to healthy peripheral tissues. Immature NK cells 
begin to express inhibitory KIR early in development; this initiates an 
education process whereby inhibitory KIR engagement of autologous HLA 
class I results in the generation of functional effector NK cells in the 
periphery. Failure to engage inhibitory receptors during development, due 
to lack of inhibitory receptor expression on the NK cell or lack of 
interaction with HLA class I results in the generation of a subset of 
hyporesponsive peripheral NK cells [28-30]. In this manner, interactions 
between inhibitory KIR and HLA class I are critical to NK cell reactivity.  
 
NK cell education is also influenced by signals received through activating 
receptors. In a process analogous to negative selection of developing T-
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cells, ligation of activating receptors on developing NK cells by 
ubiquitously expressed cognate viral or self-ligands leads to both a 
repression of cellular function through that particular receptor and a partial 
deletion of the subset repertoire [31-33]. Together these mechanisms 
ensure that mature NK cells do not attack healthy self-tissues.  
 
HLA-C is the dominant ligand for KIR 
KIRs recognize four mutually exclusive epitopes of HLA-A, -B and -C. 
These are defined by polymorphisms at positions 76-83 in the helix of the 
α1 domain [2]. The A3/11 epitope is carried by HLA-A*03 and A*11 and 
the Bw4 epitope by around 33% of HLA-A and HLA-B allotypes. The C1 
epitope is carried by HLA-C allotypes having asparagine 80 and by two 
exceptional HLA-B allotypes (HLA-B*46:01 and HLA-B*73:01). The C2 
epitope is carried by HLA-C allotypes having lysine 80. Data from 
functional immunology, clinical correlations and species comparisons are 
consistent with a model in which HLA-C evolved under natural selection to 
be a more specialized ligand for KIR than either HLA-A or HLA-B [16, 
34]. Thus, the interactions of C1 and C2 with their cognate KIR dominate 
human NK-cell regulation. For this reason, KIRs that recognize HLA-C are 
the focus of the work in this thesis. 
 
Approximately half of the >1900 known HLA-C allotypes have asparagine 
at position 80 that defines the C1 epitope [35]. Recognition of HLA-C1 is 
mediated by the inhibitory receptors KIR2DL2 and KIR2DL3, both of 
which have lysine at position 44 in the D1 protein domain [36]. Genomic 
characterization and population studies of the KIR gene family are 
consistent with the genes encoding KIR2DL2 and KIR2DL3 segregating as 
alleles of a single genetic locus, which is referred to as KIR2DL2/3 [37]. 
The inhibitory receptor that recognizes the HLA-C2 epitope is KIR2DL1, 
although KIR2DL2 does display some cross-reactivity with HLA-C2 also. 
In addition to the inhibitory receptors, both KIR2DL1 and KIR2DL2/3 
have short-tailed, activating counterparts, KIR2DS1 and KIR2DS2 
respectively, whose extracellular Ig-like domains are highly homologous to 
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those of their inhibitory partners. Like its homologous inhibitory partner, 
KIR2DS1 recognizes the HLA-C2 epitope [38]. By contrast, KIR2DS2, 
does not have a well-characterized HLA class I ligand, although a recent 
study has raised the possibility that it binds to A*11:02 with a restricted 
peptide repertoire [39]. 
 
Humans have four phylogenetic lineages of KIR that have different 
structures and specificities for HLA class I. Human lineage II KIR 
recognize the Bw4 and A3/11 epitopes carried by HLA-A and HLA-B. In 
contrast, all KIR that recognize HLA-C, and it orthologs in other hominoid 
species, belong to the lineage III KIR. Old world monkeys have 
counterparts to HLA-A and –B, but not to HLA-C [40]. Consistent with 
this distribution, Old world monkeys have diverse lineage II KIR genes, but 
limited lineage III KIR diversity [41-43]. Only hominoid species with a 
counterpart to HLA-C – chimpanzee, bonobo, gorilla and orangutan – have 
diverse lineage III KIR evolved to recognize HLA-C [44, 45].  
 
Lineage III KIRs are characterized by having two extracellular binding 
domains, D1 and D2. Crystal structures of the KIR alone, or in 
combination with their cognate HLA class I ligands, provide great insight 
into the molecular mechanisms that govern KIR interactions with HLA 
class I and determine the C1 and C2 specificities [46, 47].  Lysine at 
position 44 of KIR2DL2 forms a hydrogen bond with the C1-determining 
asparagine-80 of HLA-C*03 whereas methionine 44 of KIR2DL1 forms 
part of a charge pocket that accommodates the lysine-80 of HLA-C*04. 
 
KIR are diversified by gene content and allelic polymorphism 
KIRs are encoded by a compact cluster of genes that forms part of the 
leukocyte receptor complex (LRC) on chromosome 19q13.4 [48, 49]. An 
important component of KIR variation is that the KIR haplotypes vary in 
gene content [49, 50]. Conserved genes are present at the centromeric 
(KIR3DL3) and telomeric (KIR3DL2) ends of the haplotype, as well as in 
the central part (KIR3DP1 and KIR2DL4) of the locus [51]. These 
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framework genes define two regions of gene-content variation, one in the 
centromeric part of the locus, the other in the telomeric part. Found in both 
parts of the locus are two types of alternative gene-content motifs that are 
qualitatively different called Cen-A, Cen-B, Tel-A and Tel-B. The 
combination of the Cen-A and Tel-A form the group A KIR haplotype, a 
relatively short haplotype with a predominance of inhibitory receptors that 
recognize HLA class I. The three other combinations Cen-B with Tel-B, 
Cen-B with Tel-A and Cen-A with Tel-B are collectively called the group B 
KIR haplotypes. Characterizing the Cen-B and Tel-B motifs are activating 
KIR and KIR that have reduced or lost recognition of HLA class I. Gene 
content variation of KIR haplotypes has evolved through asymmetric 
recombination, which is facilitated by the short intergenic regions with high 
sequence similarity. Complementing this mechanism is homologous 
recombination at the center of the locus, which assorts the difference Cen 
and Tel motifs [49, 51].  
 
KIR are further diversified by allelic variation, which is a common feature 
of all HLA-C reactive KIR. A systematic evaluation of the functional 
consequences of this allelic variation is lacking. However, two broad 
allotypic groups of KIR2DL1 have been identified on the basis of a 
dimorphism at position 245 in the transmembrane domain. KIR2DL1 
encoding C245 form weaker receptors than those that encode R245 [52]. In 
an analogous fashion, two broad and functionally distinct allotypic groups 
have been identified for KIR2DL2/3. KIR2DL3 encodes weak C1-specific 
receptors whereas KIR2DL2 encodes a stronger C1 receptor that also 









Objectives of the studies described in the publications 
The work presented in this thesis builds upon the observations presented in 
the introduction with the overall goal being to better describe the genetics 
and functional interactions between the polymorphic lineage III KIR and 
their HLA-C ligands. The specific aims can be summarized as follows:  
 
1. Identify and characterize key functional residues in lineage III KIR 
2. Determine the true genetic diversity of naturally occurring lineage 
III KIR 
3. Determine the functional range of lineage III KIR and HLA-C 
interactions 
4. Refine the Luminex multiplex platform for the investigation of 
KIR-Fc fusion proteins and monoclonal antibodies for MHC class I 
 
Chapter 1 describes an investigation of amino acid residues that have been 
subject to positive selection during hominoid evolution [53]. Central to our 
mission of correlating genetic variation with functional immune variation, 
this approach not only yielded specific information regarding the nature of 
the interactions between lineage III KIR and HLA-C, but also provided an 
evolutionary context for the development of a bipartite receptor-ligand 
system and how that might be beneficial for the control of human NK cells.  
 
Expanding on this study, Chapter 2 examines how natural polymorphism of 
lineage III KIR and HLA-C influences the avidity and specificity of their 
interactions. My study of the KhoeSan, a genetically diverse hunter-
gatherer population from Southern Africa discovered two new KIR2DL1 
alleles that encode receptors with highly divergent function. Examination 
of the function of these novel receptors and those found in 5 other global 
populations with different demographic histories and genetic backgrounds 
shed light on the selective pressures that have shaped the evolution of the 
human immune system [54]. This topic is explored in greater detail in 
Chapter 3 that focuses on the functional variation between the KIR A and B 
haplotypes [55] .  
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One methodological advance that forms the backbone of each of these three 
studies was our development of a multiplex binding assay in which a 
specific KIR can be tested for reactivity against a panel of around 100 HLA 
class I allotypes. It is examination of this methodological advance and its 
further adaptation for investigation of monoclonal antibody reactivity that 
is the subject of Chapters 4 and 5. The specific KIR of interest is first 
solubilized by replacing its cytoplasmic tail with that of a human IgG1 
antibody (Fc). The resultant KIR-Fc, produced in recombinant form in 
insect cells, can then be incubated with microbeads, each coated with a 
specific HLA class I allotype to determine its reactivity. This method was 
developed in the Parham lab and I have refined the production of these 
proteins and the multiplex immunoassay to allow reliable recombinant 
protein production and reduce inter-assay variability [56]. I have also 
adapted this platform to investigate the reactivity of monoclonal antibodies 
that recognize polymorphic epitopes of HLA class I [57]. This work refined 
the epitopes of these antibodies thereby allowing more accurate 
interpretation of flow-cytometry results. This platform was adapted to 
investigate the reactivity of antibodies directed against Patr-AL, a non-
















Functional significance of positively selected residues in 
lineage III KIR ligand-binding domains 
 
Interaction of KIR with HLA-C is sensitive to single amino acid 
substitutions in the KIR that can change its epitope specificity [36] or 
abrogate recognition entirely [36, 59, 60]. In the context of KIR2DL1 and 
KIR2DL3, mutagenesis at position 44 was sufficient to “swap” the C1 and 
C2 specificities. Thus, the KIR2DL1 mutant with lysine-44 acquired C1 
specificity, whilst the KIR2DL3 mutant with methionine acquired C2 
specificity [36]. On this basis, position 44 has been described as the 
specificity-determining position of the lineage III KIR [61].  
 
Comparing the binding of inhibitory KIR2DL1 to its closely related 
activating counterpart KIR2DS1 revealed a second residue in lineage III 
KIR that modified ligand recognition. Although both receptors recognize 
the HLA-C2 epitope, the avidity of KIR2DS1 for C2 was lower than that of 
KIR2DL1 [59, 62]. Mutational analysis showed that lysine at position 70, 
naturally present in KIR2DS1, reduced affinity for HLA-C*04 to 
approximately half that of KIR2DL1 which encodes threonine at position 
70. Consistent with their effect on receptor-ligand interaction, examination 
of the crystallographic structures of KIR2DL1 and KIR2DL3 showed that 
both position 44 and position 70 are found in the HLA class I binding 
footprint [46, 47].  
 
To identify additional functionally important residues in the KIR molecule 
Abi-Rached et al [44] performed maximum-likelihood analysis on the 
aligned sequences of 110 lineage III KIR from humans and apes (including 
hominoid species chimpanzee, gorilla, orangutan and gibbon). This 
analysis, which uses the ratio of the number of non-synonymous 
substitutions per non-synonymous site to the number of synonymous 
substitutions per synonymous site as an indicator of selective pressure 
acting on a protein-coding gene, identified 16 sites in the extracellular, 
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ligand-binding domains and 3 sites in the signaling domains that had been 
subject to positive selection.  
 
Ten of these positions (6, 13, 16, 44, 50, 68, 70, 71, 84 and 90) mapped to 
the D1 protein domain with the remaining 6 residues found in the D2 
protein domain (119, 123, 131, 148, 182 and 190). Consistent with their 
previously documented effect on HLA-C recognition both positions 44 and 
70 were amongst those identified as having been subject to positive 
selection. Just six of these residues (44, 68, 70 and 71 in the D1 domain 
and 131 and 182 in the D2 domain) are found in the HLA class I binding 
footprint (Figure 1). For these six positions, sequence variability is notably 
higher in the D1 domain than in the D2 domain, both in the number of 
positively selected positions and the number of alternative residues at each 
position. Nonetheless, there is a variety of residues with distinctive 
chemistry and functional potential at all six positions. Lysine 44, proline 68, 
arginine 131 and arginine 182 are the only residues present in all five 
hominoid species examined, consistent with them having been present in a 
common hominoid ancestor. Greater variability and species specificity are 
observed for positions 70 and 71. Position 70 stands out for its 
diversification in humans but relative conservation in other species, 
whereas position 71 is more variable in chimpanzees and gorillas than in 
humans. These suggested that variation at these six positions had been 
selected for their direct effect on the functional interactions of hominoid 
lineage III KIR with MHC class I. To test this hypothesis, we introduced 
all naturally occurring variations at the six positions into human C2 
specific KIR2DL1 and C1-specific KIR2DL3 and then determined the 
effects of these mutations on KIR specificity and avidity for HLA-C [53]. 
The results of these experiments have informed not only our understanding 
of the detailed molecular architecture of the KIR-HLA-C interface, but 
have also informed our understanding of the evolution and function of the 





Figure 1: Six positively selected residues in the binding site of hominoid lineage III KIR 
(A) Alignment of partial amino acid sequences of hominoid lineage III KIR showing the 
loops of the D1 and D2 domains that contact HLA-C. Sequences were aligned to 2DL1*003, 
identities being indicated by dashes (–). The six positively selected residues in the binding 
site for HLA class I are colored yellow, as is also the case for panels B and C. (B) Ribbon 
diagram of KIR2DL1 (grey) bound to HLA-C*04:01 (green) (PDB1IM9) (56). The loops of 
the KIR molecule are colored blue and positively selected residues are colored yellow. (C) 
Details of the binding between the D1 domain contact loop of KIR2DL1*003 (in blue with 
positively selected residues in yellow) and the α1 domain helix of HLA-C*04:01 (green).	
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Summary of results 
Evolution of a switch and a rheostat: position 44 controls KIR specificity 
and position 70 controls avidity for HLA class I 
Consistent with previous studies, swapping the position 44 residues of 
KIR2DL1 and KIR2DL3 was sufficient to swap their HLA class I 
specificities. Thus, the 2DL3-44M mutant has C2 specificity like KIR2DL1 
and the 2DL1-44K mutant has C1 specificity like KIR2DL3. On average, 
the binding of KIR2DL1 to C2 was approximately twice that of KIR2DL3 
to C1, indicating that KIR2DL1 is a stronger receptor than KIR2DL3. That 
mutant 2DL1-44K bound to C1 at a much higher level (180%) than 
KIR2DL3 confirms that 2DL1 is an inherently stronger receptor, as well as 
demonstrating that substitutions other than the lysine-methionine 
dimorphism at position 44 contribute to the avidity difference. [Note: in the 
context of describing the differences in binding between naturally occurring 
and mutant KIR-Fc I have used the term “avidity”. Although the differences 
in binding are likely to depend in large part on the specific avidity of 
binding between the two protein moieties, there are likely to be other factors 
that contribute to the binding differences.  Thus, this term represents a short-
hand. I have also used this term to correspond to the language used in the 
published papers that describe this work and that are included in this thesis.] 
However, the observation that mutant 2DL3-44M binds C2 almost as well 
(85%) as KIR2DL1 shows clearly that methionine 44 must also contribute to 
KIR2DL1 having higher avidity than KIR2DL3.  
 
Threonine 44 is naturally present in KIR2DS3 and KIR2DS5, activating 
receptors exhibiting no detectable avidity for any HLA class I allotype when 
tested in the same binding assay as that used in this study [62]. In contrast, 
KIR2DL1 and KIR2DL3 mutants with 44T recognize some HLA-C 
allotypes. KIR2DL3-44T abrogated binding to C1, with the exception of 
C*16:01, which retained ~50% of binding. Accompanying the loss of C1 
reactivity was acquisition of C2 specificity, but with much lower avidity 
than 2DL1 or 2DL3-44M. The 2DL1-44T mutant retained the C2 specificity 
of 2DL1 but with avidity reduced by ~50% (binding avidity comparable to 
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2DL3 for C1 and therefore well within the functional range). Thus human 
lineage III KIR with threonine 44 have the potential to be C2-specific 
receptors, suggesting that KIR2DS3 and KIR2DS5, for which ligands have 
yet to be determined, likely evolved from C2 receptors that lost the capacity 
to bind HLA class I through selected substitutions at positions other than 
position 44. That threonine 44 is present only in human lineage III KIR 
suggests that these receptors both arose and became attenuated during the 
course of human evolution. Interestingly, since the publication of the paper 
on which this chapter is based, both epidemiological [24] and direct 
experimental evidence (Blokhuis et al unpublished) point to a subset of 
KIR2DS5 alleles (commonly found in African populations) that encode 
weak HLA-C2 specific receptors.  
 
Although orangutan, gorilla and chimpanzee have KIR with glutamate 44, 
such KIR were lost during human evolution. Mutant 2DL1-44E retained the 
C2 specificity of KIR2DL1 but with 36% loss of avidity, properties similar 
to those of chimpanzee KIR2DL9 that has glutamate 44 [63]. By contrast, 
2DL3-44E acquired reactivity with C2, while retaining 87% of the avidity 
for C1. Consequently, 2DL3-44E binds with comparable avidity to C1 and 
C2, thus having pan specificity for HLA-C. This C1+C2 specificity of 
2DL3-44E is very similar to that of Popy-2DLB and Popy-2DSB, paired 
inhibitory and activating orangutan KIR that have glutamate 44 [34].  
 
Substitutions at position 70 had no effect on either the C2 specificity of 
KIR2DL1 or the C1 specificity of KIR2DL3, but did have a profound effect 
on the avidity of the interactions. Substitution of threonine 70 in KIR2DL1 
to lysine, methionine or arginine reduced the avidity by 43-66%, with the 
greatest effect seen with methionine, the residue present at position 70 in 
KIR2DL3. In contrast, substitution of methionine 70 in KIR2DL3 with 
arginine or threonine (the residue present in KIR2DL1) gave a modest 
increase (16-38%) in the avidity for C1, whereas the lysine substitution 
reduced the avidity by 48%. The results obtained for the position 70 swap 
mutants indicate that the threonine-methionine difference at position 70 is a 
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major factor contributing to the higher avidity of KIR2DL1 and lower 
avidity of KIR2DL3.  
 
Thus, like a switch, mutation at position 44 can turn on or turn off reactivity 
of KIR2DL1 and KIR2DL3 for C1 or C2. By contrast, like a rheostat, 
position 70 controls the subsequent avidity of binding between receptor and 
ligand. 
 
Mutation at position 71 and 131 introduce binding to HLA-A*11:02 in 
KIR2DL3 but not KIR2DL1 
The introduction of proline at position 71 in 2DL3 broadened the specificity 
of mutant 2DL3-71P to include HLA-A*11:02. KIR2DS4 is an activating 
lineage III KIR that naturally has proline 71 and exhibits similar reactivity 
[64]. However, proline 71 is not necessary for recognition of HLA-A*11:02, 
as became apparent from analysis of the position 131 mutants. Substitution 
of arginine 131 in KIR2DL3 with glutamine introduced reactivity with 
HLA-A*11:02 while preserving avidity for C1-bearing HLA-C. In contrast, 
substitution of arginine 131 for tryptophan caused 86% loss of avidity for 
C1 but no binding to HLA-A*11:02. For KIR2DL1, replacement of arginine 
131 by glutamine preserved the avidity and specificity for C2 with no 
acquisition of reactivity for HLA-A*11:02, whereas replacement with 
tryptophan preserved a pure C2 specificity but reduced avidity by 40%.  
 
Of the four HLA class I epitopes (A3/11, Bw4, C1 and C2) recognized by 
KIR, the functional significance of A3/11 remains uncertain. Carried by 
HLA-A*03 and HLA-A*11 allotypes, the A3/11 epitope was first shown to 
engage the lineage II KIR KIR3DL2 [65, 66]. Although Bw4, C1 and C2 
mediate robust inhibition and education of NK cells on binding their cognate 
KIR, the interaction of the A3/11 epitope with KIR3DL2 provides weak 
inhibition [67], and no detectable education [68]. Previous studies of lineage 
III KIR2DS4 [64] and orangutan lineage III KIR [34], demonstrated their 
recognition of HLA-A allotypes carrying the A3/11 epitope, with the 
strength of binding A*11:02>A*11:01>A*0301. This same hierarchy is seen 
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again for mutant 2DL3-71P, which binds significantly to A*11:02 but not to 
A*11:01 or A*03:01. With this background and context, we tested whether 
the recognition of HLA-A*11:02 by 2DL3-71P could influence NK cell 
function. 
 
In cytotoxic assays G4-NKL (that lack the potentially confounding 
inhibitory receptor LILRB1) cells expressing KIR2DL3 killed 221-A*11:02 
cells showing that A*11:02 is not a ligand for wild-type KIR2DL3. In 
contrast, killing of 221-A*11:02 was strongly inhibited when G4-NKL cells 
expressed the 2DL3-71P mutant, showing that binding of A*11:02 to 2DL3-
71P is a functional ligand–receptor interaction that leads to the transduction 
of an inhibitory signal.  
 
Major conclusions 
Overall, mutation had a wider range of effects on KIR2DL3 than on 
KIR2DL1. The C1 specificity of KIR2DL3 was changed in two ways: a 
major broadening to give a pan HLA-C receptor with C1 plus specificity 
and a minor broadening to give reactivity with HLA-A*11:02, as well as C1. 
The avidity of KIR2DL3 was also changed in two ways: 2 of the mutations 
increased avidity for C1 by 10%, 13 decreased the avidity by >10%, and 3 
had little effect. In comparison, the ligand binding properties of KIR2DL1 
were more resistant to mutation: none of the 18 mutations altered the C2 
specificity, and none of them increased the avidity for C2. Ten mutations in 
KIR2DL1 reduced C2 avidity by >10% and eight had little effect. 
Consideration of all the mutants, with the exception of those at position 44, 
shows that all KIR2DL1 mutants retained a minimum of 32% of the wild-
type binding, whereas the binding of KIR2DL3 mutants ranged from 0-
138% of wild-type binding. Exemplifying the variety of effects that 
mutation had on KIR2DL3 and their limited effect on KIR2DL1 are the 
avidities and specificities of the mutants containing glutamate 44, proline 71 
and glutamate 131. Thus KIR2DL3 is seen as the weaker and less selective 
receptor, which, by being less refined, retains greater potential for change. 
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By contrast, having acquired specificity for C2, KIR2DL1 is now more 
specialized and comparatively inflexible. 
 
These contrasting and complimentary properties fit well with an 
evolutionary model in which the C1 epitope and their cognate C1-specific 
KIR evolved first and subsequently underwent mutation and selection to 
give rise to the C2 epitope and C2-speififc KIR [34]. The crucial feature of 
this model is the flexibility of the C1 receptor and its cross-reactivity with 
C2, which, while maintaining function as a C1 receptor, provides a potential 
C2 receptor prior to formation of the C2 epitope. Thus, the inherent 
flexibility of the C1 receptor allows C2 and C2-specific KIR to evolve by 
stepwise point mutation through a series of intermediate forms that all have 
biological function and could be maintained by natural selection. 
 
Critical appraisal of results and conclusions 
This study investigated the effect of mutation on six amino acids found in 
the HLA class I binding site of lineage III KIR. These residues were 
hypothesized to have been subject to positive selection because they 
influence KIR-HLA interactions and therefore influence the downstream 
function of NK cells. My experimental approach used single amino acid 
mutations to investigate the specific functions of these residues, identifying 
changes that informed both the function and evolution of the C2 receptor 
KIR2DL1 and the C1 receptor KIR2DL3.  
 
One major drawback of determining the effect of single amino acid 
substitutions is that the effect of these mutations is seen in isolation. 
Although clearly informative and a practical experimental approach to cover 
as many positions as possible, this approach will not reveal any synergy 
between positions. Synergy describes the process by which mutation at two 
residues has an effect greater than single mutations at either position.  
 
There is clear precedent for this mechanism having occurred in KIR 
evolution. Positions 16 in the D1 domain and 148 in the D2 domain are 
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found in the hinge region of the KIR molecule. These residues, both of 
which have been subject to positive selection, account for the differences in 
specificity and avidity between KIR2DL2 and its allelic counterpart 
KIR2DL3 [69]. KIR2DL3 is a C1 specific receptor that displays relatively 
minimal binding to C2 targets whereas KIR2DL2 has higher avidity for C1 
and significant cross-reactivity with C2. Single mutations at either position 
16 or position 148 do not result in receptors with these properties, but 
mutating both residues is sufficient to change the binding properties 
consistent with there being synergy between these two positions. The 
changes in specificity were hypothesized to occur as a result of a shift in the 
relative orientation of the D1 and D2 domains. Another study subsequently 
showed that this synergy in the hinge region was not restricted to positions 
16 and 148, but may be a more widespread feature of residues in the hinge 
region of the molecule [70]. A more detailed analysis of the effect of 
mutation at positions 16 and 148 is presented in chapter 3. 
 
Traditionally, the specificity of primate KIR has been difficult to determine 
because of a comparative lack of cellular reagents. In this study, several 
non-human primate-specific amino acid residues were introduced into either 
KIR2DL1 or KIR2DL3. The results of these assays were interpreted in the 
context of the evolution of hominoid KIR. Indeed, the KIR-Fc HLA bead-
binding assay has been used in previous studies to explore the binding 
characteristics of KIR in several simian primates. In Old World Monkeys, 
the lineage III KIR are represented by a single gene [71] while lineage II 
KIR genes have expanded and diversified. To identify their MHC epitope-
specificity and avidity, a panel of rhesus macaque lineage II KIR-Fc was 
assayed [45]. Although MHC-C is not present in macaques, their KIR 
recognize HLA-C epitopes more effectively than they recognize HLA-A and 
HLA-B, suggesting that MHC-C evolved to become a stronger ligand for 
KIR than HLA-A and –B. The emergence of MHC-C in the orangutan was 
accompanied by an expansion of lineage III KIR and their evolution as 
MHC-C receptors [45]. All orangutan MHC-C allotypes have asparagine 80 
and display the C1 epitope. Correspondingly, the results from the KIR-Fc 
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HLA bead-binding assay showed that orangutan has C1-specific KIR but 
not C2-specific KIR [34]. In chimpanzees the MHC-C gene became fixed 
and the C2 epitope emerged. As a consequence, out of nine chimpanzee 
lineage III KIR genes [44], eight encode receptors with high avidity for 
HLA-C, comprising three C1-specific receptors and 5 C2-specific receptors 
[63]. Together, the results of the assays, from these studies, and those from 
my study, provide a compelling timeline for the evolution of hominoid KIR. 
However, one major confounding factor is that the results of these assays 
were interpreted without knowing how these human KIR mutants or 
naturally occurring non-human primate KIR-Fc react with their cognate 
MHC class I. The results of these assays correlate well with cytotoxicity 
assays using human NKL and 221 cells expressing HLA class I, but some 
simple experiments, for example transfecting a 221 cell with orangutan 






















Investigation of functional polymorphism in naturally occurring 
lineage III KIR 
 
Chapter 1 details the results of my work that investigated the effect of 
mutation on six positively selected residues in human lineage III KIR. The 
results of that study not only shed light on the function of those six residues, 
but also provided insight into the broader characteristics of KIR2DL1 and 
KIR2DL3. KIR2DL1 was found to be a strong C2 receptor that was 
relatively resistant to changes in specificity whilst KIR2DL3 was found to 
be a weaker C1 specific receptor that was significantly more malleable in 
terms of both specificity and avidity for HLA class I. Varying only those 
residues that had been subject to positive diversifying selection, distilled the 
functional elements of those receptors. However, given that both KIR2DL1 
and KIR2DL3 are highly polymorphic, with 26 and 38 allotypic variants 
having been described (at the outset of this second study) I wanted to 
investigate the functional consequences of this diversity and to try and 
identify some of the selective pressures that have driven this diversity in 
specific human populations. It is the results of these experiments, which 
focus on a genetically diverse southern African hunter-gatherer population, 
that are the subject of this chapter. 
 
For reasons of practicality, the functional properties of KIR2DL1 and 
KIR2DL2/3 have been studied mainly in the context of allotypic variants 
that combine high avidity, high specificity and high frequency in Europeans 
[2]. In contrast, for sub-Saharan African populations, which have the highest 
genetic diversity [72, 73] and among the highest mortality from infectious 
disease and pregnancy complications [74], KIR investigation is in its infancy 
and has so far focused on West African and Bantu-speaking populations 
[75]. Within sub-Saharan Africa, some indigenous populations are as 
different from each other as they are from Europeans [72, 73]. Notably, the 
KhoeSan who reside across Southern Africa descend from the deepest 
human population divergence and have among the greatest genetic diversity 
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of any population [76, 77]. During the last 2,000 years there has been 
admixture between the KhoeSan and Bantu-speaking agriculturalists who 
expanded southwards. More recently, the arrival of European colonists over 
the past 500 years has introduced novel infectious diseases including 
smallpox and tuberculosis. In this study I undertook high-resolution genetic 
and functional studies on the HLA-C specific KIR of the KhoeSan and four 
other global populations that represent the range of human immunogenetic 
diversity.  
 
Summary of results and key findings 
Two novel KIR2DL1 alleles are unique to the KhoeSan 
From analysis of 61 KhoeSan ten KIR2DL1 alleles were identified. Of these, 
two alleles, subsequently given the designations 
2DL1*022 and 2DL1*026, were new discoveries that have frequencies in 
the KhoeSan of 17.2% and 4.2%, respectively. Being absent from all 
previously studied populations suggested that 2DL1*022 and 2DL1*026 are 
specific to the KhoeSan. To test this hypothesis we examined additional 
populations for the presence of these alleles. We first examined data from 
the 1000 Genomes project dataset by probing for sequence-specific reads 
that correspond to the KIR2DL1*022 and 2DL1*026 alleles. KIR3DL3, a 
framework gene present on all KIR haplotypes, served as the positive 
control. All 2,496 individuals sampled had reads corresponding to KIR3DL3 
but none of the 2496 individuals in the current release of the 1000 Genome 
dataset, representing 26 different populations worldwide, was found to have 
either 2DL1*022 or 2DL1*026. Because the 1000 Genome dataset 
represents a limited subset of sub-Saharan African population diversity, we 
expanded our search to include four further groups including three hunter-
gatherer populations (the Tanzanian Hadza, Mbuti and Baka Pygmies) and 
the South African Zulu. Neither allele was found in the hunter-gatherer 
populations, but we did detect both KIR2DL1*022 and KIR2DL1*026 
present at 1.5% and 1% respectively in the Zulu population. Haplotype 
analysis and admixture mapping were consistent with these alleles having 
been recently transferred from the KhoeSan into the Zulu. Together, these 
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data support an evolutionary model in which 2DL1*022 and 2DL1*026 
increased in frequency in the KhoeSan people after their divergence from 
other populations.  
 
Neither KIR2DL1*022 nor KIR2DL1*026 can mediate NK cell responses 
via HLA-C2  
KIR2DL1*022 differs from 2DL1*001, also present in the KhoeSan, by a 
single non-synonymous substitution in codon 44. Thus 2DL1*022 likely 
evolved from 2DL1*001 by a point mutation that caused methionine to be 
replaced by lysine at position 44. Position 44 dimorphism determines 
whether a given KIR2DL has specificity for the C1 or C2 epitope of HLA-C 
[36]. Prior to investigation of the KhoeSan, all the known KIR2DL1 
allotypes (n=23) had methionine 44 and were predicted to be C2-specific. 
Conversely, and in complementary fashion, the known KIR2DL2/3 
allotypes (n=36) all had lysine 44 and were predicted to be C1 specific. 
Using the same assay described in chapter 1 and critically reviewed in 
chapter 4 of this thesis, we showed that KIR2DL1*022 binds to all nine C1-
bearing HLA-C allotypes but to none of the seven C2-bearing HLA-C 
allotypes in the test panel. Indeed, 2DL1*022 has higher avidity for C1 than 
any of the KIR2DL2/3 allotypes we tested, but no significant C2 cross 
reactivity. 
 
KIR2DL1*026, the other KhoeSan-specific KIR2DL1 allele, differs from 
2DL1*012, also present in the KhoeSan, by one nucleotide substitution. 
Thus KIR2DL1*026 likely arose from 2DL1*012 by point mutation. This 
substitution converted the tryptophan codon at position 246 to a termination 
codon. Position 246 is situated at the boundary between the transmembrane 
domain and the cytoplasmic tail. Consequently, 2DL1*026 lacks the 
immunoreceptor tyrosine-based inhibitory motifs (ITIMs) of the 
cytoplasmic tail that mediate inhibitory signaling function [78]. Less 
obvious is the effect that absence of a cytoplasmic tail could have on the 
association of 2DL1*026 with cellular membranes. Thus, the mutation that 
created 2DL1*026 clearly has a major effect in abrogating inhibitory 
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signaling function, but it also has potential to alter the amount of receptor 
that reaches the NK cell-surface.  
 
Polymorphism produces KIR with a range of avidity and specificity for 
HLA-C 
As predicted, 2DL1*022 functions as a C1-specific receptor and not a C2-
specific receptor like eleven of the 13 other KIR2DL1-Fc. These eleven 
KIR2DL1-Fc varied in their avidity for C2 by half an order of magnitude. In 
contrast, 2DL1*013N-Fc and 2DL1*014-Fc bound to no HLA class I 
allotype. For 2DL1*013N this result was anticipated, because the protein is 
a fragment that terminates prematurely at residue 34 in the D1 domain. On 
the other hand, 2DL1*014 was expected to bind HLA class I, because it 
differs from 2DL1*003 only by substitution of glycine for serine at position 
179 in the D2 domain. KIR2DL2/3 exhibit a range of avidity for C1, but 
with increasing avidity for C1 there is also rising cross-reactivity with C2. 
This is not the case for 2DL1*022, which has a higher avidity for C1 than 
any of the KIR2DL2/3 allotypes, but no significant C2 cross reactivity. 
Overall, these results vividly illustrate how the natural polymorphism of 
KIR2DL1 and KIR2DL2/3 modulates the avidity, specificity and 
functionality of these NK cell receptors in human populations.  
 
The KhoeSan have a high frequency of weak C2 receptors 
Unlike some populations, there is no single KIR2DL1 allele that is present at 
high frequency in the KhoeSan. The ten KhoeSan KIR2DL1 alleles vary in 
frequency from 1.1-21.3%. In addition, 18% of KhoeSan KIR haplotypes 
lack the KIR2DL1 gene, constituting an eleventh allele: the ‘blank’. In 
addition to KIR2DL1*022 and 2DL1*026 that have lost the ability to 
mediate an inhibitory signal via engagement with C2 the KhoeSan have a 
high frequency of weak inhibitory C2 receptors. Amongst these are the 
‘blank’ and 2DL1*004 and 2DL1*011 receptors that have low avidity for 
C2 as well as reduced signaling capacity [52]. In sum, the frequency of 
weak or inactive KIR2DL1 allotypes in the KhoeSan is 71.8% whereas the 
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28.2% frequency of strong KIR2DL1 allotypes in the KhoeSan and much 
lower than that of other populations (Figure 2).  
 
 
Figure 2: The KhoeSan have high KIR2DL1 diversity compared to other human populations 
(A and B) The pie charts show the number and relative frequencies of KIR2DL1 alleles in the 
KhoeSan of Southern Africa (A), and four other populations representing four continents (B): 
the Ga-Adangbe from Ghana in Western Africa [14], Northern Ireland Caucasians from 
Europe [21], Japanese from East Asia [24] and Yucpa Amerindians from South America [20]. 
The 'blank' is the frequency of KIR haplotypes that lack theKIR2DL1 gene. (C) Also 
compared in the five populations are the frequencies of strong KIR2DL1, weak KIR2DL1, 
KIR2DL1 that are not inhibitory C2 receptors (inactive) and the absence of KIR2DL1 
(blank).  
 
Polymorphism produces KIR with a range of cell-surface expression 
KIR2DL1*026 and KIR2DL1*012 encode identical extracellular domains 
that bind C2 with high avidity and specificity. To determine if 2DL1*026, 
which lacks a cytoplasmic tail, reaches the cell-surface, we examined the 
expression of FLAG-tagged 2DL1*026 and 2DL1*012 in transiently 
transfected HeLa cells. For comparison, eight other KIR2DL1 allotypes 
were included in the analysis. KIR2DL1*026 is cell-surface expressed at a 
significantly lower level than 2DL1*012 (p=0.0087), but within the range 
observed for other KIR2DL1 allotypes. Although KIR2DL1*026 cannot 
mediate NK cell inhibition directly, because it lacks a cytoplasmic domain, 
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it could have indirect effects, either by preventing C2 from binding to other 
receptors or by contributing to the adhesive interactions of NK cells with 
target cells. That 2DL1*014 is not cell-surface expressed and cannot bind 
HLA class I suggests that its defining residue, serine 179, prevents proper 
protein folding. Other KIR allotypes with impaired folding that causes 
intracellular retention have been described [79-82]. 
 
Major conclusions 
This study showed how KIR2DL1 polymorphism has given rise to NK cell 
receptors that vary substantially in their capacity to recognize HLA-C and 
propagate intracellular signals. Emphasizing the value of defining structural 
and functional KIR variation at high resolution is our discovery in the 
KhoeSan of two unusual allotypes of KIR2DL1 (2DL1*022 and 2DL1*026), 
both of which have lost the ability to recognize the C2 epitope of HLA-C. 
That KIR2DL1*022 and KIR2DL1*026 have lost the capacity to function as 
inhibitory C2 receptors, exemplifies the accumulation of KIR2DL1 
allotypes in the KhoeSan with low avidity or weakened signaling function, 
as well as KIR B haplotypes lacking the KIR2DL1 gene. We hypothesize 
that the emergence of 2DL1*022 and 2DL1*026, as well as the general 
increase of weaker inhibitory KIR2DL1 allotypes in the KhoeSan could 
have acted to reduce the incidence of preeclampsia, to which the KhoeSan 
are likely to be predisposed on account of their high frequency of the C2 
epitope [23, 24].  
 
For other allotypes of KIR2DL1 and KIR2DL2/3, the effects of their 
defining substitutions can act to alter different functional properties: 
receptor avidity [53, 69, 70], stability [81, 82], cell-surface abundance and 
signal transduction [52]. Throughout the KIR molecule are sites where 
natural substitutions affect receptor functions. Many of these are away from 
the HLA-C binding site and likely involve conformational changes, 
including ones that affect the relative orientation of the extracellular D1 and 
D2 domains that combine the form the binding site [69, 70]. 
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Critical review of results 
In this study we showed that allotypic variation of KIR2DL1 and 
KIR2DL2/3 results in receptors that display a range of avidity for HLA-C. 
This functional range was shown using the HLA class I bead-binding assay 
that is discussed in greater detail in chapter 4. Although the results of this 
assay correspond well with cell-based assays of cytotoxicity, this correlation 
has been studied only superficially and with receptor variants that bind with 
high avidity or no avidity to the HLA-C ligand under test. As a result, there 
is little information regarding how minor changes in avidity between KIR 
and HLA class I influence downstream NK cell function. Our interpretation 
has been that the changes in avidity represent a linear functional range i.e. 
that a receptor that binds with twice the avidity of its counterpart will 
educate an NK cell twice as well. However, NK cell reactivity may be 
determined by threshold rather than a true linear response. In this model, 
any receptor-ligand interaction above a certain threshold would educate the 
NK cell similarly, effectively nullifying any effect from higher avidity 
interactions. Similarly, a threshold effect may occur at the lower end of the 
binding spectrum such that any interactions below a given threshold are 
insufficient to induce receptor signaling via ligand engagement. To 
determine whether the linear or threshold models better fits with true NK 
cell biology would need extensive cellular assays. Other than the time 
constraints, one potential problem with this approach is that cellular assays 
of cytotoxicity have a notoriously high noise to signal readout. Indeed, it 
was this characteristic of these tests that first inspired our development of 
the bead-based assay. Flow cytometric analysis of cytoplasmic tail 
phosphorylation may be an appropriate experimental approach to investigate 
this open question. 
 
In addition to the variation that we observed in receptor avidity and 
specificity, we also showed that KIR2DL1 receptors display a range of cell-
surface expression. A similar criticism could be leveled at this work; the 
functional implications of this variation are not clear. Our assumption has 
been that an increase in cell-surface expression of a given receptor correlates 
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with an increase in the potential of that receptor to educate an NK cell via 
engagement with an HLA class I ligand. However, evidence for this 
assumption is lacking. Differences in the expression of HLA-C have been 
correlated with disease outcome [83], but it remains unknown as to whether 
this effect is mediated via engagement of NK cell receptors, TCR, or 
another immune system receptor. One pitfall of attempting to address this 
question is that an assay would have to be designed in which the cell-surface 
expression of a given KIR would have to be modified without influencing 
the avidity of binding to HLA-C. In this capacity, 2DL1*003 and 2DL1*005, 
which share an identical extracellular domain, but have different cell-surface 
expression, have potential. However, experimental design would need to 
ensure that the mutation in the cytoplasmic tail that distinguishes these 
allotypes does not play a role in regulating intracellular signaling.  
 
This study concentrated on the functional aspects of single KIR allotypes, 
documenting the functional variation that is the result of genetic 
polymorphism. We did not consider the broader functional characteristics of 
the combinations of KIR allotypes inherited on specific KIR haplotypes. 
This is a deficiency that I sought to address in a follow-up study. The results 
of this in-depth characterization of the functional variation between the KIR 
A and B haplotypes that results from allotypic variation in HLA-C receptors 














Contribution of polymorphism to diversification of KIR 
haplotypes 
 
The human KIR locus comprises two haplotype groups, termed A and B. 
KIR A haplotypes encode a fixed suite of largely inhibitory receptors 
whereas KIR B haplotypes have a variable number of inhibitory receptors 
and several activating receptors. That these haplotype groups are present in 
all human populations but with different relative frequencies, suggests that 
they have different functional properties that have been subject to balancing 
selection. 
 
In addition to their accumulation of activating receptors, the KIR B 
haplotypes also have a subset of alleles for the inhibitory receptor genes that 
are common to KIR A and B haplotypes [37, 50, 84]. Furthermore, although 
a limited number of KIR haplotypes have been studied in detail there 
appears to be functional differences between the inhibitory receptors 
encoded by the KIR A and B haplotypes [52, 60, 68, 69]. In this chapter I 
present the findings from my study that determined the haplotypic 
association, phylogeny and function of every KIR2DL1, KIR2DL2/3 and 
KIR2DS1 allele yet defined. The results from this study shed light on the 
evolution and function of human HLA-C receptors and their contribution to 
the distinct functions of the KIR A and B haplotypes. 
 
Summary of results and key findings 
KIR2DL1/S1 and KIR2DL2/3 form four distinct phylogenetic clades that 
segregate on distinct haplotypes 
KIRs that recognize HLA-C divide into two groups on the basis of their 
epitope recognition: the inhibitory KIR2DL2/3 recognize the C1 epitope of 
HLA-C, and the inhibitory KIR2DL1 and activating KIR2DS1 recognize the 
C2 epitope of HLA-C. Both KIR2DL2/3 and KIR2DL1 are highly 
polymorphic whereas KIR2DS1 is relatively conserved [35].  
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Phylogenetic analysis of the coding sequence of 26 KIR2DL1 and KIR2DS1 
alleles distinguishes four clades of KIR (Figure 3).  
 
 
Figure 3: KIR2DL1 and KIR2DS1 form four phylogenetic clades  
(A) Shown is a phylogenetic analysis of 33 KIR2DL1 and 2DS1 nucleotide sequences 
representing the domains encoding amino acids 1-328. The phylogenetic relationships were 
inferred using three tree-building algorithms that showed broad consensus. Shown is a 
representative tree created using the Neighbor-Joining Method [85]. The analysis identified 
four clades that have been color shaded for clarity. The optimal tree with sum of branch 
length = 0.071 is shown. The percentage of replicate trees in which the associated taxa 
clustered together in the bootstrap test (500 replicates) is shown next to the branches when 
greater than, or equal to, 50. The evolutionary distances were computed using the Tamura-
Nei method and are in the units of the number of base substitutions per site. All positions 
containing gaps and missing data were eliminated. In the final dataset there was a total of 872 
positions. Evolutionary analysis was conducted in MEGA6 [86]. (B) Shown is a sequence 
alignment of the most common allotypes in each of the four KIR2DL1 and 2DS1 clades 
identified by the phylogenetic analysis. Dots indicate identity with consensus (2DL1*001) 
and an asterisk indicates a termination codon. The lines beneath the alignment show the 
structural domains: Ig-like domains (D1+D2), stem (St), transmembrane domain (Tm) and 
cytoplasmic tail (Cyt). (C) Schematic diagram indicating the likely sites of recombination 




The alleles grouped in clades 1 and 2 are associated with the centromeric 
part of the KIR A haplotype (Cen-A). Exceptions are the KhoeSan specific 
alleles KIR2DL1*022 and KIR2DL1*026 (discussed in detail in chapter 2) 
that phylogenetically form part of clade 1, but genetically associate with 
centromeric KIR B haplotypes (Cen-B) [54]. Clade 3 contains six 
KIR2DL1*004-like alleles, whose products are distinguished from those of 
clades 1 and 2 by a 4 amino acid sequence motif comprising threonine 154, 
asparagine 163, arginine 182 and glutamate 216. Clade 3 alleles map to the 
Cen-B haplotype with one exception (KIR2DL1*011) that maps to the Cen-
A haplotype. That this motif is shared by KIR2DS1 suggests that KIR2DL1  
acquired this motif by recombination with KIR2DS1. Clade 4 comprises the 
KIR2DS1 alleles that are found in the telomeric region of KIR B haplotypes. 
(Tel-B). 
 
The KIR2DL2/3 gene encodes receptors that recognize HLA-C allotypes 
carrying the C1 epitope. In an analogous fashion to that identified for 
KIR2DL1, phylogenetic analysis of KIR2DL2/3 identified 4 clades of alleles 
that segregate with specific KIR haplotypes (Figure 4). Clades 1 and 2 
comprise 24 KIR2DL3 alleles that predominantly map to Cen-A 
(KIR2DL3*014 and 2DL3*018 are exceptions found on Cen-B); clades 3 
and 4 comprise 11 KIR2DL2 alleles that map to Cen-B. In summary, for 
both KIR2DL1 and KIR2DS1 and KIR2DL2/3 there are four phylogenetic 
clades of alleles that correlate with genomic location in the Cen-A, Cen-B or 












Figure 4: KIR2DL2 and KIR2DL3 form four phylogenetic clades  
(A) Shown is a phylogenetic analysis of 36 KIR2DL2/3 nucleotide sequences representing the 
domains encoding amino acids 1-328. The phylogenetic relationships were inferred using 
three tree-building algorithms. Shown is a representative tree created using the Neighbor-
Joining Method [85]. The analysis identified four clades that have been color shaded for 
clarity. The optimal tree with sum of branch length = 0.079 is shown. The percentage of 
replicate trees in which the associated taxa clustered together in the bootstrap test (500 
replicates) is shown next to the branches when greater than or equal to 50. The evolutionary 
distances were computed using the Tamura-Nei method and are in the units of the number of 
base substitutions per site. All positions containing gaps and missing data were eliminated. In 
the final dataset there was a total of 952 positions. Evolutionary analysis was conducted in 
MEGA6 [86].(B) Shown is an alignment of four KIR2DL2/3 allotypes representing the four 
clades identified using phylogenetic analysis. Dots indicate identity with the consensus 
(2DL3*001) and an asterisk indicates a termination codon. The lines beneath the alignment 
show the structural domains: Ig-like domains (D1+D2), stem (St), transmembrane domain 
(Tm) and cytoplasmic tail (Cyt). (C) Schematic diagram indicating the likely sites of 
recombination that define the four phylogenetic clades identified in part (A).  
 
 
Cen A encodes stronger C2 receptors and weaker C1 receptors than Cen B 
A synthesis of the binding data from each of the receptors encoded by 
alleles associated with the Cen-A or Cen-B haplotypes showed that 
KIR2DL1 encoded by Cen-A alleles bind C2 with significantly greater 
avidity than Cen-B encoded KIR2DL1. Receptor function of three Cen-B 
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associated KIR2DL1 allotypes is further weakened by substitutions in the 
transmembrane or cytoplasmic domain [52, 54]. A similar analysis for 
KIR2DL2/3 allotypes showed that Cen-A encoded KIR2DL2 and KIR2DL3 
receptors have significantly lower avidity for C1 than do the Cen-B encoded 
KIR2DL2 and KIR2DL3 receptors. 
 
Four D2 domain substitutions give Cen A associated KIR2DL1*003 and 
Cen B associated KIR2DL1*004 different C2 avidity 
To determine the basis for the weaker C2 avidity of Cen-B associated 
KIR2DL1, we compared KIR2DL1*003 and KIR2DL1*004, respectively the 
most common Cen-A and Cen-B associated alleles [51, 87-91]. In the D1 
and D2 domains that form the ligand-binding site, KIR2DL1*003 and 
KIR2DL1*004 differ only in D2, at positions 114, 154, 163 and 182. We 
made KIR-Fc fusion proteins from KIR2DL1*003, KIR2DL1*004 and the 
set of 14 KIR2DL1 mutants that represents all possible combinations of the 
four dimorphic positions. These 16 KIR-Fc fusion proteins were tested for 
binding to the panel of 97 HLA class I allotypes. Substitution at all of the 
four positions affects receptor avidity for HLA-C2 with single mutations at 
three of the positions (154, 163 and 182) showing that the residue present in 
KIR2DL1*003 increases and the KIR2DL1*004 residue decreases avidity. 
For position 114 the opposite effect was seen. Thus, the four dimorphic sites 
have not co-evolved to produce the strongest and weakest C2 receptors 
possible. Instead, there exists a more moderate balance between a stronger 
and a weaker C2 receptor.  
 
The N-terminal half of the KIR2DL1 transmembrane domain is essential for 
cell-surface expression 
KIR2DL1*004 is one example of a Cen-A associated allotype that is 
functionally affected by polymorphism at the junction between the 
transmembrane and cytoplasmic domains. Another is KIR2DL1*026 that 
has a termination codon at position 246. This substitution has two effects. 
First, it eliminates the cytoplasmic tail with its ITIMs that mediate inhibitory 
signaling function [78]. Second, it reduces the cell surface expression of 
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KIR2DL1*026 [54]. This observation raised the question: how much of the 
transmembrane domain is necessary for KIR2DL1 to become surface 
associated? To address this question we introduced termination codons at 
five evenly spaced positions within the sequence encoding the 
transmembrane domain (residues 225-245) of KIR2DL1*003, as well as at 
position 224 in the stem domain and positions 246, 250 and 256 in the 
cytoplasmic tail. After incorporation of N-terminal FLAG tags, we 
determined the cell-surface expression of the 12 mutant constructs and wild-
type KIR2DL1*003 using an anti-FLAG antibody. 
 
Termination in the N-terminal half of the transmembrane region (residues 
225-235) completely abrogated cell-surface expression of the mutant 
KIR2DL1*003. In contrast, termination in the carboxyl-terminal half of the 
transmembrane domain (residues 236-245) permitted cell surface expression 
of mutant KIR2DL1*003, with levels corresponding to 53-72% of the wild-
type. Thus, the N-terminal half of the transmembrane domain is required for 
membrane association of KIR2DL1. 
 
A terminal mutation in KIR2DL1*014 prevents its cell-surface expression 
KIR2DL1*014 differs from KIR2DL1*003 by substitution of glycine for 
serine at position 179 in the D2 domain. Serine 179 prevents cell surface 
expression of KIR2DL1*014 and the binding of KIR2DL1*014-Fc to HLA 
class I [54]. These properties suggest that serine 179 prevents 
KIR2DL1*014 from folding properly, thereby leading to its intracellular 
retention.  
 
We used confocal microscopy to examine the intracellular localization of 
the FLAG-tagged KIR2DL1*014 in HeLa cells, showing that although 
KIR2DL1*014 protein is produced, it is retained in the interior of the cell, 
consistent with an unfolded protein response. An analysis of the three-
dimensional structure of KIR2DL1*001 (PDB: 1NKR) [47] showed that 
position 179 of the D2 domain is buried beneath the binding site for HLA-C. 
We modeled the effect of replacing glycine 179 of KIR2DL1*001 with the 
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serine 179 of KIR2DL1*014. In this model the side chain substitution of a 
hydrogen atom for a methyl group displaces the tyrosine at position 134 and 
this is the likely mechanism that disrupts the folding of the receptor.  
 
Variation at positions 16 and 148 diversifies the recognition of HLA-C by 
KIR2DL2/3 
Moesta et al. previously showed that the residues at positions 16 and 148 in 
the hinge region of the KIR molecule account for KIR2DL2*001 and 
KIR2DL3*001 having different avidities for HLA-C [69]. Having proline 
16 and arginine 148 renders KIR2DL3*001 a C1-specific receptor of 
moderate avidity. In contrast, arginine 16 and cysteine 148 give 
KIR2DL2*001 higher avidity for C1 and cross-reactivity with C2 [36, 69]. 
Sequence comparison of 61 KIR2DL1, KIR2DL2 and KIR2DL3 variants 
showed that arginine and proline are the only residues present at position 16, 
whereas arginine, proline and cysteine can occur at position 148. Five of the 
six possible combinations are represented in the 36 KIR2DL2/3 allotypes, 
but only two combinations are represented in the 33 KIR2DL1 and 
KIR2DS1 allotypes. To see how the variability at positions 16 and 148 
influence avidity and specificity for HLA-C, I made 18 KIR-Fc fusion 
proteins in which all six combinations of the natural residues at positions 16 
and 148 were introduced into KIR2DL1*003, KIR2DL2*001 and 
KIR2DL3*001. 
 
Consistent with the findings presented in chapter 1, KIR2DL1 appears 
comparatively insensitive to mutation, with 5 of the 6 KIR2DL1 mutants 
exhibiting <15% variability in the binding to HLA-C. In contrast, the mutant 
combining proline 16 with proline 148 retained high specificity for C2 but 
with avidity only 60% of wild-type. In comparison with the relative 
insensitivity of KIR2DL1 to mutation, all KIR2DL2 and KIR2DL3 mutants 
exhibited detectable differences. For KIR2DL2, the major effect of mutation 
was to change the avidity, whereas the specificity of stronger binding to C1 
and weaker binding to C2 was largely preserved. By contrast, the five 
KIR2DL3 mutants showed greater cross-reactivity with C2 than wild-type 
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KIR2DL3*001. For both KIR2DL2 and KIR2DL3, mutants with arginine 16 
and arginine 148 produce receptors with high avidity for HLA-C whereas 
mutants with proline 16 and proline 148 consistently produced receptors 
with low avidity for HLA-C. 
 
In summary, these results indicate that polymorphism in all of the structural 
domains of the mature KIR protein can impact the function of KIR with 
respect to the initiation and propagation of inhibitory or activating signals. 
Substitutions that change the avidity of KIR2DL1 for HLA-C are usually in 
the D2 domain, whereas substitutions that change the avidity of KIR2DL2/3 
for HLA-C are usually in the hinge region connecting the D1 and D2 
domains. The only site where substitution has significant impact on the 
specificity of KIR2DL1 for C2 or KIR2DL2/3 for C1, is position 44 in the 
D1 domain. Substitutions that affect the cell surface expression of KIR2DL 
are more often in the transmembrane or the cytoplasmic domain, but there 
are also substitutions in the extracellular domains that alter receptor function 
in this way. An extreme example is KIR2DL1*014, which is completely 
retained inside the cell as a consequence of having serine, rather than 
glycine at position 179 in the D2 domain.  
 
Major conclusions 
This study showed that inhibitory KIR2DL1, activating KIR2DS1, and 
inhibitory KIR2DL2/3 alleles form distinctive clades that associate with 
specific KIR haplotypes. Typifying KIR Cen-A haplotypes are KIR2DL1 
alleles that encode strong inhibitory C2 receptors and KIR2DL2/3 alleles 
encoding weak inhibitory C1 receptors. In striking contrast, Cen-B 
haplotypes combine KIR2DL1 alleles that encode weak inhibitory C2 
receptors with KIR2DL2/3 alleles encoding strong inhibitory C1 receptors. 
 
Although the relative frequency of KIR A and B haplotypes varies 
substantially across the world, as do C1 and C2 frequencies, there is a strong 
correlation between C2 and KIR B and a corresponding inverse correlation 
between C2 and KIR A. thus, it appears that in populations with high C2 
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frequency, such as those in Africa, there has been selection for weak C2 
receptors and strong C1 receptors (found on KIR B haplotypes). Underlying 
these observations and implicating a strong inhibitory C2 receptor-ligand 
interaction in their pathogenesis, are correlations with pregnancy syndromes. 
Thus, women who are pregnant with a fetus expressing C2 are at increased 
risk of preeclampsia. Those same strong inhibitory KIR-ligand interactions 
are, however, vital for the development of well-educated NK cells that are 
both self-tolerant and responsive to virally infected and malignantly 
transformed cells. Thus, a pattern emerges in which KIR haplotypes with 
contrasting functional properties are subject to selection in response to the 
relative abundance of HLA-C ligand. In this way, we propose that the KIR 
system may be considered a buffering mechanism by which optimal NK cell 
function is preserved, despite fluctuations in the frequency of available 
ligand.  
 
Critical review of results 
A key finding of this study was that KIR Cen-A haplotypes encode stronger 
C2 receptors and weaker C1 receptors than Cen-B haplotypes. Supporting 
this conclusion was our analysis in which we compared the avidity and 
specificity of allotypes known to segregate with specific KIR haplotypes. 
However, there are three major weaknesses of this analysis: 
 
1. Incomplete haplotype and allele data: because the high-resolution 
genotyping of KIR remains in its infancy, both the true allelic diversity 
of KIR2DL1 and KIR2DL2/3 and their haplotype associations are yet to 
be fully elucidated. Because our analysis used only known alleles with 
known haplotype associations, this dearth of information may skew the 
results of our analysis. Repeating our analysis using every known allele 
with putative haplotype associations confirmed our original findings. 
However, this secondary analysis may erroneously include alleles that 
display “haplotype infidelity” and skew the results for this reason.  
 
	 42	
2. Signaling capacity and cell-surface expression not included in allotype 
weighting: our analysis accounted for the avidity and specificity of the 
allotypes of KIR2DL1 and KIR2DL2/3 as measured by the KIR-Fc bead 
binding assay, but did not account for the differences in either cell-
surface expression or the variable signaling capacity of the allotypes. 
Our rationale for excluding cell-surface expression information was 
twofold: (a) little is known regarding how cell-surface expression 
influences downstream NK cell education and function and (b) this 
study did not investigate the cell-surface expression of KIR2DL2/3. Our 
rationale for excluding signaling capacity was the lack of information 
available for KIR2DL2/3. Thus, as an example, the Cen-B associated 
allotype KIR2DL1*026, which binds strongly and specifically to HLA-
C2, but does not generate an inhibitory signal because it lacks a 
cytoplasmic domain, artificially decreases the significance of the 
association that found. Conversely, the Cen-A associated KIR2DL1*006, 
which binds strongly and specifically to HLA-C2 but is weakened due 
to having cysteine at position 245, biases the finding in the opposite 
direction. 
 
3. Frequency of alleles not accounted for in analysis: In this comparative 
analysis, each allele is weighted equally, regardless of their frequency in 
a given population. As an example, KIR2DL1*022 is included in the 
Cen-B associated alleles. This allele encodes a receptor that does not 
recognize HLA-C2. However, our work (presented in chapter 2) showed 
that this allele is has a very restricted population distribution, being 
found almost exclusively in the southern African hunter-gatherer 
KhoeSan population. As a result, low frequency alleles or those that 
have a very restricted distribution may have too great an influence on 
the results of our analysis. A further analysis (which is currently being 
performed) that combines the frequency of specific KIR alleles with 





Refining the production of KIR-Fc fusion proteins and their use 
in a multiplex binding assay 
 
One of the central methodological advancements that allowed us to map the 
functional variation of KIR-HLA-C receptor ligand interactions (presented 
in chapters 1-3) was the development and refinement of the KIR-Fc - HLA 
class I multiplex binding assay. First described by Moesta et al [69] for the 
investigation of the reactivity of KIR2DL2 and KIR2DL3, this test has since 
been adopted widely in the field of NK cell biology [34, 45, 53-55, 62-64, 
70]. The first studies that described this assay produced just a few KIR-Fc 
proteins whose reactivity was tested on the new multiplex platform [64, 69]. 
My research has expanded the use of these KIR-Fc proteins, mapping the 
reactivity of over 100 KIR-Fc that represent both naturally occurring KIR 
allotypes as well as mutant KIR, created to investigate the function of 
specific amino acid residues [53-55]. This exponential expansion in KIR-Fc 
production required devising new protein production systems, internal 
quality assurance controls and standard assay operating procedures [56]. 
These advances, which are the subject of this chapter, have increased the 
reproducibility and functionality of this assay.  
 
NK cells encode a diverse repertoire of receptors that complicates 
understanding of how single receptors contribute to NK reactivity 
Because the genes encoding KIR and HLA class I are on different 
chromosomes, their independent segregation during meiosis produces 
diversity in the number and type of KIR-HLA gene combinations inherited in 
individuals [67, 92]. The result is that NK cells from individuals of different 
genetic backgrounds are educated by different receptor ligand combinations 
resulting in a range of NK cell function. Further, NK cells can express more 
than one KIR at a time. This inherent diversity complicates the investigation 
of the specific KIR-HLA class I interactions that modulate immune response. 
Development of soluble KIR proteins, for which the reactivity for single 
HLA class I molecules was determined by direct binding assay, facilitated 
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understanding of how particular receptor-ligand combinations contributed to 
NK cell reactivity [93]. These recombinant proteins were made in a 
mammalian cell expression system by fusing the extracellular domains of a 
two-domain KIR with two Fc domains of a human IgG1 to form a soluble 
homodimer (Figure 5).  
 
 
Figure 5: (A) Schematic diagram showing the configuration of a recombinant KIR-Fc fusion 
gene. The recombinant fusion gene consisting of the D1, D2 and stem domains of a KIR2D 
molecule (grey box) and the Fc region of a human IgG1 antibody (white box) is cloned using 
BamH1 and Not1 restriction sites into the multiple cloning site (MCS) of the pAcGP67a 
vector (B) downstream of the polyhedrin and GP67 promoters. Transfection into insect cells 
produces a soluble recombinant KIR-Fc dimer (C) consisting of the D1, D2 and stem regions 
(extracellular domain – ECD) of the KIR molecule (grey ovals) and the Fc region (white 
ovals) of the IgG1 antibody. (S-S) shows the location of the di-sulphide bonds that lead to 
formation of a dimer.  
 
The reactivity of these KIR-Fc was then tested in a cellular binding assay 
[93]. Whilst this approach was critical to determining the basic “rules” that 
governed KIR and HLA class I interaction, the assay had two major 
drawbacks: (1) mammalian cells are comparatively difficult and expensive 
to culture and they produce relatively small quantities of protein and (2) the 
BamHI NotI



























assay only allowed examination of the reactivity between one specific KIR 
and one specific HLA class I molecule at any time. To address these issues, 
Moesta et al. [69] first developed a method for the production of KIR-Fc 
from insect cells and secondly, adapted an assay originally designed for the 
identification of human alloantibodies to test the reactivity of a single KIR 
for around 100 HLA class I molecules at one time. 
 
KIR-Fc production from insect cells 
The advantages of insect cells are that they are simple to culture. They also 
have a short doubling time that facilitates scaling and they are capable of 
higher protein yields than comparative mammalian cell expression systems. 
Because of these advantages, the baculovirus-insect cell system is now one 
of the most widely used methods for the production of recombinant proteins 
[94]. Although not equivalent to higher eukaryotic cells, most post-
translational modifications are made correctly in insect cells, and proteins 
unable to be expressed in E.coli have been successfully expressed in the 
insect cell system [95].  The baculovirus family are species-specific double-
stranded DNA viruses that infect insects as their natural host [96]. Once 
inserted into the host nucleus, the baculovirus is packaged into flexible 
nucelocapsids, into which foreign DNA may readily be inserted. The target 
gene, in our case the KIR-Fc fusion gene, is inserted into a transfer vector 
and positioned between sequences that are homologous to the ones in the 
baculoviral genome. When the viral genome and transfer vector are 
transfected into insect cells, recombination occurs and produces intact viral 
genomes harboring the target-gene sequence. The strong promoter of the 
polyhedrin gene is co-opted for production of recombinant target protein. 
 
Development of a multiplex KIR-Fc binding assay 
In seeking to improve upon previous iterations of the KIR-Fc binding assay 
(that investigated the reactivity of a single HLA class I allotype using a cell-
based assay), Moesta et al [69] developed a multiplex assay that detects the 
binding of KIR-Fc to 97 HLA class I allotypes. This assay uses the Luminex 
platform, in which the antigenic targets are not cells but microbeads, each 
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coated with a defined HLA class I allotype. Such beads were developed 
originally for studying the specificity of human alloantibodies [97], but the 
platform was adapted for use with recombinant two-domain KIR-Fc fusion 
proteins [69] and monoclonal antibodies [57] (see chapter 5).  By adjusting 
the relative concentration of two fluorescent dyes, a set of 97 individually 
identifiable beads is generated. Each bead is then coated with a different 
HLA class I allotype, allowing the results of the immune assay to be 
correlated with HLA class I specificity. The panel of HLA class I allotypes 
annealed to the beads represents a broad range of the HLA class I diversity 
found worldwide, allowing evaluation of interactions between KIR-Fc and 
rare, population specific and divergent HLA class I allotypes. Crucially, 
although HLA-C represents the minority of the HLA class I allotypes found 
in the panel (16/97 allotypes), both HLA-C1 and HLA-C2 encoding alleles 
are well represented.  
 
The results of this assay can be used to predict the reactivity of KIR 
expressing NK and T cells when their KIR bind to cognate HLA class I 
ligands. It is designed to inform cellular assays of lymphocyte function in 
which receptor deficient effector NK cells transfected with a specific KIR 
are incubated with ligand-deficient target cells transfected with a specific 
HLA class I molecule.  The correlation between the results from our 
multiplex assay and assays of lymphocyte function is very strong. As an 
example, our initial study with the bead-binding assay showed that 
KIR2DL2*001-Fc recognized HLA-C2 allotypes with higher avidity than its 
allotypic variant KIR2DL3*001-Fc. A cellular cytotoxicity assay 
subsequently showed that KIR2DL2*001, but not KIR2DL3*001 effectively 
inhibited lysis when incubated with HLA class deficient target cells 
transfected with the HLA-C2 bearing allotype HLA-C*04:01 [69]. Other 
groups have also demonstrated similar correlations between the bead-
binding assay and assays of lymphocyte function, as well as assays such as 
surface plasmon resonance that directly measure the avidity of binding 
between two protein moieties [70].  
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Summary of results and key findings 
In refining this assay I sought to address two major problems: (1) variable 
baculovirus amplification from Sf9 insect cells and variable protein yield 
from Hi5 insect cells and (2) inter-assay variability and high background 
binding. In previous iterations of the protocol, the failure of baculovirus 
amplification was only evidenced by a failure of protein production from 
Hi5 cells. A positive control (using Sf9 supernatant with known capacity to 
produce recombinant protein) could be used to determine whether the Hi5 
cells were functional, but this method still required several weeks of work 
without positive evidence of success. Additionally, first-time users were at a 
significant disadvantage if they did not have access to a suitable positive 
control. In combating these deficiencies I introduced steps aimed at (a) 
optimizing baculoviral recombination during initial transfection (b) ensuring 
optimal cell health during culture and detecting unhealthy cells or 
contamination early (c) using an independent marker of baculoviral 
amplification to determine successful viral infection and replication. To 
reduce inter-assay variability and background binding in the assay itself I 
introduced a series of standard operating procedures that addressed these 
deficiencies. These refinements to the protocol are summarized in the 
paragraphs below. 
 
Creating optimal insect cell health and assessing baculoviral amplification 
For the formation of intact baculovirus it is essential that transfer vector and 
linearized baculoviral DNA recombine during initial co-transfection of Sf9 
cells. We have obtained the best results with freshly isolated transfer vector 
and baculoviral DNA that has not been stored at 4°C for more than two 
weeks. Additionally, freeze/thaw cycles of the transfer vector should be 
avoided where possible. Because the linearized baculovirus is a large DNA 
fragment (~130kb), it is particularly susceptible to shear stress; over-zealous 
pipetting during transfection should therefore be avoided to minimize DNA 
damage and maximize transfection success. 
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 Sf9 cells should have a doubling time of between 24 and 30h. Hi5 cells 
should have a doubling time of between 18 and 24 hours. Slow doubling 
times usually indicate that Sf9 of Hi5 cell cultures are unhealthy. Unhealthy 
cells will not amplify baculovirus successfully or produce adequate 
recombinant protein. Cell viability for both Sf9 and Hi5 cells, as determined 
by trypan blue staining, should be greater than 95% at all times. Both 
bacterial and fungal infections in the insect cell culture will reduce viability 
and doubling times. These can be prevented with good cell culture technique 
and the addition of antibiotics (1% Penicillin-Streptomycin) and/or anti-
fungals (0.25ug/ml Amphotericin B) to the culture medium. Cultures should 
be discarded immediately if there is evidence of microorganism 
contamination. A second reason for slow-doubling times is oxygen 
restriction. If the cell culture does not have sufficient surface area exposed 
to the air, cell growth will be retarded. This can be prevented by ensuring 
that the flasks are filled not more than one-third (by volume) with culture 
medium. Shaking the flasks between 120 and 150 rpm also ensures adequate 
oxygenation. Shaking at a higher rpm may lead to cell damaging shearing 
stress and should be avoided. 
 
Identification of baculovirus-infected Hi5 cells by flow cytometry 
GP64 is a baculovirus encoded glycoprotein that is expressed on insect cells 
upon infection with baculovirus [98]. As a result, identification of the 
expression of this surface protein by flow cytometry can be used as a proxy 
for the successful amplification of baculovirus in Sf9 cells. We showed that 
GP64 expression is not detected on un-transfected Hi5 cells but is expressed 
following transfection with high viral titre Sf9 supernatant. P0 viral stock 
was not sufficient to induce GP64 expression whereas surface expression 
was typically detected after transfection with P1 viral stock and with each 
subsequent amplified viral stock. Surface expression of GP64 was sensitive 
to the baculoviral titre with P2 transfected Hi5 cells showing a 40% increase 
in surface expression of G964 as compared to Hi5 cells transfected with P1 
viral stocks. That P3 stocks induced only marginally greater GP64 surface 
expression than P2 viral stocks suggests that GP64 is either maximally up-
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regulated by a given viral titre or Sf9 cells reach maximal viral amplification 
between the second and third amplification rounds. Because the titre of the 
transfecting supernatant corresponds to the degree of cell-surface expression 
of GP64, this method can be used to distinguish Sf9 supernatants with a 
range of baculoviral titres. 
 
Reducing inter-assay variability and background binding 
We determined that the following steps reduce both inter-assay variability 
and high background binding. For the purposes of this assay we have 
defined high background readings as those in which the negative control 
bead binding is greater than 1% of the highest positive reading obtained.  
 
Although not always the case, some KIR-Fc are not stable when stored at 
4°C and consequently, their use in the assay can lead to high background 
readings. Our assumption has been that this occurs because of aggregation 
of protein, though we lack strong evidence to support this hypothesis. To 
control for this issue, we assessed the stability of the KIR-Fc fusion proteins 
when stored at -80°C. Freezing the KIR-Fc is assumed to prevent the protein 
degradation, aggregation and misfolding that may occur when stored at 4°C. 
We determined that flash freezing of the recombinant proteins in liquid 
nitrogen, followed by storage of up to 12 months at -80°C maintained the 
stability of the proteins well (as evidenced by minimal inter-assay 
variability). Similarly, HLA class I microbeads that have been thawed and 
stored at 4°C do not remain stable for more than 3 months and are a 
potential source of inter-assay variability and high background readings. 
The beads should be divided into 10µl aliquots and frozen at -80°C if they 
are unlikely to be used within this time frame. A final standard assay 
operation that we introduced was to make certain that during the wash and 
incubation phases of the protocol that all the reagents were chilled to 4°C 
and that wash steps be completed as quickly as possible if they are unable to 
be performed in a cold room. To monitor for inter-assay variability and high 
background, we also routinely include KIR-Fc with very well characterized 
HLA-C1 and HLA-C2 binding repertoires as positive controls. 
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Major conclusions 
This chapter described the production of KIR-Fc fusion proteins in an insect 
cell expression system and their interaction in a multiplex binding assay 
with a panel of 97 HLA class I allotypes. KIR-Fc production in insect cells 
is relatively simple, allowing production of large amounts of recombinant 
protein in around 20 days. The assay is sensitive enough to discriminate 
between single amino acid substitutions in the extracellular domains of the 
KIR molecule and has, as a result, greatly facilitated investigation of even 
closely related KIR allotypes. Furthermore, the results of the direct binding 
assay correlate well with the results of cytotoxicity assays and the direct 
binding assays that were used to discover the KIR and first investigate their 
specificity for HLA class I. 
 
Critical review of results 
The microbeads we used in this assay are produced in a proprietary process 
by One Lambda (Canoga Park, CA, USA). As a result, we have limited 
information regarding their manufacture, specifically regarding the cellular 
origin of the HLA class I allotypes that are subsequently annealed to the 
microbeads. This dearth of knowledge influences the interpretation of our 
assay results in two significant ways. Firstly, we have no information 
regarding the peptide content of the HLA class I allotypes annealed to each 
bead. Given that the HLA class I protein is likely harvested from 221 cells 
transfected with a specific HLA class I variant, the peptide repertoire is 
considered to be heterogeneous, but we have no direct evidence to support 
that hypothesis. There are myriad ways in which the peptide content of the 
HLA class I presented on these microbeads might be skewed. As an 
example, the process by which the HLA class I proteins are annealed to the 
microbeads could select for just those complexes that are particularly stable. 
Given that the stability of a specific HLA class I is often directly related to 
the peptide that it is presenting, this process might easily skew the peptide 
content presented by HLA class I on the microbeads (and hence to KIR). 
Although the peptide specificity of KIR is unlikely to rival that of the TCR, 
with which it shares an overlapping (but different) binding footprint on HLA 
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class I [46, 47], recent work has shown that several two-domain KIR do 
display significant peptide specificity. Thus, any bias in peptide presentation 
might influence the results of our assay. 
 
The second feature of the microbeads that might influence KIR reactivity is 
the number of open conformers of HLA class I that are present on the 
microbeads. As noted above, we have little information regarding the nature 
of the process by which HLA class I protein is annealed to the surface of the 
microbeads. It is possible (indeed unpublished data seems to suggest it 
might be common) that several open conformers (those that lack a peptide), 
might be presented on the surface of the microbeads. Although there are no 
reports of two-domain KIR recognizing open conformers of HLA class I, 
this feature has been observed for other members of the KIR family [99, 
100]. It has also been hypothesized that many activating KIR (for which 
traditional HLA class I ligands have not been identified) might 
preferentially recognize open conformers of certain HLA class I. Thus, the 
presence of open conformers of HLA class I on the microbeads might 
influence the binding of certain KIR, especially activating variants, inducing 
a “false” positive result. Adding an additional antibody control (e.g. HC-10 
which recognizes open HLA class I conformers) would determine the 
relative amount of unfolded HLA class I protein present on the beads. 
However, if positive, we would still be unable to distinguish KIR binding to 
open HLA class I conformers as compared to correctly folded conformers 
replete with peptide. 
Although two-domain KIR are easily and reliably produced and purified 
from insect cell cultures, three-domain KIR (KIR3D) do not assemble 
efficiently. The insect cell system is capable of producing the protein, but 
we have not been able to detect reactivity of these KIR3D-Fc to any HLA 
class I. Because KIR3D are widely known to recognize the Bw4 epitope of 
HLA-A and HLA-B, this result suggests that the insect cells are incapable of 
producing an efficiently folded three-domain KIR-Fc. Recently however, 
three-domain KIR tetramers have been produced efficiently from insect cells 
[101] and KIR3D-Fc have been produced from HEK 293 cells [102]. 
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Multiplex assays using these reagents have contributed a wealth of new 
information regarding the reactivity of KIR3DL1 allotypes. 
 
This protocol uses a protein-A bead purification step to purify the 
recombinant KIR-Fc from other proteins produced by the insect cells. The 
KIR-Fc are subsequently eluted from the beads using an acid wash. This 
method produces a high concentration of pure KIR-Fc, as evidenced by 
visualization on a SDS-page gel. However, the acid-wash step may result in 
some denaturation of the protein, which would not be detected on a protein 
gel as it measures only the size of the protein, and not it’s biological activity 
or structure. The result is that our determination of the concentration of the 
purified protein by Bradford assay may overestimate the true amount of 
biologically active protein. A second purification step, for example using a 
liquid chromatography column (FPLC), would allow visualization of the 
purity of the protein and allow efficient separation of any aggregated or 
unfolded recombinant protein. If present, any denatured protein might 
contribute to the small amount of variable background binding that we 
observe in this assay. The steps that we have taken in refining the protocol 
have reduced background binding over previous iterations of the assay, but 
there remains a consistent background level of approximately 1-2% 
background binding. Evidence that supports the claim that further 
purification might reduce background binding comes from KIR tetramer 
binding studies in which the proteins used have been purified by FPLC and 












Adapting the multiplex platform to identify monoclonal antibody 
epitopes on HLA class I 
 
In chapter 4 I described our adaptation of a commercially available HLA 
class I bead-binding assay to test the reactivity of KIR-Fc fusion proteins. 
We have also adapted this assay to map the polymorphic epitopes of a panel 
of monoclonal antibodies and it is the results of these experiments that are 
the subject of this chapter. 
 
Monoclonal antibodies that recognize HLA class I have been an invaluable 
tool for basic and clinical research in human immunology. Such antibodies 
can be divided into two groups according to the types of epitope they 
recognize [103]. Monomorphic antibodies, such as W6/32, recognize 
monomorphic determinants that are common to all HLA class I variants, 
whereas polymorphic antibodies, the subject of the following two chapters, 
recognize determinants carried by a subset of such variants. In this study we 
examined the reactivity of four polymorphic monoclonal anti-HLA class I 
antibodies: PA2.1, BB7.1, BB7.2 and MA2.1.  
 
Originally, PA2.1 and BB7.2 were seen to be specific for HLA-A2 [103-
105], but with more extensive characterization were also shown to recognize 
and define HLA-A*69, a variant that is a recombinant of HLA-A*02 and 
HLA-A*68 [106]. In similar fashion, BB7.1 was originally seen to be 
specific for HLA-B*07 [103] but was subsequently shown to recognize 
HLA-B*42 [107], a recombinant of HLA-B*07 and HLA-B*08 [108] that is 
characteristic of African populations. MA2.1, which was originally 
described as recognizing HLA-A2 and HLA-B17 antigens [109] has been 
shown to react with both the B*57 and B*58 components of HLA-B17 
[110], but no additional reactivity has been reported. 
 
In large part, the HLA class I specificity of monoclonal antibodies has been 
determined using panels of cells each of which minimally expresses one 
	 54	
HLA-A, one HLA-B and one HLA-C allotype and more commonly express 
two allotypes for each. This complexity means that binding reactions cannot 
be directly attributed to particular HLA class I variants but must be inferred 
through various types of correlation. As a consequence, there are limitations 
in the extent to which data can be interpreted and thus in the resolution and 
accuracy of the data. An initial approach to address these limitations was the 
use of mutant cell lines that lacked endogenous HLA class I expression and 
could be transfected to express a single HLA class I allotype [111]. A more 
recent approach has been to replace cells as the target antigen with synthetic 
beads each of which is coated with a single HLA class I allotype [97]. 
Comparison of the reactivity patterns from the >90 HLA class I allotypes 
represented in the synthetic bead panel allows refinement of the epitopes 
recognized by each of these polymorphic monoclonal antibodies. 
 
Summary of results and key findings 
Specificity of the MA2.1 monoclonal antibody 
MA2.1 bound strongly to the five HLA-A*02 subtypes tested and also to 
HLA-B*57:01, B*57:03 and B*58:01 (which correspond to the serological 
B17 antigen). These results are consistent with the previously defined 
specificity of MA2.1 for the HLA-A2 and B-17 antigens [109]. However, 
we also observed weak reactivity of MA2.1 with HLA-B*15:16 and an even 
weaker one with HLA-A*11.  
 
The critical epitope for MA2.1 recognition is the GETR motif at positions 
62-65 in the helix of the α-1 domain [112]. Within this motif, glycine 62 is 
the only residue that is not found in any of the other 89 HLA-A, -B or –C 
allotypes tested. HLA-B*15:16 and HLA-A*11 differ only at position 62, 
having RETR and QETR motifs respectively, which correlates with them 
having some avidity for MA2.1. 
 
Specificity of the PA2.1 and BB7.2 monoclonal antibodies 
When used at a concentration of 1µg/ml, the PA2.1 and BB7.2 antibodies 
gave similarly strong reactions with five subtypes of HLA-A*02 and with 
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HLA-A*69:01. However, when a much higher concentration was used 
(50µg/ml), cross-reactions of the PA2.1 and BB7.2 antibodies were 
observed with HLA-A*23:01, A*24:02, A*24:03, A*68:01, A*68:02 and 
A*69:01. These cross-reactions correspond well with the cross-reactivity 
first described in the 1960s [113] between the serological A2, A28 (A*68 
and A*69) and A9 (A*23 and A*24) antigens and more recently described 
for cell-binding assays with the I-145 monoclonal antibody [114]. These 
cross-reactions were stronger for BB7.2 than PA2.1 and much stronger for 
A*24:03 than either A*24:02 or A*23:01. This must be due to the two 
substitutions that distinguish A*24:03 from the other allotypes and which 
are at positions 166 and 167 in the α-2 domain. The combination of 
sequence comparisons [103, 104, 106, 110] and site-directed mutagenesis 
[112, 115, 116] has shown that tryptophan 107 in the α-2 domain is a critical 
factor in forming the epitope recognized by PA2.1 and BB7.2. In addition, 
mutations at positions 161, 163, 166, 167 and 169 can lead to loss of binding 
by PA2.1 and BB7.2, showing that these residues also contribute to forming 
the epitope [115, 117]. 
 
Specificity of the BB7.1 monoclonal antibody 
BB7.1 reacts with HLA-B*07:02 and HLA-B*42:01. In addition, we found 
that HLA-B*81:01, an African allotype [118, 119] also strongly reacts with 
BB7.1, which fits with both HLA-B*81:01, B*42:01 and B*07:01 having α-
1 domains with identical sequence and residues 63-70 of the α-1 domain 
being critical for the BB7.1 epitope [103, 107, 120-124]. Both HLA-
B*56:01 and B*82:01 have identical α-1 domains with identical sequence to 
that of HLA-B*07:02, B*42:01 and B*81:01 but these allotypes are not 
bound by BB7.1 suggesting that residues in the α-2 domain abrogate their 
recognition. HLA-B*07:02, B*42:01 and B*81:01 encode arginine at 
position 131 whereas B*56:01 and B*82:01 encode serine at this position. 
Similarly, both B*56:01 and B*82:01 encode leucine at position 163 
whereas HLA-B*07:02 and B*81:01 both have glutamic acid. That BB7.1 
interacts with residues in the α-2 domain is further supported by the 
observation that mutation at positions 166 and 169 of HLA-B*07 eliminates 
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the BB7.1 epitope [121]. Therefore, whilst the α-1 domain residues between 
positions 63-71 likely form the dominant epitope for recognition by BB7.1, 
binding is influenced by polymorphism in the α-2 domain, suggesting that 
this antibody binds both the α-1 and α-2 regions of HLA class I. Given that 
this footprint would span the peptide binding cleft, peptide variability is 
likely to influence BB7.1 recognition of HLA class I.  
 
In summary, we find that the patterns of antibody reactivity observed here 
are entirely consistent with those obtained previously and extend those 
results by being able to detect and distinguish reactions and cross-reactions 
in a quantitative manner, All the observed reactions are with HLA-A and 
HLA-B variants, with no cross-reactivity for HLA-C, further emphasizing 
the distinct properties of HLA-C [125-127]. 
 
Using the multiplex platform to map the reactivity of the monoclonal 
antibody 10A5 
Counterparts to the HLA class I genes are restricted to simian primates, and 
the chimpanzee (Pan troglodytes) has orthologs of all six expressed HLA 
class I genes [40]. For some 50% of chimpanzee MHC haplotypes, these 
genes (Patr-A, B, C, E, F and G) are the only expressed MHC class I genes, 
but the other 50% of haplotypes have a seventh expressed gene, Patr-AL, 
that is within an additional ~125kb block of genomic DNA that is next to the 
~80kb block containing the Patr-A gene [128]. More closely related to Patr-
A than the other expressed genes, Patr-AL is one of a group of A-related 
genes (hence the name A-like) that includes the non-functional MHC-H and 
MHC-J genes [129]. Although not yet proved, there is evidence for the 
existence of two forms of human MHC haplotype that correspond to the 
Patr-AL+ and Patr-AL- haplotypes [128]. Called HLA-Y, the human 
equivalent of Patr-AL is non-functional and contains a 5’ region of high 
sequence similarity with Patr-AL that is recombined with a 3’ region from 
another A-related gene [128]. Neither Patr-AL nor HLA-Y exhibit significant 
polymorphism. Patr-AL originated long before the separation of human and 
chimpanzee ancestors [128, 129] and was specifically inactivated during 
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human evolution. Such inactivation could have been driven by selection or 
by the demographic factors of population bottleneck and genetic drift. Study 
of Patr-AL will therefore define an immune system component that humans 
have lost. 
 
Patr-AL forms a heterotrimeric complex with β2-microglobulin (β2m) and 
nonamer peptides to give a three-dimensional structure in which the Cα 
traces of the H chain and β2M superimpose with their counterparts in other 
HLA class I structures [128]. The peptide-binding specificity of Patr-AL is 
essentially the same as that of HLA-A*02, although the two molecules 
differ by >40 amino acid substitutions, of which 30 are in the α-1 and α-
2 domains and 13 are predicted to contact peptide [128]. These properties 
suggest that Patr-AL, like HLA-A and Patr-A, presents peptide antigens to 
αβ TCRs. Supporting this hypothesis, Patr-AL is an alloantigen recognized 
by the highly specific cytotoxic CD8 αβ T cells that are present in 
chimpanzees lacking Patr-AL [128]. This implies that Patr-AL is expressed 
in the thymus and mediates negative selection. 
 
The major structural difference between Patr-AL and other human and 
chimpanzee MHC class I molecules is the upper face of the α helix of the α-
2 domain, which is unusually electropositive and makes Patr-AL 
exceptional in having a basic isoelectric point [128]. Previous preliminary 
analysis of mRNA levels indicated that the expression of Patr-AL was either 
very low or restricted to a minority of PBMCs [129]. In the investigation 
reported in this chapter, Abs against Patr-AL were made and used to study 
both endogenous Patr-AL protein expression and recombinant Patr-AL 
stably expressed in an MHC class I–deficient cell line and compared its 
expression with the well-characterized human HLA-A*02 protein. Central 
to this process was the characterization of the reactivity of the 10A5 (anti-




The anti Patr-AL monoclonal antibody 10A5 does not recognize HLA class I 
on either cells or microbeads 
Previously it was shown that the Patr-AL protein can be detected in 
chimpanzee PBMCs and B lymphoblastoid cell lines (BLCL), but at a much 
lower level than classical MHC class I molecules [129]. To facilitate further 
expression of Patr-AL expression, mAbs from the B cells of mice 
immunized with soluble, recombinant Patr-AL were made. This Ag 
comprised the extracellular domains of Patr-AL, β2M and the nonamer Patr-
AL binding peptide ALDKATVLL [128]. Of the many mAbs obtained, the 
10A5 antibody was selected for further investigation because it bound 
strongly to Patr-AL but exhibited no detectable interaction with other MHC 
class I transfected into HLA class I deficient cell lines. Thus, 10A5 binds to 
HLA-A, B, -C deficient 221 cells transfected with Patr-AL, but not to 
untransfected 221 cells or to 221 cells transfected with either HLA-A or 
Patr-A.  
 
The exquisite specificity of the 10A5 Ab for Patr-AL was demonstrated by 
analysis to measure the binding of 10A5 to the wider HLA class I panel 
represented in the Luminex panel described above and comparing the results 
to the binding achieved with W6/32. Whereas the binding of W6/32 to the 
97 HLA class I coated beads varied between a fluorescence intensity of 
17,715 and 28,136, the binding of 10A5 varied between 9 and 77. Thus, 
none of the 31 HLA-A, 50 HLA-B and 16 HLA-C allotypes was bound 
significantly by the anti-Patr-AL mouse mAb 10A5. 
 
Critical review of results 
Although we have speculated based on the predicted epitopes of the 
monoclonal antibodies that we investigated in this chapter that peptide may 
play an important role in the reactivity of certain monoclonal antibodies 
directed against HLA class I, we have little information regarding the 
peptide content of the beads used in this assay, although we have assumed 
them to be heterogeneous in nature. A simple cellular experiment 
documenting the binding effect of different pulsed peptides by flow 
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cytometry would go some way to confirm the true role of peptide in the 
antibody epitopes. 
 
In similar fashion, if a particular antibody is highly sensitive to bound 
peptide, it is possible for an antibody to display no reactivity to HLA class I-
peptide repertoire presented in the bead binding assay but to have specific 
reactivity to a particular peptide or group of peptides presented by an 
identical HLA class I allotype in a cellular system. This has particular 
relevance to our investigation of the 10A5 antibody that we demonstrated 
has no reactivity for HLA class I.  
 
In designing this assay we used a wide range of antibody concentrations and 
interpreted the relatively low levels of binding seen with some antibodies as 
weak cross-reactivity for an epitope. However, as previously stated in 
chapter 4, there is a possibility that a portion of the HLA class I molecules 
annealed to the beads are present in the form of open conformers (unfolded 
HLA class I lacking peptide). As a result, these low levels of binding at high 
concentration may simply represent exposed epitopes to which the antibody 
would otherwise have no distinguishable reactivity. The result is that we 
over estimate the number and types of residues that form the binding 















This thesis summarizes the results from 6 published studies that investigated 
how genetic variation of KIR and HLA-C contributes to the functional 
diversity found in human immune systems. Also presented are several 
methodological advances that have facilitated our understanding of these 
complex immune interfaces.  
 
Each of the six positions that have undergone positive selection in the 
extracellular ligand binding domains of KIR contribute to differences in 
binding to HLA-C. Position 44 governs the specificity of these interactions 
whereas position 70 plays the dominant role in the avidity of interactions.  
 
The critical role of position 44 was further highlighted by our study of 
KIR2DL1*022. This allele, which evolved in the KhoeSan and is not found 
in other human populations, has switched specificity from HLA-C2 to HLA-
C1. The increase in the frequency of this allele, and other weakened 
KIR2DL1 alleles that predominate in the KhoeSan likely occurred to balance 
the unusually high frequency of the HLA-C2 epitope in this population.  
 
The balance that characterizes the distribution and function of KIR and 
HLA-C in the KhoeSan is also evident for KIR haplotypes more generally. 
KIR A haplotypes are replete with alleles that encode strong HLA-C2 
receptors but weak HLA-C1 receptors. Conversely, KIR B haplotypes have 
alleles that encode weaker HLA-C2 receptors but stronger HLA-C1 
receptors.  
 
Our results highlight the need for determining both the KIR and HLA class I 
genotype at the highest possible resolution and the need for functional 
studies that document the functional consequences of that variation. Such 
studies are likely to be critical for determining immune responses in 






1.	 Cooper,	 M.A.,	 M.	 Colonna,	 and	 W.M.	 Yokoyama,	 Hidden	
talents	 of	 natural	 killers:	 NK	 cells	 in	 innate	 and	 adaptive	
immunity.	EMBO	Rep,	2009.	10(10):	p.	1103-10.	
2.	 Parham,	 P.	 and	 A.	 Moffett,	Variable	NK	 cell	 receptors	 and	
their	 MHC	 class	 I	 ligands	 in	 immunity,	 reproduction	 and	
human	evolution.	Nat	Rev	Immunol,	2013.	13(2):	p.	133-44.	
3.	 Kiessling,	 R.,	 et	 al.,	 "Natural"	 killer	 cells	 in	 the	 mouse.	 II.	
Cytotoxic	cells	with	 specificity	 for	mouse	Moloney	 leukemia	
cells.	Characteristics	of	the	killer	cell.	Eur	J	 Immunol,	1975.	
5(2):	p.	117-21.	
4.	 Kiessling,	R.,	E.	Klein,	 and	H.	Wigzell,	 "Natural"	killer	cells	
in	 the	 mouse.	 I.	 Cytotoxic	 cells	 with	 specificity	 for	 mouse	
Moloney	 leukemia	 cells.	 Specificity	 and	 distribution	
according	to	genotype.	Eur	J	Immunol,	1975.	5(2):	p.	112-7.	
5.	 Pross,	 H.F.	 and	 M.	 Jondal,	 Cytotoxic	 lymphocytes	 from	
normal	 donors.	 A	 functional	 marker	 of	 human	 non-T	
lymphocytes.	Clin	Exp	Immunol,	1975.	21(2):	p.	226-35.	
6.	 Pross,	 H.F.	 and	 M.	 Jondal,	 Letter:	 Spontaneous	 cytotoxic	
activity	 as	 a	 test	 of	 human	 lymphocyte	 function.	 Lancet,	
1975.	1(7902):	p.	335-6.	
7.	 Caligiuri,	 M.A.,	 Human	 natural	 killer	 cells.	 Blood,	 2008.	
112(3):	p.	461-9.	
8.	 Vivier,	 E.,	 et	 al.,	 Functions	 of	 natural	 killer	 cells.	 Nat	
Immunol,	2008.	9(5):	p.	503-10.	




trigger	 the	 release	 of	 endocytosed	 granzyme	 B	 into	 the	
cytosol	of	target	cells.	Nat	Immunol,	2011.	12(8):	p.	770-7.	
11.	 Cooper,	 M.A.,	 et	 al.,	 Human	 natural	 killer	 cells:	 a	 unique	
innate	 immunoregulatory	 role	 for	 the	CD56(bright)	 subset.	
Blood,	2001.	97(10):	p.	3146-51.	
12.	 De	 Maria,	 A.,	 et	 al.,	 Revisiting	 human	 natural	 killer	 cell	
subset	function	revealed	cytolytic	CD56(dim)CD16+	NK	cells	






14.	 Parham,	 P.,	 MHC	 class	 I	 molecules	 and	 KIRs	 in	 human	
history,	health	and	survival.	Nat	Rev	 Immunol,	2005.	5(3):	
p.	201-14.	
15.	 Braud,	 V.M.,	 et	 al.,	 HLA-E	 binds	 to	 natural	 killer	 cell	
receptors	CD94/NKG2A,	B	and	C.	Nature,	1998.	391(6669):	
p.	795-9.	
16.	 Guethlein,	 L.A.,	 et	 al.,	 Co-evolution	 of	 MHC	 class	 I	 and	
variable	NK	cell	receptors	 in	placental	mammals.	 Immunol	
Rev,	2015.	267(1):	p.	259-82.	
17.	 Alter,	 G.,	 et	 al.,	 HIV-1	 adaptation	 to	 NK-cell-mediated	
immune	pressure.	Nature,	2011.	476(7358):	p.	96-100.	
18.	 Khakoo,	S.I.,	et	al.,	HLA	and	NK	cell	inhibitory	receptor	genes	
in	 resolving	 hepatitis	 C	 virus	 infection.	 Science,	 2004.	
305(5685):	p.	872-4.	




receptor,	 KIR2DS1,	 is	 associated	 with	 susceptibility	 to	
psoriasis	vulgaris.	Hum	Immunol,	2004.	65(7):	p.	758-66.	
21.	 Suzuki,	 Y.,	 et	 al.,	 Genetic	 polymorphisms	 of	 killer	 cell	
immunoglobulin-like	 receptors	 are	 associated	 with	
susceptibility	to	psoriasis	vulgaris.	 J	 Invest	Dermatol,	2004.	
122(5):	p.	1133-6.	
22.	 van	 der	 Slik,	 A.R.,	 et	 al.,	KIR	 in	 type	 1	 diabetes:	 disparate	
distribution	 of	 activating	 and	 inhibitory	 natural	 killer	 cell	
receptors	 in	 patients	 versus	 HLA-matched	 control	 subjects.	
Diabetes,	2003.	52(10):	p.	2639-42.	
23.	 Hiby,	 S.E.,	 et	 al.,	 Combinations	 of	 maternal	 KIR	 and	 fetal	
HLA-C	 genes	 influence	 the	 risk	 of	 preeclampsia	 and	
reproductive	success.	J	Exp	Med,	2004.	200(8):	p.	957-65.	
24.	 Nakimuli,	 A.,	 et	 al.,	A	KIR	B	 centromeric	 region	 present	 in	
Africans	but	not	Europeans	protects	pregnant	women	from	
pre-eclampsia.	 Proc	Natl	Acad	 Sci	U	 S	A,	 2015.	112(3):	 p.	
845-50.	
25.	 Cooley,	 S.,	 et	 al.,	 Donor	 killer	 cell	 Ig-like	 receptor	 B	
haplotypes,	recipient	HLA-C1,	and	HLA-C	mismatch	enhance	
the	 clinical	 benefit	 of	 unrelated	 transplantation	 for	 acute	
myelogenous	leukemia.	J	Immunol,	2014.	192(10):	p.	4592-
600.	
26.	 Cooley,	 S.,	 et	 al.,	 Donor	 selection	 for	 natural	 killer	 cell	
receptor	 genes	 leads	 to	 superior	 survival	 after	 unrelated	
transplantation	 for	 acute	 myelogenous	 leukemia.	 Blood,	
2010.	116(14):	p.	2411-9.	
	 63	
27.	 Karre,	 K.,	 et	 al.,	 Selective	 rejection	 of	 H-2-deficient	
lymphoma	 variants	 suggests	 alternative	 immune	 defence	
strategy.	Nature,	1986.	319(6055):	p.	675-8.	
28.	 Anfossi,	 N.,	 et	 al.,	 Human	 NK	 cell	 education	 by	 inhibitory	
receptors	for	MHC	class	I.	Immunity,	2006.	25(2):	p.	331-42.	
29.	 Kim,	 S.,	 et	 al.,	HLA	 alleles	 determine	 differences	 in	 human	
natural	 killer	 cell	 responsiveness	 and	 potency.	 Proc	 Natl	
Acad	Sci	U	S	A,	2008.	105(8):	p.	3053-8.	
30.	 Yu,	 J.,	 et	 al.,	 Hierarchy	 of	 the	 human	 natural	 killer	 cell	
response	 is	 determined	 by	 class	 and	 quantity	 of	 inhibitory	
receptors	 for	 self-HLA-B	 and	 HLA-C	 ligands.	 J	 Immunol,	
2007.	179(9):	p.	5977-89.	
31.	 Ogasawara,	 K.,	 et	 al.,	 Function	 of	 NKG2D	 in	 natural	 killer	
cell-mediated	 rejection	 of	 mouse	 bone	 marrow	 grafts.	 Nat	
Immunol,	2005.	6(9):	p.	938-45.	
32.	 Oppenheim,	 D.E.,	 et	 al.,	 Sustained	 localized	 expression	 of	




their	 viral	 ligand	 during	 development.	 J	 Exp	 Med,	 2008.	
205(8):	p.	1819-28.	
34.	 Older	 Aguilar,	 A.M.,	 et	 al.,	 Coevolution	 of	 killer	 cell	 Ig-like	
receptors	 with	 HLA-C	 to	 become	 the	 major	 variable	
regulators	of	human	NK	cells.	 J	 Immunol.	185(7):	p.	4238-
51.	
35.	 Robinson,	 J.,	 et	 al.,	 IPD--the	 Immuno	 Polymorphism	
Database.	Nucleic	Acids	Res,	2013.	41(Database	 issue):	p.	
D1234-40.	




37.	 Uhrberg,	M.,	 P.	 Parham,	 and	 P.	Wernet,	Definition	of	gene	
content	 for	 nine	 common	 group	 B	 haplotypes	 of	 the	
Caucasoid	 population:	 KIR	 haplotypes	 contain	 between	
seven	and	eleven	KIR	genes.	 Immunogenetics,	2002.	54(4):	
p.	221-9.	
38.	 Stewart,	 C.A.,	 et	 al.,	 Recognition	 of	 peptide-MHC	 class	 I	
complexes	 by	 activating	 killer	 immunoglobulin-like	
receptors.	 Proc	 Natl	 Acad	 Sci	 U	 S	 A,	 2005.	 102(37):	 p.	
13224-9.	
	 64	








42.	 Kruse,	 P.H.,	 C.	 Rosner,	 and	 L.	 Walter,	 Characterization	 of	
rhesus	 macaque	 KIR	 genotypes	 and	 haplotypes.	
Immunogenetics,	2010.	62(5):	p.	281-93.	
43.	 LaBonte,	 M.L.,	 et	 al.,	 The	 KIR	 and	 CD94/NKG2	 families	 of	
molecules	in	the	rhesus	monkey.	Immunol	Rev,	2001.	183:	p.	
25-40.	
44.	 Abi-Rached,	 L.,	 et	 al.,	 Human-specific	 evolution	 and	




(KIR)	 genes:	 definition	 of	 an	 orangutan	 KIR	 haplotype	
reveals	 expansion	 of	 lineage	 III	 KIR	 associated	 with	 the	
emergence	of	MHC-C.	J	Immunol,	2007.	179(1):	p.	491-504.	
46.	 Boyington,	 J.C.,	 et	 al.,	 Crystal	 structure	 of	 an	 NK	 cell	






MHC	 and	 NK	 receptor	 genes.	 Immunity,	 2001.	 15(3):	 p.	
363-74.	
49.	 Wilson,	 M.J.,	 et	 al.,	 Plasticity	 in	 the	 organization	 and	
sequences	of	human	KIR/ILT	gene	 families.	 Proc	Natl	Acad	
Sci	U	S	A,	2000.	97(9):	p.	4778-83.	
50.	 Uhrberg,	M.,	 et	 al.,	Human	diversity	 in	killer	cell	 inhibitory	
receptor	genes.	Immunity,	1997.	7(6):	p.	753-63.	
51.	 Pyo,	 C.W.,	 et	 al.,	 Different	 patterns	 of	 evolution	 in	 the	
centromeric	 and	 telomeric	 regions	 of	 group	 A	 and	 B	
haplotypes	 of	 the	 human	 killer	 cell	 Ig-like	 receptor	 locus.	
PLoS	One,	2010.	5(12):	p.	e15115.	
52.	 Bari,	 R.,	 et	 al.,	 Significant	 functional	 heterogeneity	 among	
KIR2DL1	 alleles	 and	 a	 pivotal	 role	 of	 arginine	 245.	 Blood,	
2009.	114(25):	p.	5182-90.	
	 65	




54.	 Hilton,	 H.G.,	 et	 al.,	 Loss	 and	 Gain	 of	 Natural	 Killer	 Cell	
Receptor	 Function	 in	 an	 African	 Hunter-Gatherer	
Population.	PLoS	Genet,	2015.	11(8):	p.	e1005439.	




and	 their	 use	 in	 a	 multiplex	 HLA	 class	 I	 binding	 assay.	 J	
Immunol	Methods,	2015.	425:	p.	79-87.	
57.	 Hilton,	H.G.	and	P.	Parham,	Direct	binding	to	antigen-coated	
beads	 refines	 the	 specificity	 and	 cross-reactivity	 of	 four	
monoclonal	antibodies	that	recognize	polymorphic	epitopes	
of	HLA	 class	 I	molecules.	 Tissue	 Antigens,	 2013.	81(4):	 p.	
212-20.	




59.	 Biassoni,	 R.,	 et	 al.,	 Role	 of	 amino	 acid	 position	 70	 in	 the	
binding	 affinity	 of	 p50.1	 and	 p58.1	 receptors	 for	 HLA-Cw4	
molecules.	Eur	J	Immunol,	1997.	27(12):	p.	3095-9.	
60.	 Winter,	C.C.,	et	al.,	Direct	binding	and	functional	transfer	of	
NK	cell	 inhibitory	 receptors	 reveal	novel	patterns	of	HLA-C	
allotype	recognition.	J	Immunol,	1998.	161(2):	p.	571-7.	
61.	 Vilches,	 C.	 and	 P.	 Parham,	 KIR:	 diverse,	 rapidly	 evolving	
receptors	 of	 innate	 and	 adaptive	 immunity.	 Annu	 Rev	
Immunol,	2002.	20:	p.	217-51.	




and	 ligands	 than	 humans	 for	 inhibitory	 killer	 cell	 Ig-like	
receptor	recognition	of	the	MHC-C1	and	MHC-C2	epitopes.	 J	
Immunol,	2009.	182(6):	p.	3628-37.	
64.	 Graef,	 T.,	 et	 al.,	 KIR2DS4	 is	 a	 product	 of	 gene	 conversion	
with	 KIR3DL2	 that	 introduced	 specificity	 for	 HLA-A*11	





66.	 Pende,	D.,	 et	 al.,	The	natural	killer	cell	receptor	specific	for	
HLA-A	allotypes:	 a	 novel	member	 of	 the	 p58/p70	 family	 of	
inhibitory	 receptors	 that	 is	 characterized	 by	 three	
immunoglobulin-like	domains	and	 is	expressed	as	a	140-kD	
disulphide-linked	dimer.	 J	 Exp	Med,	 1996.	184(2):	 p.	 505-
18.	
67.	 Valiante,	 N.M.,	 et	 al.,	Functionally	 and	 structurally	 distinct	
NK	 cell	 receptor	 repertoires	 in	 the	peripheral	 blood	of	 two	
human	donors.	Immunity,	1997.	7(6):	p.	739-51.	
68.	 Yawata,	M.,	 et	 al.,	MHC	class	 I-specific	 inhibitory	 receptors	
and	 their	 ligands	 structure	 diverse	 human	 NK-cell	
repertoires	toward	a	balance	of	missing	self-response.	Blood,	
2008.	112(6):	p.	2369-80.	
69.	 Moesta,	 A.K.,	 et	 al.,	 Synergistic	 polymorphism	 at	 two	
positions	distal	to	the	ligand-binding	site	makes	KIR2DL2	a	





71.	 Sambrook,	 J.G.,	 et	 al.,	 Single	 haplotype	 analysis	
demonstrates	rapid	evolution	of	 the	killer	 immunoglobulin-
like	 receptor	 (KIR)	 loci	 in	 primates.	 Genome	 Res,	 2005.	
15(1):	p.	25-35.	
72.	 Henn,	 B.M.,	 et	 al.,	 Hunter-gatherer	 genomic	 diversity	
suggests	a	southern	African	origin	for	modern	humans.	Proc	
Natl	Acad	Sci	U	S	A,	2011.	108(13):	p.	5154-62.	




in	women	of	African	ancestry.	 Am	 J	 Obstet	 Gynecol,	 2014.	
210(6):	p.	510-520	e1.	
75.	 Norman,	P.J.,	et	al.,	Co-evolution	of	human	leukocyte	antigen	
(HLA)	 class	 I	 ligands	 with	 killer-cell	 immunoglobulin-like	
receptors	 (KIR)	 in	 a	 genetically	 diverse	 population	 of	 sub-
Saharan	Africans.	PLoS	Genet,	2013.	9(10):	p.	e1003938.	
76.	 Lachance,	J.,	et	al.,	Evolutionary	history	and	adaptation	from	
high-coverage	 whole-genome	 sequences	 of	 diverse	 African	
hunter-gatherers.	Cell,	2012.	150(3):	p.	457-69.	
77.	 Schuster,	 S.C.,	 et	 al.,	Complete	Khoisan	and	Bantu	genomes	
from	southern	Africa.	Nature,	2010.	463(7283):	p.	943-7.	
	 67	
78.	 Burshtyn,	 D.N.,	 et	 al.,	Recruitment	of	 tyrosine	phosphatase	






80.	 Thomas,	 R.,	 et	 al.,	 Novel	 KIR3DL1	 alleles	 and	 their	
expression	 levels	 on	 NK	 cells:	 convergent	 evolution	 of	
KIR3DL1	phenotype	variation?	J	Immunol,	2008.	180(10):	p.	
6743-50.	
81.	 VandenBussche,	 C.J.,	 et	 al.,	A	single	polymorphism	disrupts	
the	killer	Ig-like	receptor	2DL2/2DL3	D1	domain.	J	Immunol,	
2006.	177(8):	p.	5347-57.	
82.	 VandenBussche,	 C.J.,	 et	 al.,	 Dramatically	 reduced	 surface	
expression	 of	 NK	 cell	 receptor	 KIR2DS3	 is	 attributed	 to	
multiple	 residues	 throughout	 the	 molecule.	 Genes	 Immun,	
2009.	10(2):	p.	162-73.	
83.	 Apps,	 R.,	 et	 al.,	 Influence	 of	HLA-C	 expression	 level	 on	HIV	
control.	Science.	340(6128):	p.	87-91.	
84.	 Shilling,	 H.G.,	 et	 al.,	 Evidence	 for	 recombination	 as	 a	








C	 in	 a	 human	 population	 retaining	 minimal	 essential	
diversity	of	KIR	and	HLA	class	I	ligands.	Proc	Natl	Acad	Sci	U	
S	A,	2009.	106(44):	p.	18692-7.	
88.	 Hou,	 L.,	 et	 al.,	 African	 Americans	 exhibit	 a	 predominant	
allele	 in	 the	 midst	 of	 extensive	 KIR2DL1	 allelic	 diversity.	
Tissue	Antigens,	2010.	76(1):	p.	31-4.	
89.	 Hou,	 L.H.,	 et	 al.,	KIR2DL1	allelic	 diversity:	 four	new	alleles	
characterized	in	a	bone	marrow	transplant	population	and	
three	families.	Tissue	Antigens,	2007.	69(3):	p.	250-4.	
90.	 Middleton,	 D.,	 et	 al.,	 Killer	 immunoglobulin	 receptor	 gene	
and	 allele	 frequencies	 in	 Caucasoid,	 Oriental	 and	 Black	
populations	 from	 different	 continents.	 Tissue	 Antigens,	
2008.	71(2):	p.	105-13.	
91.	 Vierra-Green,	 C.,	 et	 al.,	 Allele-level	 haplotype	 frequencies	
and	 pairwise	 linkage	 disequilibrium	 for	 14	 KIR	 loci	 in	 506	
	 68	
European-American	 individuals.	 PLoS	One,	 2012.	7(11):	 p.	
e47491.	
92.	 Norman,	 P.J.,	 et	 al.,	Meiotic	 recombination	 generates	 rich	
diversity	 in	NK	 cell	 receptor	 genes,	 alleles,	 and	 haplotypes.	
Genome	Res,	2009.	19(5):	p.	757-69.	
93.	 Winter,	C.C.	and	E.O.	Long,	Binding	of	soluble	KIR-Fc	fusion	
proteins	 to	 HLA	 class	 I.	 Methods	 Mol	 Biol,	 2000.	 121:	 p.	
239-50.	
94.	 Hitchman,	 R.B.,	 R.D.	 Possee,	 and	 L.A.	 King,	 Baculovirus	
expression	 systems	 for	 recombinant	 protein	 production	 in	
insect	cells.	Recent	Pat	Biotechnol,	2009.	3(1):	p.	46-54.	
95.	 Victor,	 M.E.,	 et	 al.,	 Insect	 cells	 are	 superior	 to	 Escherichia	
coli	 in	 producing	 malaria	 proteins	 inducing	 IgG	 targeting	
PfEMP1	on	infected	erythrocytes.	Malar	J,	2010.	9:	p.	325.	
96.	 Kost,	T.A.	and	J.P.	Condreay,	Recombinant	baculoviruses	as	
expression	 vectors	 for	 insect	 and	 mammalian	 cells.	 Curr	
Opin	Biotechnol,	1999.	10(5):	p.	428-33.	
97.	 Pei,	 R.,	 et	 al.,	 Simultaneous	 HLA	 Class	 I	 and	 Class	 II	
antibodies	 screening	 with	 flow	 cytometry.	 Hum	 Immunol,	
1998.	59(5):	p.	313-22.	
98.	 Blissard,	 G.W.	 and	 G.F.	 Rohrmann,	 Location,	 sequence,	
transcriptional	 mapping,	 and	 temporal	 expression	 of	 the	
gp64	 envelope	 glycoprotein	 gene	 of	 the	 Orgyia	
pseudotsugata	 multicapsid	 nuclear	 polyhedrosis	 virus.	
Virology,	1989.	170(2):	p.	537-55.	
99.	 Goodridge,	 J.P.,	 et	 al.,	 HLA-F	 and	 MHC	 class	 I	 open	
conformers	 are	 ligands	 for	 NK	 cell	 Ig-like	 receptors.	 J	
Immunol,	2013.	191(7):	p.	3553-62.	










103.	 Brodsky,	 F.M.,	 et	 al.,	Monoclonal	 antibodies	 for	analysis	 of	
the	HLA	system.	Immunol	Rev,	1979.	47:	p.	3-61.	
104.	 Parham,	 P.	 and	 W.F.	 Bodmer,	 Monoclonal	 antibody	 to	 a	




properties	 of	 BB7.2.	 A	 cytotoxic	monoclonal	 antibody	 with	
specificity	 for	 HLA-A2	 and	 a	 variant	 of	 HLA-A28.	 Hum	
Immunol,	1981.	3(4):	p.	277-99.	











109.	 McMichael,	 A.J.,	 et	 al.,	 A	 monoclonal	 antibody	 that	
recognizes	an	antigenic	determinant	shared	by	HLA	A2	and	
B17.	Hum	Immunol,	1980.	1(2):	p.	121-9.	
110.	 Ways,	 J.P.	 and	 P.	 Parham,	 The	 binding	 of	 monoclonal	
antibodies	to	cell-surface	molecules.	A	quantitative	analysis	
with	 immunoglobulin	 G	 against	 two	 alloantigenic	
determinants	of	the	human	transplantation	antigen	HLA-A2.	
Biochem	J,	1983.	216(2):	p.	423-32.	
111.	 Shimizu,	 Y.,	 et	 al.,	 Transfer	 of	 cloned	 human	 class	 I	major	
histocompatibility	 complex	 genes	 into	 HLA	mutant	 human	
lymphoblastoid	cells.	Mol	Cell	Biol,	1986.	6(4):	p.	1074-87.	




platelet	 iso-antibodies.	 V.	 HL-A	 typing.	 Vox	 Sang,	 1970.	
18(1):	p.	12-20.	
114.	 Mizuno,	S.,	et	al.,	A	new	murine	lymphocytotoxic	monoclonal	
antibody	 recognizing	 HLA-A2,	 -A28	 and	 -A9.	 Tissue	
Antigens,	1996.	48(3):	p.	224-7.	
115.	 Hogan,	 K.T.	 and	 S.L.	 Brown,	 Localization	 and	
characterization	 of	 serologic	 epitopes	 on	 HLA-A2.	 Hum	
Immunol,	1992.	33(3):	p.	185-92.	
116.	 Salter,	 R.D.,	 et	 al.,	 In	 vitro	mutagenesis	 at	 a	 single	 residue	
introduces	B	and	T	cell	epitopes	into	a	class	I	HLA	molecule.	J	
Exp	Med,	1987.	166(1):	p.	283-8.	
117.	 Taketani,	 S.,	 et	 al.,	 Structural	 analysis	 of	 HLA-A2	 antigen	
from	immunoselected	mutant	8.6.1:	 further	definition	of	an	
	 70	
HLA-A2-specific	 serological	 determinant.	 J	 Immunol,	 1983.	
131(6):	p.	2935-8.	
118.	 Ellexson,	M.E.,	 et	 al.,	Nucleotide	 sequence	analysis	 of	HLA-
B*1523	and	B*8101.	Dominant	alpha-helical	motifs	produce	
complex	 serologic	 recognition	 patterns	 for	 the	 HLA-B"DT"	
and	HLA-B"NM5"	antigens.	Hum	Immunol,	1995.	44(2):	p.	
103-10.	
119.	 Vilches,	 C.,	 et	 al.,	 Molecular	 characterization	 of	 the	 new	
alleles	 HLA-B*8101	 and	 B*4407.	 Tissue	 Antigens,	 1996.	
47(2):	p.	139-42.	
120.	 Domenech,	N.,	 J.	 Santos-Aguado,	 and	 J.A.	Lopez	de	Castro,	





for	 anti-HLA	 antibodies.	 Hum	 Immunol,	 1992.	 35(2):	 p.	
125-31.	
122.	 Parham,	P.,	Antigenic	determinants	of	the	HLA-B7	molecule;	
Bw6-	 and	 B7-specific	 determinants	 are	 spatially	 separate.	
Immunogenetics,	1983.	18(1):	p.	1-16.	
123.	 Toubert,	A.,	et	al.,	Epitope	mapping	of	HLA-B27	and	HLA-B7	
antigens	 by	 using	 intradomain	 recombinants.	 J	 Immunol,	
1988.	141(7):	p.	2503-9.	
124.	 Wan,	A.M.,	et	al.,	The	primary	structure	of	HLA-A32	suggests	







127.	 Sibilio,	 L.,	 et	 al.,	 Impaired	 assembly	 results	 in	 the	
accumulation	 of	 multiple	 HLA-C	 heavy	 chain	 folding	
intermediates.	J	Immunol,	2005.	175(10):	p.	6651-8.	
128.	 Gleimer,	M.	and	P.	Parham,	Stress	management:	MHC	class	I	







The Journal of Immunology
Mutation at Positively Selected Positions in the Binding Site
for HLA-C Shows That KIR2DL1 Is a More Refined but Less
Adaptable NK Cell Receptor Than KIR2DL3
Hugo G. Hilton,*,†,1 Luca Vago,*,†,‡,1 Anastazia M. Older Aguilar,*,† Achim K. Moesta,*,†
Thorsten Graef,*,† Laurent Abi-Rached,*,† Paul J. Norman,*,† Lisbeth A. Guethlein,*,†
Katharina Fleischhauer,x and Peter Parham*,†
Through recognition of HLA class I, killer cell Ig-like receptors (KIR) modulate NK cell functions in human immunity and re-
production. Although a minority of HLA-A and -B allotypes are KIR ligands, HLA-C allotypes dominate this regulation, because
they all carry either the C1 epitope recognized by KIR2DL2/3 or the C2 epitope recognized by KIR2DL1. The C1 epitope and C1-
specific KIR evolved first, followed several million years later by the C2 epitope and C2-specific KIR. Strong, varying selection
pressure on NK cell functions drove the diversification and divergence of hominid KIR, with six positions in the HLA class I binding
site of KIR being targets for positive diversifying selection. Introducing each naturally occurring residue at these positions into
KIR2DL1 and KIR2DL3 produced 38 point mutants that were tested for binding to 95 HLA- A, -B, and -C allotypes. Modulating
specificity for HLA-C is position 44, whereas positions 71 and 131 control cross-reactivity with HLA-A*11:02. Dominating avidity
modulation is position 70, with lesser contributions from positions 68 and 182. KIR2DL3 has lower avidity and broader specificity
than KIR2DL1. Mutation could increase the avidity and change the specificity of KIR2DL3, whereas KIR2DL1 specificity was
resistant to mutation, and its avidity could only be lowered. The contrasting inflexibility of KIR2DL1 and adaptability of
KIR2DL3 fit with C2-specific KIR having evolved from C1-specific KIR, and not vice versa. Substitutions restricted to activating
KIR all reduced the avidity of KIR2DL1 and KIR2DL3, further evidence that activating KIR function often becomes subject to
selective attenuation. The Journal of Immunology, 2012, 189: 1418–1430.
M
ajor histocompatibility complex class I molecules
function as ligands for a variety of activating and in-
hibitory receptors expressed by NK cells and CD8
T cells (1–4). In the human MHC, the HLA complex, six genes
encode MHC class I molecules: HLA-A, -B, -C, -E, -F, and -G;
all, with the exception of HLA-F, are known to interact with NK
cell receptors. Of these, HLA-E is the oldest and most conserved;
it binds a restricted set of peptides that is largely derived from the
leader sequences of other HLA class I molecules and is the ligand
for conserved CD94:NKG2 lectin-like receptors (5, 6).
In contrast, HLA-A, -B, -C, and -G bind diverse peptides and
furnish ligands for diverse and polymorphic killer cell Ig-like
receptors (KIR). This family of variable NK cell receptors is of
very recent origin, being restricted to the simian primates: mon-
keys, apes, and humans (7, 8). HLA-G, the ligand for KIR2DL4, is
expressed only by extravillous trophoblast (EVT) and is impli-
cated in the interactions between EVT and uterine NK cells, which
are critical for placentation and successful reproduction (9–11).
HLA-A, -B, and -C are highly polymorphic and function as
ligands for both KIR and the ab TCR of CD8 T cells. Of these
three, HLA-C is the most recently evolved and the only one for
which all of the variant forms (allotypes) are ligands for KIR (12–
14). Dimorphism at position 80 in HLA-C defines two epitopes,
C1 (asparagine 80) and C2 (lysine 80), which are ligands for
different forms of KIR (15). In contrast, only approximately one
third of the HLA-A and HLA-B allotypes has the capacity to in-
teract with KIR (8). Such comparisons indicate that HLA-C,
which arose from an HLA-B–like ancestor (16), diverged under
selection to become a specialized and dominant source of ligands
for KIR. That HLA-C but not HLA-A or -B is expressed by EVT,
and uterine NK cells selectively express KIR that recognize HLA-
C, further argues that selection pressure from reproduction con-
tributed to the evolution of HLA-C (17, 18).
The C2 epitope, carried by the subset of HLA-C allotypes having
lysine 80, is recognized by the inhibitory receptor KIR2DL1 and
the activating receptor KIR2DS1. The signaling domains of these
two receptors are divergent, but their Ig-like domains, which form
the ligand binding site, have high sequence similarity. The C1
epitope, carried by the subset of HLA-C allotypes having aspar-
agine 80, and two unusual HLA-B allotypes (HLA-B*46:01 and
HLA-B*73:01) are recognized by the inhibitory receptor
KIR2DL2/3 (19–21). Corresponding to the dimorphism at position
80 in HLA-C is a dimorphism at position 44 in the D1 domain of
the KIR that determines the receptors’ specificities. Thus, C2-
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specific KIR2DL1 and KIR2DS1 have methionine 44, whereas
C1-specific KIR2DL2/3 has lysine 44. That mutation at this po-
sition was demonstrated to be sufficient to swap the receptors’
specificities led to position 44 being described as the specificity-
determining residue (22, 23). Functional studies and clinical
correlations point to the C1 and C2 epitopes of HLA-C being the
dominant ligands for KIR (24–26). And because C1 and C2 are
alternatives, all human individuals have at least one of these
epitopes and some have both of them; this is not the case for the
A*03/11 epitope of HLA-A recognized by KIR3DL2 (27, 28) or
the Bw4 epitope of HLA-A and -B recognized by KIR3DL1 (29,
30). The KIR that recognize epitopes of HLA-A and -B form
a phylogenetic lineage (lineage II KIR) that is distinguished from
the lineage III KIR to which the HLA-C receptors belong (31).
Comparison of primate species shows how KIR coevolve with
their cognate MHC class I ligands. Old World monkeys haveMHC
class I genes resembling HLA-A and -B but no equivalent to HLA-
C. Correspondingly, in these species there are multiple lineage II
KIR genes but only one lineage III KIR (32–37). An equivalent to
HLA-C is present only in the hominids (great apes and humans)
and exists in a more primitive state in the orangutan MHC where
the gene is not fixed, as it is in human and chimpanzee MHCs, and
all of the allotypic variants carry the C1 epitope (12, 13). None-
theless, there are multiple lineage III KIR in the orangutan but
only one lineage II KIR, indicating the functional impact of the
emergence of MHC-C and its cognate lineage III KIR.
By the time of the last common ancestor of humans and
chimpanzees, the C2 epitope and its interaction with lineage III
KIR had evolved from the C1 epitope and its cognate receptors. The
chimpanzee maintains a diverse array of nine lineage III KIR that
recognize the C1 and C2 epitopes with good avidity, which includes
both inhibitory and activating KIR (7). In contrast, of the seven
human lineage III KIR, only four bind to HLA-C, and the other
three have no demonstrable binding to any HLA class I allotype
(38, 39). These comparisons show how the selection pressures
acting upon the interactions of lineage III KIR with human HLA-
C, and its MHC-C counterparts in other species, have been re-
markably variable throughout hominid evolution.
To investigate the effects of natural selection on hominid lineage
III KIR, we identified sites of positive diversifying selection within
the ligand binding site and assessed the functional effects of this
variation by mutagenesis directed at these sites in human C2-
specific KIR2DL1 and C1-specific KIR2DL2/3. For KIR2DL1,
the 2DL1*003 allele was chosen as the target for mutagenesis,
because it is the most common allele in many human populations.
KIR2DL2/3 has two distinctive allelic lineages: KIR2DL2 and
KIR2DL3. We chose 2DL3*001, the most frequent KIR2DL3 allele,
as the target for mutagenesis because KIR2DL2 is a recombi-
nant form (with greater sequence similarity to KIR2DL3 in the Ig-
like domains and to KIR2DL1 in the stem, trans-membrane, and
cytoplasmic regions) that, in functional assays, recognizes both C1
and C2, whereas KIR2DL3 appears functionally specific for C1,
although it exhibits some cross-reactivity with C2-bearing allo-
types in direct-binding assays (21). The disadvantage to choosing
KIR2DL3 over KIR2DL2 is the availability of a crystallographic
structure only for KIR2DL2 bound to HLA-C (40) but not for
KIR2DL3 bound to HLA-C.
Materials and Methods
Cell lines
The human cell line NKL was maintained as described (41). The G4-NKL
cell line was derived from NKL by specific small interfering RNA (siRNA)
knockdown of LILRB1 expression using the pSIREN-RetroQ vector
(Clontech, Mountain View, CA) (42). Transduction of NKL and G4-NKL
with wild-type (wt) and mutant KIR was performed as described (13), with
minor modifications. The full-length KIR-coding region was cloned into
the pIB2 expression vector (kindly provided by Dr. Mark Davis, Stanford
University) and transduced into Phi-NX cells (kindly provided by Dr.
Garry Nolan, Stanford University) to generate recombinant amphotrophic
retrovirus, which was then used to infect NKL cells. After 2 wk of in-
fection, the NKL cells were FACS purified using KIR-specific mAbs. After
such selection, .95% of the cells expressed KIR. Transduced cells were
periodically checked for surface expression of KIR using specific mAbs.
Transduced NKL cells express GFP driven by an internal ribosome entry
site from the same promoter as the KIR. This allowed cells transduced with
different KIR to be sorted by FACS for equivalent GFP expression. Sub-
sequently, the sorted transductants were analyzed for KIR expression using
several KIR-specific mAbs that interact with lineage III KIR (EB-6, CH-L,
anti-2DS4, and NKVFS1) (BD Biosciences, San Jose, CA). Among these,
the reactivity of NKVFS1, which has a very broad reactivity for lineage III
KIR from all hominid species, was particularly constant and allowed us to
select cells with similar levels of KIR expression for use in functional
assays (13, 21, 38, 39).
The HLA-A, HLA-B, and HLA-C–deficient cell-line 721.221 (subse-
quently referred to as 221 cells) was transfected with individual HLA class
I alleles that had been mutated in the leader peptide so that, on binding to
HLA-E, the derived peptides do not permit interaction with CD94:NKG2A
(43). Lacking transporter-associated proteins, the T2 human cell line has
a reduced amount of HLA-A*02 on the cell surface and no detectable
amount of the other endogenous HLA class I allotypes (44). Permanent
transduction of T2 with HLA-A*11:02 was achieved using the Amaxa
Nucleofector Kit (Lonza, Cologne, Germany), according to the manu-
facturer’s instructions. After transduction and 2 wk of growth in selective
medium, T2 HLA-A*11:02 cells were pulsed with the A*11-specific
peptide RLRAEAQVK, and cells with high expression of HLA-A*11 were
FACS purified using mAb specific for HLA-A*11 (One Lambda, Canoga
Park, CA). The new nomenclature for HLA class I is used throughout this
article (45).
T2 cell incubation with synthetic peptides
The HLA-A*11–restricted RLRAEAQVK peptide from EBV and the
HLA-A*02–restricted NLVPMVATV peptide from CMV were purchased
from Synthetic Biomolecules (San Diego, CA). A total of 106 T2 cells was
incubated overnight in 500 ml serum-free medium with peptide at a final
concentration of 100 mM. To assess cell surface expression of HLA-
A*11:02 by peptide-pulsed cells, the cells were first incubated with uncon-
jugated monoclonal anti–HLA-A*11 Ab (reconstituted in 100 ml distilled
water; 2 ml used per test) (One Lambda), followed by goat anti-mouse
FITC-conjugated secondary Ab (10 mg/ml; Southern Biotech, Birmingham,
AL), and then analyzed by flow cytometry.
Assay of NK cell cytotoxicity
NKL-mediated cell lysis was assessed in the standard 4-h chromium-release
assay, as described (21). Effector cells were incubated with 51Cr-labeled
target cells at various E:T ratios. For Ab-inhibition experiments, 51Cr-
labeled 221-A*11:02 target cells (106) were incubated for 30 min at
37˚C in 10 ml undiluted anti–HLA-A*11 mAb (One Lambda) and then
washed two times before incubation with effector cells. Following 4 h of
incubation at 37˚C, cell supernatants were harvested, and [51Cr] content
was quantified using a Wallac gamma counter (Turku, Finland). Specific
lysis was calculated using the formula (specific release 2 spontaneous
release)/(total release 2 spontaneous release). Each set of conditions was
performed in triplicate; each experiment was independently replicated
three or more times.
Generation of KIR-Fc fusion proteins
Wt and mutant KIR-Fc fusion proteins were generated according to pub-
lished protocols (21, 46). The insect cell lines Sf9 and Hi5 (kindly provided
by Dr. K. Chris Garcia, Stanford University) were cultured as described
(47). Regions encoding the Ig-like domains and the stem of KIR2DL1*003
and KIR2DL3*001 were fused with the region encoding the Fc portion of
the human IgG1 H chain. Site-directed mutagenesis was performed with
the QuikChange Kit (Stratagene, La Jolla, CA), according to the manu-
facturer’s instructions. The chimeric constructs were transferred into the
pACgp67 vector and cotransfected into Sf9 cells with linearized baculo-
virus (BD Biosciences), using Cellfectin (Invitrogen, Carlsbad, CA). After
two rounds of amplification, high-titer virus was used to infect Hi5 cells
for 72 h. Cell supernatant was then collected, filtered, and neutralized with
HEPES-buffered saline. After overnight incubation with protein A con-
jugated to Sepharose beads (Invitrogen), the beads were washed with PBS,
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and the KIR-Fc fusion proteins were then eluted from the beads with 0.1 M
glycine (pH 2.7) and immediately neutralized using 0.2 M Tris-base (pH
9).
Binding assay of KIR-Fc fusion proteins to beads coated with
HLA class I
KIR-Fc fusion proteins were tested for binding to a panel of microbeads,
with each bead coated with one of 95 HLA class I allotypes: 29 HLA-A,
50 HLA-B, and 16 HLA-C (LABScreen Single-Antigen Bead Sets; One
Lambda). These beads were originally developed for studying the speci-
ficity of human alloantibodies (48, 49) and were subsequently adapted by
our group for the study of KIR specificity (21). The HLA class I proteins
that coat the beads are purified from EBV-transformed B cell lines and,
therefore, are highly heterogeneous with regard to bound peptide.
KIR-Fc fusion proteins, at a concentration of 100 mg/ml, were incubated
with LABScreen microbeads for 60 min at 4˚C on a shaker. After three
washes, secondary staining with anti-human Fc-PE (One Lambda) was
performed for 60 min. Samples were then analyzed on a Luminex 100
reader (Luminex, Austin, TX). Independently, the beads were incubated
with W6/32 (50 mg/ml) an anti-HLA class I Ab that recognizes an epitope
shared by HLA-A, -B, and -C variants (50), which showed strong binding
to all 95 microbeads, and with limited variability (,20%) in the amount
bound. To take into account differences in the amount of HLA class I
protein coating each bead, the binding obtained with KIR was normalized
to the binding obtained with W6/32. Thus, the binding avidities for KIR-Fc
were expressed as relative fluorescence ratios and calculated using the
formula (specific binding 2 bead background fluorescence)/(W6/32
binding 2 bead background fluorescence) to normalize KIR-Fc binding
to the amount of HLA class I on each bead type. Comparison of the
specificity and avidity of W6/32 for HLA class I with other monoclonal
anti-HLA class I Ab, particularly the anti–b2-microglobulin Ab BBM1
(51) that recognizes an epitope away from the polymorphic HLA class I H
chain and involving arginine 45 of b2-microglobulin (52), is consistent
with W6/32 recognizing an epitope shared by all HLA-A, -B, and -C
allotypes (53, 54).
Results
Six positively selected residues in the HLA binding site of
lineage III KIR
KIR of phylogenetic lineage III, which includes all of the KIR that
recognize HLA-C, comprises three inhibitory receptors (KIR2DL1,
2, and 3) and five activating receptors (KIR2DS1, 2, 3, 4, and 5). In
addition to sequence variation among the different receptors, all of
them exhibit allelic polymorphism, but to a varying degree (http://
www.ebi.ac.uk/ipd/kir/). To identify sites of sequence variation
that have been subject to natural selection, we previously per-
formed maximum-likelihood analysis on the aligned sequences of
110 lineage III KIR from humans and apes (7). Positive diversi-
fying selection was evident at 16 sites in the extracellular, ligand-
binding domains of the KIR molecule: positions 6, 13, 16, 44, 50,
68, 70, 71, 84, and 90 in the D1 domain and positions 119, 123,
131, 148, 182, and 190 in the D2 domain. Examination of the
crystallographic structures of HLA-C bound to KIR2DL (40, 55)
showed that six of the positively selected residues lay within
regions that directly contact HLA class I (Fig. 1A, 1B): positions
44, 68, 70, and 71 in the D1 domain (Fig. 1C) and positions 131
and 182 in the D2 domain. Therefore, these positions were chosen
for further study.
For these six positions, sequence variability is notably higher in
the D1 domain than in the D2 domain, both in the number of
positively selected positions and the number of alternative residues
at each position (Fig. 2). Nonetheless, there is a variety of residues
with distinctive chemistry and functional potential at all six
positions. Lysine 44, proline 68, arginine 131, and arginine 182
are the only residues present in all five hominoid species exam-
ined, consistent with them having been present in the common
hominoid ancestor. Greater variability and species specificity are
observed for positions 70 and 71. Position 70 stands out for its
diversification in humans but relative conservation in other spe-
cies, whereas position 71 is more variable in chimpanzees and
gorillas than in humans, particularly for the inhibitory KIR (Fig.
2). Given these properties, we hypothesized that variation at these
six positions had been selected for its direct effect on the func-
tional interactions of hominoid lineage III KIR with MHC class I.
To test this hypothesis, we introduced all naturally occurring
variations at the six positions (Fig. 2) into human C2-specific
KIR2DL1 and C1-specific KIR2DL3 and then determined the
effects of these mutations on KIR specificity and avidity for HLA
class I.
Fc fusion proteins were made from the mutant and wt KIR and
tested for binding to 95 HLA class I allotypes using a robust,
sensitive assay in which the targets are microbeads, each coated
with a single HLA class I allotype (13, 21, 39, 42, 56). Being
purified from EBV-transformed B cell lines, each single HLA
class I allotype is highly diverse with regard to the sequence of the
bound peptide (48).
Variation at position 44 modulates specificity and strength of
KIR recognition of MHC-C
Consistent with previous studies (22, 23), we find that swapping
the position 44 residues of KIR2DL1 and KIR2DL3 is sufficient to
swap their HLA class I specificities. Thus, the 2DL3-44M mutant
has C2 specificity like KIR2DL1 (Fig. 3A), and the 2DL1-44K
mutant has C1 specificity like KIR2DL3 (Fig. 3B). Two excep-
tional HLA-B allotypes, B*46:01 and HLA-B*73:01, also carry
the C1 epitope (21, 57) and bind well to both KIR2DL3 and
mutant 2DL1-44K (Fig. 3C). It is on the basis of data such as these
that position 44 has been described as the specificity-determining
position of the lineage III KIR (22, 23).
On average, the binding of KIR2DL1 to C2 (Fig. 3A) was ap-
proximately twice that of KIR2DL3 to C1 (Fig. 3B), indicating
that KIR2DL1 is a stronger receptor than KIR2DL3. That mutant
2DL1-44K bound C1 at a much higher level (180%) than
KIR2DL3 (Fig. 3B) confirms that 2DL1 is an inherently stronger
receptor, as well as demonstrating that substitutions other than the
lysine–methionine dimorphism at position 44 contribute to the
avidity difference. However, the observation that mutant 2DL3-
44M binds C2 almost as well (85%) as KIR2DL1 shows clearly
that methionine 44 must also contribute to KIR2DL1 having
higher avidity than KIR2DL3 (Fig. 3A). Consistent with this
proposition, the mean binding of mutant 2DL1-K44 to C1 is 83%
of that achieved by 2DL1 to C2, a comparison in which the only
difference between the two KIR-Fc is at position 44 (Fig. 3).
Likewise, the mean binding of 2DL3 to C1 (not including the
poorly reactive HLA-C*12:03 and HLA-C*14:02) is 69% of that
achieved by 2DL3-M44 binding to C2 (Fig. 3). These comparisons
show that methionine 44 produces a stronger avidity than does
lysine 44, consistent with the qualitatively different bonding pat-
terns observed between KIR residue 44 and HLA-C residue 80
in the crystallographic structures of complexes of KIR2D and
HLA-C (40, 55, 58).
Threonine 44 is naturally present in KIR2DS3 and KIR2DS5
(Fig. 1A), activating receptors exhibiting no detectable avidity for
any HLA class I allotype when tested in the same binding assay as
that used in this study (39). In contrast, KIR2DL1 and KIR2DL3
mutants with threonine 44 recognize some HLA-C allotypes.
Replacement of lysine 44 by threonine in KIR2DL3 (mutant
2DL3-44T) abrogated binding to C1, with the exception of
C*16:01, which retained ∼50% of binding (Fig. 3B). Accompa-
nying the loss of C1 reactivity was acquisition of C2 specificity by
2DL3-44T, but with much lower avidity than KIR2DL1 or 2DL3-
44M (Fig. 3A). The 2DL1-44T mutant retained the C2 specificity
of KIR2DL1 but with avidity reduced by ∼50%. The avidity of
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2DL1-44T for C2 was greater than that of 2DL3-44T, the same
hierarchy as observed for the 2DL1 and 2DL3 mutants with me-
thionine and lysine at position 44. Moreover, the avidity of 2DL1-
44T for C2 (Fig. 3A) is comparable to that of 2DL3 for C1 (Fig.
3B), well within the functional range of inhibitory NK cell
receptors. Thus, human lineage III KIR with threonine 44 have the
potential to be C2-specific receptors, suggesting that KIR2DS3
and KIR2DS5, for which ligands remain unknown (39, 59, 60),
FIGURE 1. Six positively-selected residues
in the binding site of hominoid lineage III KIR.
(A) Alignment of partial amino acid sequences
of hominoid lineage III KIR showing the loops
of the D1 and D2 domains that contact HLA-C.
Sequences were aligned to 2DL1*003, with
identities indicated by dashes (-). The six pos-
itively selected residues in the binding site for
HLA class I are highlighted in yellow. (B)
Ribbon diagram of KIR2DL1 (gray) bound to
HLA-C*04:01 (green) (PDB1IM9) (55). The
loops of the KIR molecule that contact HLA
ligands are blue, and positively selected resi-
dues are yellow, as in (A). (C) Details of the
binding between the D1 domain contact loop of
KIR2DL1*003 (in blue with positively selected
residues in yellow) and the a1 domain helix of
HLA-C*04:01 (green).
FIGURE 2. Sequence variation in human
and ape lineage III KIR at each of the six
positively selected positions located within the
binding site for MHC-C. For each of the six
positions (44, 68, 70, 71, 131, and 182), the
variety of residues is shown. For each species,
the presence of a given residue in their KIR is
indicated by a gray-shaded box; a box with
a dash (–) denotes its presence in inhibitory
KIR, and a box with a plus sign (+) denotes its
presence in activating KIR.
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evolved from activating C2 receptors that lost the capacity to bind
HLA class I through selected substitutions at positions other than
44. That threonine 44 is present only in human lineage III KIR
suggests that these receptors both arose and became attenuated
during the course of human evolution.
Although orangutan, gorilla, and chimpanzee have KIR with
glutamate 44, such KIR were lost during human evolution (Fig. 2).
Mutant 2DL1-44E retained the C2 specificity of KIR2DL1 but
with 36% loss of avidity (Fig. 3A), properties similar to those of
chimpanzee KIR2DL9 that has glutamate 44 (38). In contrast,
mutant 2DL3-44E acquired reactivity with C2, while retaining
87% of the avidity for C1. Consequently, 2DL3-44E binds with
comparable avidity to C1 and C2, thus having pan specificity
for HLA-C (Fig. 3A, 3B). This C1+C2 specificity of 2DL3-44E
is very similar to that of Popy-2DLB and Popy-2DSB, paired
inhibitory and activating orangutan KIR that have glutamate
44 (13). The only difference between 2DL3-44E and the orang-
utan KIR is in the recognition of the two C1-bearing HLA-B
allotypes; the orangutan KIR recognize both HLA-B*46:01
and HLA-B*73:01, whereas 2DL3-44E recognizes only HLA-
B*46:01 (Fig. 3C).
Variation at positions 68, 70, and 182 modulates the avidity of
KIR2DL for MHC-C
Substitution at position 68 did not perturb the specificities of
KIR2DL1 and KIR2DL3 for HLA-C, but it did affect their avidities
for HLA-C. Mutation of arginine 68 in KIR2DL1 to histidine or
proline (the residue present in KIR2DL3) had little effect, but
mutation to leucine reduced the avidity by 34% while preserving
C2 specificity (Fig. 4A). For KIR2DL3, mutation of proline 68
to histidine, leucine, or arginine reduced the avidity for C1 by
19–40% (mean, 27%), while preserving C1 specificity (Fig. 4B).
Thus, KIR2DL3 is seen to be more sensitive than KIR2DL1 to
substitution at position 68.
Substitutions at position 70 had no effect on either the C2
specificity of KIR2DL1 or the C1 specificity of KIR2DL3, but they
altered their avidities to a greater extent than seen for the position
68 mutations. Substitution of threonine 70 in KIR2DL1 to lysine,
methionine, or arginine reduced the avidity by 43–66%, with the
greatest effect seen with methionine, the residue present at posi-
tion 70 in KIR2DL3 (Fig. 4C). In contrast, substitution of me-
thionine 70 in KIR2DL3 with arginine or threonine (the residue
present in KIR2DL1) gave a modest increase (16–38%) in the
avidity for C1, whereas the lysine substitution reduced the avidity
by 48% (Fig. 4D). The results obtained for the position 70 swap
mutants indicate that the threonine–methionine difference at po-
sition 70 is a major factor contributing to the higher avidity of
KIR2DL1 and lower avidity of KIR2DL3.
Substitution of histidine 182 in KIR2DL1 for arginine (the
residue in KIR2DL3) had no effect, whereas substitution for
cysteine reduced the avidity for C2 by 50% (Fig. 4E). The effect of
the cysteine substitution in KIR2DL3 was even greater. When
arginine 182 of KIR2DL3 was replaced by cysteine, the avidity for
C1 was reduced by 87%, whereas the introduction of histidine had
only a modest effect (10% reduction) (Fig. 4F). A common
property of the mutations at positions 68, 70, and 182 is that they
affect the avidity, but not the specificity, of the receptors. For
KIR2DL1, these mutations led only to retention or reduction of
avidity for C2, whereas for KIR2DL3, they could also lead to
increased avidity for C1. Comparison of the properties of the swap
mutations between 2DL1 and 2DL3 at positions 68, 70, and 182
indicates that the difference at position 70 contributes significantly
to the differential avidity of the two receptors, whereas the effects
of the reciprocal substitutions at positions 68 and 182 are weaker
and less clear cut.
Position 71 and 131 variation can alter avidity for HLA-C and
introduce recognition of HLA-A*11:02
Both KIR2DL1 and KIR2DL3 have glutamine 71. In KIR2DL1, its
substitution with glutamate, histidine, and proline had little effect
on the specificity or avidity for C2. In contrast, the 2DL1-71R
FIGURE 3. The residue at position 44 determines the HLA-C specificity
of lineage III KIR. Shown are the results of assays to measure the binding
of wt and mutant KIR2DL1-Fc and KIR2DL3-Fc fusion proteins to beads
coated with a representative range of HLA-A, -B, and -C allotypes.
Mutations were restricted to position 44 where KIR2DL1 has methionine
and KIR2DL3 has lysine. Fusion proteins tested were 2DL1 (d), 2DL3-
44M (N), 2DL1-44T (¤), 2DL3-44T ()), 2DL1-44E (:), 2DL3-44E (4),
2DL1-44K (n), and 2DL3-WT (s). Shown are representative results from
7 C2-bearing HLA-C allotypes (A), 9 C1-bearing HLA-C allotypes (B),
and 29 HLA-A and 50 HLA-B allotypes (C). The mean value for each
allotype group is denoted by a horizontal line. Allotypes showing unusual
patterns of binding are indicated by their official names (45).
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mutant exhibited a general reduction of avidity, while preserving
C2 specificity (Fig. 5A). For HLA-C*04:01, the avidity was di-
minished by 88%; for other C2-bearing allotypes, the reduction
was 38% (Fig. 5A). For the 2DL1-71K mutant, this selective trend
was more extreme: binding to HLA-C*04:01 was reduced by
82%, whereas the binding to other C2-bearing allotypes was un-
perturbed.
Replacing glutamine 71 in KIR2DL3 with either glutamate or
histidine had little effect on C1 specificity or avidity. In contrast,
lysine 71 abrogated the interaction of KIR2DL3 with C1, and
arginine 71 reduced the mean avidity for C1 by 64% while in-
creasing the avidity for C1-bearing HLA-C*12:03 (Fig. 5B).
Proline 71 caused a modest decrease in the avidity for C1 (25%),
but it broadened the specificity of mutant 2DL3-71P to include
FIGURE 4. The avidity of KIR2D for MHC-C has
been modulated by positive selection at positions 68,
70, and 182. Shown is the binding of wt and mutant
KIR2DL-Fc fusion proteins to beads coated with 16
HLA-C allotypes: 9 having the C1 epitope (HLA-C1)
and 7 having the C2 epitope (HLA-C2). Binding to
each HLA-C allotype is given (left panels), as well as
mean values for the HLA-C1 and HLA-C2 allotype
groups (middle and right panels). (A) Mutation at po-
sition 68 of KIR2DL1: 2DL1-68H, 2DL1-68L, 2DL1-
68R (wt), and 2DL1-68P. (B) Mutation at position
68 of KIR2DL3: 2DL3-68H, 2DL3-68L, 2DL3-68R,
and 2DL3-68P (wt). (C) Mutation at position 70 of
KIR2DL1: 2DL1-70K, 2DL1-70M, 2DL1-70R, and
2DL1-70T (wt). (D) Mutation at position 182 of
KIR2DL3: 2DL3-70K, 2DL3-70M (wt), 2DL3-70R,
and 2DL3-70T. (E) Mutation at position 182 of
KIR2DL1: 2DL1-182C, 2DL1-182H (wt), and 2DL1-
182R. (F) Mutation at position 182 of KIR2DL3:
2DL3-182C, 2DL3-182H, and 2DL3-182R (wt). HLA-
C*12:03 and C*14:02 routinely bind weakly compared
to other C1-bearing allotypes.
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HLA-A*11:02 (Fig. 5B). KIR2DS4 is an activating lineage III
KIR that naturally has proline 71 and exhibits similar reactivity
with HLA-A*11:02 (42). However, proline 71 is not necessary for
recognition of HLA-A*11:02, as became apparent from analysis
of the position 131 mutants (Fig. 5C, 5D). Substitution of arginine
131 in KIR2DL3 with glutamine introduced reactivity with HLA-
A*11:02 while preserving avidity for C1-bearing HLA-C (Fig.
5D). In contrast, substitution of arginine 131 for tryptophan
caused 86% loss of avidity for C1 but no binding to HLA-
A*11:02. For KIR2DL1, replacement of arginine 131 by gluta-
mine preserved the avidity and specificity for C2, with no ac-
quisition of reactivity toward HLA-A*11:02, whereas replacement
FIGURE 5. Positive selection at positions 71 and 131 of KIR2D can introduce reactivity with HLA-A*11:02 and alter avidity for HLA-C. Shown is the
binding of wt and mutant KIR2D-Fc fusion proteins to beads coated with HLA-C (nine HLA-C1 and seven HLA-C2) and A*11:02 allotypes. (A) Mutation
at position 71 of KIR2DL1: 2DL1-71E, 2DL1-71H, 2DL1-71K, 2DL1-71P, 2DL1-71Q (wt), and 2DL1-71R. (B) Mutation at position 71 of KIR2DL3:
2DL3-71E, 2DL3-71H, 2DL3-71K, 2DL3-71P, 2DL3-71Q (wt), and 2DL3-71R. (C) Mutation at position 131 of KIR2DL1: 2DL1-131Q, 2DL1-131R (wt),
and 2DL1-131W. (D) Mutation at position 131 of KIR2DL3: 2DL3-131Q, 2DL1-131R (wt), and 2DL1-131W. HLA-C*12:03 and C*14:02 routinely bind
weakly compared with other C1-bearing allotypes.
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with tryptophan preserved a pure C2 specificity but reduced
avidity by 40% (Fig. 5C).
In structural and functional studies of KIR interaction with HLA-
C, it has been common practice to use HLA-C*04:01 as the
prototypical C2-bearing allotype (23, 55, 61). Because the selec-
tive loss of HLA-C*04:01 reactivity by the 2DL1-71K and 2DL1-
71R (Fig. 5A) implies that HLA-C*04:01 has unusual properties,
we investigated the capacity of 2DL1-71K to recognize HLA-
C*04:01 in a functional assay of NK cell killing (Fig. 6). NKL
cells transduced with 2DL1, 2DL1-71K, 2DL3, and 2DL3-71K
lysed untransfected 221 cells effectively and to a similar degree
(Fig. 6B). KIR-Fc fusion constructs made from 2DL1, 2DL1-71K,
2DL3, and 2DL3-71K bound to transfected 221 cells expressing
HLA-C*03:04 (C1) and HLA-C*04:01 (C2) with similar specif-
icities and avidities to those obtained in the bead-binding assay.
Thus, KIR2DL3 bound to 221-C*03:04 (Fig. 6C) but not to 221-
C*04:01 (Fig. 6D), whereas KIR2DL1 bound to 221-C*04:01
(Fig. 6D) but not 221-C*03:04 (Fig. 6C). No binding of 2DL3-
71K was detected on either target cell, whereas 2DL1-71K bound
weakly, but specifically, to 221-C*04:01 (Fig. 6D). In cytolytic
assays, 221-C*03:04 cells were resistant to lysis by NKL cells ex-
pressing KIR2DL3, but they were killed by NKL cells expressing
KIR2DL1, 2DL1-71K, or 2DL3-71K (Fig. 6E). Conversely, 221-
C*04:01 cells were resistant to lysis by NKL cells expressing
KIR2DL1, but they were killed by NKL cells expressing either
KIR2DL3 or 2DL3-71K (Fig. 6F). NKL cells expressing 2DL1-
71K lysed 221-C*04:01 cells to a much lesser extent than did
KIR2DL1, consistent with the weak, but detectable signal observed
with 2DL1-71K in the binding assay (Fig. 6D). In conclusion, a
positive correlation was observed between the results obtained in
the direct binding assay and functional assays of cellular cy-
totoxicity. Consequently, our analysis points to HLA-C*04:01
having unusual properties that could challenge its prototypical
stature.
Functional recognition of HLA-A*11:02 by mutant
KIR2DL3-71P
Of the four HLA class I epitopes (A3/11, Bw4, C1, and C2)
recognized by KIR, the functional significance of A3/11 remains
uncertain. Carried by HLA-A*03 and HLA-A*11 allotypes, the
A3/A11 epitope was first shown to engage the lineage III KIR,
KIR3DL2 (28, 62). Although Bw4, C1, and C2 mediate robust
inhibition and education of NK cells on binding their cognate
KIR, the interaction of the A3/11 epitope with 3DL2 provides
weak inhibition (25) and no detectable education (63, 64). In
previous studies of lineage III KIR2DS4 (42) and orangutan lin-
eage III (13), we detected binding HLA-A allotypes carrying the
A3/11 epitope, for which the strength of binding is A*11:02 .
A*11:01 . A*03:01. This hierarchy is again seen for mutant
2DL3-71P, which binds significantly to A*11:02 but not to
A*11:01 or A*03:01 (Fig. 6A). With this background and context,
we tested whether the recognition of HLA-A*11:02 by 2DL2-71P
could influence NK cell function.
In cytotoxic assays, NKL cells killed 221 cells (Fig. 7A) but not
221 cells transfected with HLA-A*11:02 (Fig. 7B), an inhibitory
effect not seen with 221 cells expressing either C*03:04 or
C*04:01 (20) (Fig. 6E, 6F). Because the leader peptides of the
transfected HLA class I are all nonpermissive for HLA-E inter-
action with CD94:NKG2A, the enhanced inhibition of cytolysis
achieved by A*11:02 was unlikely to be mediated through this
receptor. Alternatively, the inhibition could arise from interaction
of HLA-A*11:02 with the LILRB1 receptor on NKL cells. Con-
sistent with this mechanism, G4-NKL, a derivative of NKL having
siRNA that reduces LILRB1 expression by .90%, killed 221-
A*11:02 cells much more effectively than NKL cells (Fig. 7B).
Our observations that HLA-C*03:04 and HLA-C*04:01 are not
good functional ligands for LILRB1 agree with the results of
previous studies. Using a similar assay system, LILRB1 was seen
to bind HLA-G, HLA-A*03:01, B*27:02, and B*27:05 but not
HLA-C*03:01 (65). Likewise, a LILRB1-Fc fusion protein bound
well to a variety of HLA-A and -B allotypes at cell surfaces but
not to HLA-C*04:01 or C*07:02 and only weakly to C*03:04
(66). In contrast, in noncellular-binding assays, LILRB1 has de-
tectable avidity for the spectrum of HLA-C allotypes (67, 68). The
mechanisms underlying the differing results obtained in cellular-
and molecular-binding assays, as well as between HLA-A and -B
compared with HLA-C, have yet to be determined. To identify and
avoid the inhibitory effects of LILRB1, our experiments to in-
vestigate the capacity for HLA-A*11:02 to be a KIR ligand were
performed using both NKL (Fig. 7A–C, left panels) and G4-NKL
cells (Fig. 7A–C, right panels).
FIGURE 6. Lysine 71 abrogates interaction of KIR2DL3 with HLA-C
and selectively impairs interaction of KIR2DL1 with HLA-C*04:01. (A)
Shown are the residues present at position 71 in hominoid lineage III KIR.
Notably, lysine 71 is absent from humans but present in chimpanzees and
gorillas. (B) Killing of class I-deficient 221 cells by NKL cells (¤) and by
NKL cells transduced with KIR2DL1 (d), 2DL1-71K (s), KIR2DL3 (n),
and 2DL3-71K (N). Binding to 221 cells expressing C1-bearing HLA-
C*03:04 (C) and C2-bearing HLA-C*04:01 (D) of KIR2DL-Fc fusion
proteins: KIR2DL1, 2DL1-71K, 2DL3, and 2DL3-71K. Killing of 221 target
cells expressing HLA-C*03:04 (E) and HLA-C*04:01 (F) by NKL cells
expressing KIR2DL1 (d), 2DL1-71K (s), 2DL3 (n), and 2DL3-71K (N).
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That G4-NKL cells expressing KIR2DL3 killed 221-A*11:02
cells shows that A*11:02 is not a ligand for wt KIR2DL3 (Fig.
7B, right panel). In contrast, killing of 221-A*11:02 was strongly
inhibited when G4-NKL cells expressed the 2DL3-71P mutant,
showing that binding of A*11:02 to 2DL3-71P is a functional
ligand–receptor interaction that leads to the transduction of an
inhibitory signal (Fig. 7B, right panel). Preincubation of 221-
A*11:02 with an anti-A11 mAb had little effect on the interac-
tion between 2DL3-71P and HLA-A*11:02 (Fig. 7C, right
panel), but it rendered the cells susceptible to lysis by NKL cells,
with an efficiency similar to that achieved by siRNA-mediated
downregulation of LILRB1 (Fig. 7C, left panel). This result,
suggesting that the Ab recognizes an epitope of HLA-A*11:02
in or near the binding site for LILRB1, but away from the
binding site for 2DL3-71P, is consistent with crystallographic
studies showing that LILRB1 interacts with the conserved Ig-like
domains (a3 and b2-microglobulin) of HLA class I (69), whereas
lineage III KIR interact with the highly polymorphic a1 and a2
domains (58).
Mutant KIR2DL3-71P can recognize the complex of
HLA-A*11:02 and a peptide derived from EBV
Comparison of five peptides that bind to HLA-A*03:01 and
five peptides that bind to HLA-A*11:01 showed that peptide
RLRAEAQVK from the EBNA3A protein of EBV, which binds
both A*03:01 and A*11:01, was the only peptide that permitted
interaction with KIR3DL2 (27, 28, 62). With this precedent, we
investigated whether this peptide could bind to HLA-A*11:02 and
form a functional ligand for the KIR2DL3-71P mutant. To do this,
we transfected the TAP-deficient T2 cell line with A*11:02. T2
cells present very few endogenous peptides, giving a minimal
surface expression of HLA class I unless binding peptide is sup-
plied exogenously. In the absence of peptide, basal expression of
A*11:02 on transfected T2 cells was undetectable (Fig. 7E). T2
and T2-A*11:02 cells were incubated overnight either in the ab-
sence or presence of peptide RLRAEAQVK (27). Incubation of
T2-A*11:02 cells with peptide increased the amount of A*11:02
on the cell surface 10-fold over T2-A*11:02 cells incubated in the
absence of peptide (Fig. 7D) or T2 cells incubated either in the
FIGURE 7. Proline 71 present in KIR2DS4 and KIR3DL2 confers specificity for HLA-A*11:02 on KIR2DL3 but not on KIR2DL1. Results of
cytotoxicity assays in which the target cells are class I-deficient 221 cells (A), 221 cells expressing HLA-A*11:02 (B), or 221 cells expressing HLA-
A*11:02 cells preincubated with Ab specific for HLA-A*11 (C). Left panels: the effector cells included NKL cells, NKL cells expressing 2DL3, and
NKL cells expressing 2DL3-71P. Right panels: the effector cells included G4-NKL cells, G4-NKL cells expressing 2DL3, and G4-NKL cells
expressing 2DL3-71P. NKL cells express the HLA class I receptor LILRB1, whereas G4-NKL is an NKL cell in which LILRB1 expression is sup-
pressed. Flow cytometric analysis of the binding of anti-A*11 Ab to T2 cells transfected with HLA-A*11:02 (T2-A*11:02) (D) and untransfected T2
cells (E), following overnight incubation in the presence (black line) or absence (gray line) of the RLRAEAQVK peptide that binds HLA-A*11.
Results of cytotoxicity assays in which the targets were T2-A*11:02 cells (F) and T2 cells (G), following overnight incubation in the presence (black
line) or absence (gray line) of peptide RLRAEAQVK. Effector cells were G4-NKL cells (left panels) and G4-NKL cells expressing 2DL3-71P (right
panels).
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presence or absence of peptide (Fig. 7E). This result shows that
A*11:02 does bind the RLRAEAQVK peptide (Fig. 7F). Conse-
quently, the substitution of lysine for glutamate at position 19 that
distinguishes HLA-A*11:02 from A*11:01 does not affect the
binding of this peptide.
In cytotoxicity assays, T2 cells that were incubated in the
presence or absence of peptide were killed to a similar extent by
G4-NKL cells and G4-NKL cells expressing the 2DL3-71P mutant
(Fig. 7F). G4-NKL and G4-NKL–2DL3-71P resulted in a simi-
larly effective killing of T2-A*11:02 cells that had been incubated
in the absence peptide. In contrast, T2-A*11:02 cells that had been
incubated with peptide exhibited a resistance to killing by G4–
2DL3-71P (Fig. 7G). This result indicates that 2DL3-71P recog-
nizes the complex of RLRAEAQVK bound to A*11:02 to gen-
erate a functional signal that inhibits NK cells.
Discussion
MHC-C–mediated regulation of NK cells is of recent and rapid
evolution and is specific to hominids: humans and great apes. In
humans it comprises a bipartite system of two mutually exclusive
epitopes that are defined by dimorphism at position 80 of HLA-C
and that serve as ligands for different lineage III KIR (15, 19, 31).
In this study, we compared KIR2DL3 that recognizes the C1
epitope (asparagine 80) with KIR2DL1 that recognizes the C2
epitope (lysine 80). Comparison of .100 hominid lineage III KIR
identified six positions of sequence variation that have been sub-
ject to positive diversifying selection and are situated in the part of
the KIR molecule that forms the binding site for HLA-C, as vi-
sualized at high resolution in three-dimensional crystallographic
structures (55, 58, 70). To assess the effects of natural selection
upon the interactions of KIR with MHC-C, we studied the strength
and specificity of mutant KIR2DL3 and KIR2DL1 receptors, each
one substituted with one of the natural variations identified at the
six positively selected sites. Thus, each wt receptor was compared
to 18 mutants. The results of this analysis are summarized for each
mutant in Fig. 8.
Overall, mutation had a wider range of effects on KIR2DL3
than on KIR2DL1. The C1 specificity of KIR2DL3 was changed in
two ways: a major broadening to give a pan HLA-C receptor with
C1 plus C2 specificity and a minor broadening to give reactivity
with HLA-A*11:02, as well as C1. The avidity of KIR2DL3 was
also changed in two ways: 2 of the mutations increased avidity for
C1 by .10%, 13 decreased the avidity by .10%, and 3 had little
effect (Fig. 8). In comparison with KIR2DL3, the ligand-binding
properties of KIR2DL1 were more resistant to mutation: none
of the 18 mutations altered the C2 specificity, and none of them
increased the avidity for C2. Ten mutations in KIR2DL1 reduced
C2 avidity by .10%, and eight had little effect. Consideration of
all of the mutants, with the exception of those at specificity-
determining position 44, shows that all KIR2DL1 mutants
retained a minimum of 32% of the wt binding, with an average of
75%, whereas the binding of KIR2DL3 mutants ranged from 0–
138% of wt binding, with an average of 68%. Exemplifying the
variety of effects that mutation had on KIR2DL3 and their limited
effect on KIR2DL1 are the avidities and specificities of the
mutants containing glutamate 44, proline 71, and glutamine 13
(Fig. 9).
In functional and epidemiological studies, the interactions of
KIR2DL1 with C2 and KIR2DL2/3 with C1 are often considered
complementary but equivalent. From the molecular analysis a
different picture emerges, one in which KIR2DL1 is seen as the
stronger and more selective receptor, which appears to have been
optimized for high-avidity recognition of C2 and, as a consequence,
became relatively resistant to further functional change by point
mutation. In contrast, KIR2DL3 is seen as the weaker and less
selective receptor, which, by being less refined, retains greater
potential for improvement and change. Having acquired a strong
and exquisite specificity for C2, KIR2DL1 is now specialized and
inflexible; by retaining a weaker C1 specificity that cross-reacts
with C2 (21, 22, 30), KIR2DL3 is less specialized but more
flexible and adaptable.
These contrasting and complementary properties fit well with an
evolutionary model in which the C1 epitope and their cognate C1-
specific KIR evolved first and subsequently underwent mutation
and selection to give rise to the C2 epitope and C2-specific KIR
(13). The crucial feature of this model is the flexibility of the C1
receptor and its cross-reactivity with C2, which, while maintaining
function as a C1 receptor, provides a potential C2 receptor prior to
formation of the C2 epitope. Thus, the inherent flexibility of the
C1 receptor allows C2 and C2-specific KIR to evolve by stepwise
point mutation through a series of intermediate forms that all have
biological function and could be maintained by natural selection.
The model’s first intermediate is a receptor with broad MHC-C
reactivity like the 2DL3-44E mutant (Fig. 8). The presence of this
C1+C2 specific receptor sets the stage for mutation at position 80
of MHC-C to produce C2 from C1 and for it to be a functional
KIR ligand. With both C1 and C2 in place, further mutation of the
KIR, including the key introduction of methionine 44, then gave
rise to highly specific C2 receptors, such as KIR2DL1.
Hominid variation at three of the six positively selected positions
is associated with changes in receptor specificity: position 44
controls HLA-C specificity, and positions 71 and 131 affect the
recognition of HLA-A*11:02. Variation at all six positions influ-
ences receptor avidity, but the major players are positions 70 and
FIGURE 8. Summary of the binding avidity of KIR2DL1 and KIR2DL3 mutants for the C1 and C2 epitopes of HLA-C and for HLA-A*11:02. Each
value is the binding of the KIR-Fc protein to the target HLA class I expressed as a percentage of the binding of the W6/32 mAb to the same HLA class I
allotype. Values for C1 and C2 are the means from nine C1-bearing and seven C2-bearing HLA-C allotypes, respectively. Gray shading indicates the
residues in KIR2DL1*003 and KIR2DL3*001.
The Journal of Immunology 1427
44. In determining both specificity and avidity, residues of the
D1 domain are the dominant influence, with D2 domain residues
taking the minor role. Because KIR2DL1*003 and KIR2DL3*001
are identical at positions 71 and 131, only positions 44, 68, 70, and
182 can contribute to their functional differences. That dimor-
phism at position 44 determines receptor specificity is well known
(22, 23), but this difference of methionine in KIR2DL1 and lysine
in KIR2DL3 also contributes to their relative strength.
The major modulator of avidity is residue 70: threonine in
KIR2DL1 and methionine in KIR2DL3. By rough estimate, 67% of
the avidity difference comes from position 70, and 19% comes
from position 44. The remaining 14% could involve synergism
between positions 44 and 70, which would go undetected in this
study of single mutations, or contributions from other positions,
including 68, 182, and the 10 positively selected positions away
from the binding site (7). A precedent for such possibilities is the
synergistic contribution that distal residues 16 and 148 make to
KIR2DL2*001 being a stronger C1 receptor than KIR2DL3*001
(21). Although residue 70 is the major influence on receptor
avidity, it has no role in receptor specificity. In their respective
crystallographic structures, glutamine 70 of KIR2DL1 makes no di-
rect contact with HLA-C*04, whereas glutamine 70 of KIR2DL2
forms a hydrophobic bond with arginine 69 of HLA-C*03 (55, 58,
70). It is not known whether glutamine 70 of KIR2DL3 makes
a similar contact with HLA-C, because a pertinent crystallo-
graphic structure has yet to be determined
Interaction of KIR2DL3 with HLA-A*11:02 was achieved by
mutation at either position 71 or 131. The A3/11 epitope, carried
by HLA-A*03 and HLA-A*11, was first described as the ligand
for KIR3DL2, a lineage II KIR (28, 62). Subsequently, lineage III
KIR2DS4 was shown to bind HLA-A*11 but not HLA-A*03, a
property associated with the proline 71 valine 72 motif acquired
from a KIR3DL2-like lineage II gene and not present in other
lineage III KIR (42). We now show that introduction of proline
71 into KIR2DL3 is sufficient to confer reactivity with HLA-
A*11:02, but it is not necessary to achieve this effect. Mutating
arginine 131 to glutamine in KIR2DL3 also conferred recognition
of HLA-A*11:02. Popy-2DLA, an orangutan receptor that has
lysine 44, proline 71, and arginine 131, also recognizes HLA-
A*11:02. Unlike C1, C2 (23), and Bw4 (71), the A3/11 epitope
cannot be described in terms of a single specificity-determining
residue.
Of the four HLA class I epitopes recognized by KIR, the A3/11
epitope is the least studied, and its functional significance remains
uncertain. Although all human populations have the Bw4, C1, and
C2 epitopes, the A3/11 epitope appears dispensable [e.g., it is absent
from Native American populations: http://www.allelefrequencies.
net (72)]. Functionally, interactions of Bw4, C1, and C2 with
cognate KIR mediate robust inhibition and education of NK
cells, whereas KIR3DL2 engagement of A3/11 provides weak
inhibition (25) and no detectable education (63, 64). Of 10 viral
or self-peptides that bind to HLA-A*03 and/or HLA-A*11,
only peptide RLRAEAQVK from EBV was shown to permit
interaction with KIR3DL2 (27), raising the possibility that only
a small fraction of the HLA-A*11 and HLA-A*03 molecules on
cell surfaces functions as a ligand for KIR3DL2. The biological
relevance of these interactions remains an open question, and
another function for KIR3DL2 as a receptor and transporter of
CpG oligodeoxynucleotides has been proposed (73).
A possible consequence of rapidly coevolving NK cell recep-
tors and MHC ligands is the circumstance of NK cell receptors
losing function, by failure to keep up with changes in MHC class I
imposed by selected pressures from other functions, such as Ag
presentation to CD8 T cells. Surviving such a crisis, with subse-
quent evolution of a new set of variable NK cell receptors, could
explain how humans and mice came to use completely unrelated
proteins as variable NK cell receptors. The human KIR and mouse
Ly49 became MHC class I receptors through convergent evolution;
being subject to similar selection pressure caused them to acquire
several similar functional characteristics, including activating and
inhibitor receptors with the same MHC class I specificity. The
activating receptors have a greater tendency than do their inhibitory
counterparts to accumulate substitutions causing loss of receptor
avidity (40, 74), a trend well illustrated by human activating lin-
eage III KIR: 2DS1 has half the C2 avidity of 2DL1; 2DS4 binds
weakly to just a few HLA class I allotypes; and 2DS2, 2DS3, and
2DS5 exhibit almost no binding to HLA class I.
Five of the substitutions that we studied are principally found in
activating KIR (threonine 44, lysine 70, arginine 71, tryptophan
131, and cysteine 182) and, therefore, were likely acquired through
mutation of the activating KIR and not from the inhibitory KIR
from which they were formed by recombinations (74). When in-
troduced into KIR2DL1 and KIR2DL3, these residues had no
effect upon receptor specificity, but they all reduced avidity for
HLA-C: KIR2DL1 avidity for C2 was reduced by 38–66% (mean,
51%), and KIR2DL3 avidity for C1 was reduced by 65–90%
(mean, 74%). That positions 44, 70, 71, 131, and 182 were subject
to positive selection implies there was a functional advantage to
reducing the potency of activating receptors with the introduction
of threonine 44, lysine 70, arginine 71, tryptophan 131, and cys-
teine 182. Exemplifying this phenomenon is KIR2DS1*002 (the
common 2DS1 allele), in which lysine substituted for threonine 70
was responsible for reducing C2 avidity to half of that of
KIR2DL1*003 (39, 75).
At an early stage of pregnancy, interplay and balance between
KIR2DL1 and KIR2DS1 appear to modulate interactions between
fetal trophoblast and maternal uterine NK cells that facilitate
FIGURE 9. KIR2DL1 has stronger avidity and narrower HLA class I
specificity than KIR2DL3. Shown is the binding of wt and mutant
KIR2DL3-Fc (upper panel) and KIR2DL1-Fc (lower panel) fusion pro-
teins to beads coated with HLA-A*11:02 (cross-hatched bars), HLA-C2
allotypes (dark gray bars; mean value for seven allotypes), and HLA-C1
allotypes (white bars; mean value for nine allotypes). The specificity and
avidity of KIR2DL1 are markedly more resistant to mutation at positions
44, 71, and 131 compared with the specificity and avidity of KIR2DL3.
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placentation. In pregnancies in which the fetus expresses C2, the
risk for preeclampsia and other disorders is less if the mother has
both KIR2DL1 and KIR2DS1 than if she has only KIR2DL1 (76).
If this balance were improved by having an activating receptor less
avid than its inhibitory partner, it could explain the positive se-
lection of lysine 70 in KIR2DS1.
Within the groups of C1-bearing and C2-bearing HLA-C, there is
a considerable and reproducible range of avidity for the cognate
KIR. Because the observed binding is stable to washing, and
residues 7 and 8 of HLA-C bound peptide contact KIR (55, 70), we
suspect that the observed avidity differences are the consequence
of substitutions in the peptide binding site that cause different
populations of peptides to be bound by the various HLA-C allo-
types. In this context, the selective and almost complete loss of
binding to HLA-C*04:01 by mutant 2DL1-71P is a striking ex-
ample of the increasing number of allotype-specific effects that are
being uncovered in the study of HLA-C binding to lineage III
KIR. This result is not an artifact of the direct-binding assay,
because 2DL1-71P on NK cell surfaces similarly fails to engage
HLA-C*04:01 on target cells. In many studies of KIR specificity,
HLA-C*04:01 and HLA-C*03:04 provided the representative C2
and C1 epitopes, respectively (22, 23, 61, 77). Notably, these
allotypes formed the complexes with KIR that were used to de-
termine the canonical three-dimensional structures (55, 70). Al-
though a good ligand for KIR2DL1 in cellular assays of NK cell
function, we noticed that the binding of KIR2DL1 to HLA-
C*04:01 is generally lower than for other C2-bearing allotypes.
Such observations suggested that HLA-C*04:01 could have some
properties that are not representative of other C2-bearing HLA-C,
a possibility that is strengthened by our results.
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Abstract
Modulating natural killer cell functions in human immunity and reproduction are diverse
interactions between the killer cell immunoglobulin-like receptors (KIR) of Natural Killer
(NK) cells and HLA class I ligands on the surface of tissue cells. Dominant interactions are
between KIR2DL1 and the C2 epitope of HLA-C and between KIR2DL2/3 and the C1 epi-
tope of HLA-C. KhoeSan hunter-gatherers of Southern Africa represent the earliest popula-
tion divergence known and are the most genetically diverse indigenous people, qualities
reflected in their KIR and HLA genes. Of the ten KhoeSan KIR2DL1 alleles, KIR2DL1*022
and KIR2DL1*026 likely originated in the KhoeSan, and later were transmitted at low fre-
quency to the neighboring Zulus through gene flow. These alleles arose by point mutation
from other KhoeSan KIR2DL1 alleles that are more widespread globally. Mutation of
KIR2DL1*001 gave rise to KIR2DL1*022, causing loss of C2 recognition and gain of C1 rec-
ognition. This makes KIR2DL1*022 a more avid and specific C1 receptor than any
KIR2DL2/3 allotype. Mutation of KIR2DL1*012 gave rise to KIR2DL1*026, causing prema-
ture termination of translation at the end of the transmembrane domain. This makes
KIR2DL1*026 a membrane-associated receptor that lacks both a cytoplasmic tail and sig-
naling function. At higher frequencies than their parental allotypes, the combined effect of
the KhoeSan-specific KIR2DL1*022 and KIR2DL1*026 is to reduce the frequency of strong
inhibitory C2 receptors and increase the frequency of strong inhibitory C1 receptors.
Because interaction of KIR2DL1 with C2 is associated with risk of pregnancy disorder,
these functional changes are potentially advantageous. Whereas all other KhoeSan
KIR2DL1 alleles are present on a wide diversity of centromeric KIR haplotypes,
KIR2DL1*026 is present on a single KIR haplotype and KIR2DL1*022 is present on two
very similar haplotypes. The high linkage disequilibrium across their haplotypes is consis-
tent with a recent emergence for these KIR2DL1 alleles that have distinctive functions.
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Author Summary
The genes that control the response of the human immune system vary enormously
between individuals. Understanding the evolution of these genetic differences and how
they individualize immune responses is central to understanding how the immune system
works in health and disease. In this regard, the KhoeSan of southern Africa are particularly
informative because they are genetically diverse, divergent from other modern human
populations and have been subject to unique demographic history. In the KhoeSan popu-
lation, we studied variable genes that control natural killer cell function. We identified two
recently evolved, novel gene variants that have unusual function; one completely changed
its ligand specificity and the other lost its capacity for signal transduction.
Introduction
Natural killer (NK) cells are versatile lymphocytes that contribute to reproduction and immune
defense [1,2]. Modulating the activities of human NK-cells are the killer-cell immunoglobulin-
like receptors (KIR). These receptors engage the HLA class I ligands (HLA-A, -B and -C)
expressed on the surface of most human cells. Such interactions direct NK cells to kill virus-
infected cells and tumor cells; they also induce the secretion of cytokines that activate other leu-
kocytes or guide fetal trophoblast cells to invade the uterus during pregnancy. In human popu-
lations, both receptors and ligands are highly polymorphic. Their combinatorial diversity
contributes to the resistance of individuals to infection, and their susceptibility to autoimmu-
nity and pregnancy syndromes [1,3]. A minority of HLA-A and -B allotypes are ligands for
KIR, whereas all HLA-C allotypes fulfill this role. HLA-C arose more recently than HLA-A and
-B and has evolved to become the predominant polymorphic KIR ligand [4]. In reproduction it
is the only polymorphic ligand, because HLA-C is expressed by fetal trophoblast cells whereas
HLA-A and -B are not [1].
KIR engage the upward face of the HLA class I molecule formed by the α1 domain, the α2
domain and the bound peptide antigen [5]. αβ T cell receptors engage the same face, in an
overlapping but different way [6]. Dimorphism at position 80 in the α1 domain of HLA-C
defines two mutually exclusive epitopes, C1 (asparagine 80) and C2 (lysine 80), recognized by
different KIR [7]. All the numerous (>1,700) HLA-C allotypes have either the C1 or C2 epi-
tope. Human KIR are comprised of four phylogenetic lineages, of which the KIR that recognize
HLA-C are all lineage III [4]. They have two extracellular immunoglobulin-like domains (D1
and D2), which together form the site that binds HLA-C [5]. Within the binding site, dimor-
phism at position 44 in the D1 domain determines if a KIR is specific for C1 (lysine 44) or C2
(methionine 44). KIR2DL1 and KIR2DS1 encode inhibitory and activating C2 receptors,
respectively. KIR2DL2/3 encodes inhibitory C1 receptors. (There is no activating C1 receptor).
The inhibitory receptors are highly polymorphic, with 25 KIR2DL1 and 36 KIR2DL2/3 vari-
ants being defined, whereas KIR2DS1 with seven variants is relatively conserved.
Among individuals and populations, KIR are further diversified by gene content variation
[8]. Whereas KIR2DL2/3 is present on almost every human KIR haplotype described, neither
KIR2DL1 nor KIR2DS1 are present on every haplotype. Represented in every human popula-
tion are two distinctive KIR haplotype groups: A and B [1]. KIR A haplotypes encode high avid-
ity inhibitory receptors for HLA class I and have one activating receptor gene; B haplotypes
encode low avidity inhibitory receptors for HLA class I and have several activating receptor
genes. This bipartite system of functionally distinctive KIR haplotypes appears unique to
humans because it is not present in chimpanzees or any other species investigated [9].
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For reasons of practicality, the functional properties of KIR2DL1 and KIR2DL2/3 have been
studied mainly in the context of allotypic variants that combine high avidity, high specificity
and high frequency in Europeans [1]. In contrast, for sub-Saharan African populations, which
have the highest genetic diversity [10–12] and among the highest mortality from infectious dis-
ease and pregnancy complications [13], KIR investigation is in its infancy and has so far
focused onWest African and Bantu-speaking populations [14]. Within sub-Saharan Africa,
some indigenous populations are as different from each other as they are from Europeans
[10,12,15]. Notably, the KhoeSan who reside across southern Africa descend from the deepest
human population divergence and have among the greatest genetic diversity of any population
[10,16,17]. During the last 2,000 years there has been admixture between the KhoeSan and
Bantu-speaking agriculturalists who expanded southwards [11,18]. More recently, the arrival
of European colonists over the past 500 years has introduced novel infectious diseases includ-
ing smallpox and tuberculosis [19]. Here we describe high-resolution genetic and functional
studies on the HLA-C specific KIR of the KhoeSan and their comparison to other populations.
Results
Two unusual KIR2DL1 alleles evolved in the KhoeSan after their
divergence from other modern humans
From analysis of 61 KhoeSan we identified ten KIR2DL1 alleles (Fig 1A and S1A Fig). Of these,
2DL1022 and 2DL1026 are new discoveries that have frequencies in the KhoeSan of 17.2%
and 4.2%, respectively. Being absent from all previously studied populations [14,20–24], sug-
gested that 2DL1022 and 2DL1026 are specific to the KhoeSan. To test this hypothesis we
examined additional populations for the presence of these alleles. We first examined data from
the 1000 Genomes project dataset [25] by probing for sequence-specific reads that correspond
to the 2DL1022 and 2DL1026 alleles. KIR3DL3, a framework gene present on all KIR haplo-
types, served as the positive control. All 2,496 individuals sampled had reads corresponding to
KIR3DL3, as did the eight KhoeSan who were analyzed similarly by whole-exome sequencing
[26]. The eight KhoeSan individuals also gave allele-specific KIR2DL1 reads consistent with
their high-resolution KIR2DL1 genotype (S2A Fig). In this context it is striking that none of
the 2,496 individuals, representing 26 different populations worldwide (S2B Fig), was found to
have either 2DL1022 or 2DL1026 (S2C Fig). Because the 1000 Genome dataset represents a
limited subset of sub-Saharan African population diversity [12,27], we expanded our search to
include four further groups.
To determine if 2DL1022 or 2DL1026 are present in African hunter-gatherer populations
other than the KhoeSan we examined three groups: the Hadza who are an isolated click-
speaking population that live in northern Tanzania [10] and the central African Mbuti and
Baka Pygmies. Together with the KhoeSan, these hunter-gatherer groups may have formed a
larger proto-KhoeSan-Pygmy population prior to their divergence 50,000–100,000 years ago
[12,28,29]. Neither 2DL1022 nor 2DL1026 was detected in any Hadza or Pygmy individual
(S2C Fig). Despite the relatively low number of individuals sampled (52 Hadza and 40 Pyg-
mies) this result indicates that 2DL1022 and 2DL1026 are not present at any appreciable fre-
quency in these groups.
To determine whether 2DL1022 and 2DL1026 are present in other southern African pop-
ulations, we examined 100 Zulu individuals whose genomes were sequenced as part of the Afri-
can Genome Variation Project [27]. With the same approach used to probe the 1000 Genomes
dataset, we identified three Zulus having 2DL1022 and two having 2DL1026 (S2C Fig). As
these five individuals were all 2DL1 heterozygous, we estimate that the frequencies of
2DL1022 and 2DL1026 in the Zulu population are approximately 1.5% and 1%, respectively.
Unusual Function of KhoeSan NK Cell Receptors
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Fig 1. A variant of KIR2DL1 originating in the KhoeSan is a C1-specific receptor and not a C2-specific receptor like other KIR2DL1. (A) This
alignment of KIR2DL1 sequence differences shows the sites of polymorphism in the D1 domain (D1), the D2 domain (D2) and the transmembrane region
(Tm). Dashes denote identity with the KIR2DL1*003 sequence, an asterisk denotes a termination codon. Sequences of the KhoeSan KIR2DL1 allotypes are
highlighted in yellow. The names of allotypes with D1, D2 and Tm identical to an aligned sequence are listed in the column at the right. (B) Binding of
KIR2DL1-Fc fusion proteins to microbeads coated with C1-bearing and seven C2-bearing HLA-C allotypes. Each binding value was normalized to that of the
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Examination of the centromeric half of the KIR haplotypes, the location of the KIR2DL1 gene,
showed that each Zulu allele is likely present on the identical haplotype background to that
found in the KhoeSan (S3 Fig). Together with their low frequencies, this suggests that these
alleles were introduced into the Zulu population as a result of admixture with KhoeSan hunter-
gatherers. This interpretation is supported by studies that have demonstrated recent KhoeSan
admixture with the Zulus [10,11,18,27] and by the absence of both 2DL1022 and 2DL1026
from a Bantu-speaking population in east Africa (Kenyan Luhya from the 1000 Genomes data-
set). These data support an evolutionary model in which 2DL1022 and 2DL1026 rose in fre-
quency in the KhoeSan populations sometime after their divergence from the other groups and
thus within the past 100,000 years [12,28,29].
KIR2DL1022 differs from 2DL1001, also present in the KhoeSan, by a single non-synony-
mous substitution in codon 44 (Fig 1A). Thus 2DL1022 likely evolved from 2DL1001 by a
point mutation that caused methionine to be replaced by lysine at position 44 (Fig 1A). Posi-
tion 44 dimorphism determines whether a given KIR2DL has specificity for the C1 or C2 epi-
tope of HLA-C [7]. Prior to investigation of the KhoeSan, all the known KIR2DL1 allotypes
(n = 23) had methionine 44 and were predicted to be C2-specific. Conversely, and in comple-
mentary fashion, the known KIR2DL2/3 allotypes (n = 36) all had lysine 44 and were predicted
to be C1 specific. In this context, 2DL1022 appears an extraordinary KIR2DL1 allotype, being
predicted to be a C1 receptor and not a C2 receptor like other KIR2DL1 allotypes. Thus, the
mutation that created 2DL1022 had two important functional effects: loss of C2 recognition
and gain of C1 recognition.
KIR2DL1026, the other KhoeSan-specific KIR2DL1 allele, differs from 2DL1012, also pres-
ent in the KhoeSan, by one nucleotide substitution. Thus KIR2DL1026 likely arose from
2DL1012 by point mutation. This substitution converted the tryptophan codon at position
246 to a termination codon (Fig 1A). Position 246 is situated at the boundary between the
transmembrane domain and the cytoplasmic tail. Consequently, 2DL1026 lacks the immu-
noreceptor tyrosine-based inhibitory motifs of the cytoplasmic tail that mediate inhibitory sig-
naling function [30]. Less obvious is the effect that absence of a cytoplasmic tail could have on
the association of 2DL1026 with cellular membranes. Thus, the mutation that created
2DL1026 clearly has a major effect in abrogating inhibitory signaling function, but it also has
potential to alter the amount of receptor that reaches the NK cell-surface.
KhoeSan specific 2DL1*022 is an unusually strong and specific C1
receptor
To determine the avidity and specificity of 2DL1022 for HLA class I, and also to compare its
binding reactivity with other KIR2DL1 allotypes, we made a panel of 14 KIR2DL1-Fc fusion
proteins that covers the allotypic range of KIR2DL1 binding sites (Fig 1A). Each KIR-Fc was
tested for binding to a panel of 97 microbeads in which each bead is coated with one of 31
HLA-A, 50 HLA-B and 16 HLA-C allotypes. Our previous work has shown that the results
W6/32 antibody and these normalized values were averaged for the C1 (N = 9) and C2 (N = 7) allotype groups. The names of allotypes present in the
KhoeSan are boldened. A dagger following the listed allotype indicates that the allotype represents a group of two or more alleles that encode identical ligand
binding domains (see Panel A). (C) This alignment of KIR2DL2/3 sequence differences shows the sites of polymorphism in the D1 and D2 domains. Dashes
denote identity with the KIR2DL2*001 sequence Sequences of the KhoeSan KIR2DL2/3 allotypes are highlighted in yellow. The names of allotypes with D1
and D2 identical to an aligned sequence are listed in the column at the right. (D) Binding of KIR2DL2/3-Fc fusion proteins to microbeads coated with
C1-bearing and C2-bearing HLA-C allotypes. Each binding value was normalized to that of theW6/32 antibody and these normalized values were averaged
for the C1 (N = 9) and C2 (N = 7) groups. The names of allotypes present in the KhoeSan are boldened. Groups of allotypes with identical D1 and D2
domains, and which are represented by a single KIR2DL2/3-Fc, are as shown in the column on the right of Panel A. A dagger following the listed allotype
indicates that the allotype represents a group of two or more alleles that encode identical ligand binding domains (see Panel A).
doi:10.1371/journal.pgen.1005439.g001
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obtained with this cell-free bead-binding assay correlate well with those derived from in vitro
functional assays of NK cell cytotoxicity [31,32].
Assessment of the pairwise interactions between 14 KIR2DL1-Fc and 16 HLA-C allotypes
shows that 2DL1022 binds to all nine C1-bearing HLA-C allotypes but to none of the seven
C2-bearing HLA-C allotypes in the test panel (Fig 1B). KIR2DL1022 also binds HLA-B46:01
and HLA-B73:01, two exceptional C1-bearing HLA-B allotypes but to no other HLA-B allo-
type, or any HLA-A allotype. Eleven HLA-C1 bearing allotypes are present in the KhoeSan
(S1C Fig). Neither HLA-B46:01 or HLA-B73:01 are present in the KhoeSan, their distribu-
tions being focused on Southeast Asia (B46:01) or West Asia (B73:01) [9,33,34]. As we pre-
dicted, 2DL1022 functions as a C1-specific receptor and not a C2-specific receptor like eleven
of the 13 other KIR2DL1-Fc. These eleven KIR2DL1-Fc molecules varied in their avidity for
C2 by half an order of magnitude. In contrast, 2DL1013N-Fc and 2DL1014-Fc bound to no
HLA class I allotype (Fig 1B). For 2DL1013N this result was anticipated, because the protein
is a fragment that terminates prematurely at residue 34 in the D1 domain. On the other hand,
2DL1014 was expected to bind HLA class I, because it differs from 2DL1003 only by substitu-
tion of glycine for serine at position 179 in the D2 domain (Fig 1A). Neither the 2DL1013N
nor the 2DL1014 allotype is present in the KhoeSan. Overall, these results vividly illustrate
how the natural polymorphism of KIR2DL1 modulates the avidity, specificity and functionality
of this NK cell receptor in human populations.
In the KhoeSan, mutation of 2DL1001, a strong C2 receptor, produced the C1 receptor,
2DL1022. We therefore examined how the properties of 2DL1022 compare to the prototypi-
cal C1 receptors encoded by the KIR2DL2/3 gene. (This gene has two distinctive allelic lineages,
2DL2 and 2DL3, hence the KIR2DL2/3 name). KIR-Fc proteins were made from six 2DL2 and
nine 2DL3 allotypes (Fig 1C) and their binding to HLA class I coated beads was compared to
2DL1022 (Fig 1D). As a group, the KIR2DL2/3 allotypes are not as specific for C1 as the
KIR2DL1 allotypes are for C2. KIR2DL2/3 exhibit a range of avidity for C1, but increasing
avidity for C1 is accompanied by increased cross-reactivity with C2 (Fig 1D). This is, however,
not the case for 2DL1022, which has a higher avidity for C1 than any of the KIR2DL2/3 allo-
types, but no significant C2 cross-reactivity. KIR2DL1022 has completely lost recognition of
C2 while gaining a stronger, more specific, recognition of C1 than any KIR2DL2/3 allotype.
Thus KIR2DL1022 is seen to have unique functional properties, ones that will clearly have a
profound functional impact on the KhoeSan and Zulu individuals who carry this allele.
The interactions of KIR2DL with HLA-C are not only diversified by KIR2DL1 and
KIR2DL2/3 polymorphism, but also by polymorphism within the subsets of C1-bearing and
C2-bearing HLA-C allotypes. Binding to C2 by the 11 KIR2DL1 allotypes varied over half an
order of magnitude and with a similar hierarchy for each of the KIR allotypes (Fig 2A). Thus
HLA-C15:02 is always the strongest ligand for KIR2DL1 and HLA-C04:01 the weakest. Anal-
ogous patterns were observed for the binding of 2DL1022 and the 15 KIR2DL2/3 allotypes to
C1-bearing HLA-B and -C allotypes (Fig 2B). Here, HLA-B73:01 is the strongest ligand for
2DL1022 and KIR2DL2/3 and HLA-C16:01 the weakest. The basis for these hierarchies
within the C1- and C2-bearing allotypes arise from either the differing peptide repertoires pre-
sented by specific HLA-C or by polymorphism at sites other than position 80 that defines the
C1 and C2 epitopes.
KhoeSan specific 2DL1*026 lacks a cytoplasmic tail but is cell-surface
expressed
KIR2DL1026 and 2DL1012 encode identical extracellular domains that bind C2 with high
avidity and specificity (Fig 1B). To determine if 2DL1026, which lacks a cytoplasmic tail,
Unusual Function of KhoeSan NK Cell Receptors
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Fig 2. KIR polymorphismmodulates the avidity and specificity for HLA-C, as well as KIR abundance
at the cell surface. (A) Binding of KIR2DL1-Fc fusion proteins to C2-bearing HLA-C allotypes. For each
C2-bearing HLA-C allotype, the KIR2DL1 binding is the mean of the values obtained with 11 different
KIR2DL1-Fc (2DL1*001, *003, *004, *007, *008, *012, *020, *021, *023 *024, *025). Each individual
binding value was normalized to the binding of the W6/32 antibody before calculating the average. (B)
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reaches the cell-surface, we examined the expression of FLAG-tagged 2DL1026 and
2DL1012 in transiently transfected HeLa cells. For comparison, eight other KIR2DL1 allo-
types were included in the analysis (Fig 2C). KIR2DL1026 is cell-surface expressed at a signifi-
cantly lower level than 2DL1012 (p = 0.0087), but within the range observed for other
KIR2DL1 allotypes. Although KIR2DL1026 cannot mediate NK cell inhibition directly,
because it lacks a cytoplasmic domain, it could have indirect effects, either by preventing C2
from binding to other receptors or by contributing to the adhesive interactions of NK cells with
target cells. That 2DL1014 is not cell-surface expressed and cannot bind HLA class I suggests
that its defining residue, serine 179, prevents proper protein folding. Other KIR allotypes with
impaired folding that causes intracellular retention have been described [35–37].
Characterizing the KhoeSan population is a high frequency of weak C2
receptors
Unlike some other populations, there is no single 2DL1 allele that is present at high frequency
in the KhoeSan (Fig 3 and S1A Fig). The ten KhoeSan 2DL1 alleles vary in frequency from 1.1–
21.3%. In addition, 18% of KhoeSan KIR haplotypes lack the KIR2DL1 gene, constituting an
eleventh allele: the 'blank'. The frequency of 2DL1022, (17.2%) is more than double that of
2DL1001 (7.0%), the parental allele from which it evolved. Likewise, 2DL1026 (4.2%) has a
higher frequency than 2DL1012 (1.1%), the parental allele from which it evolved. The impact
of both 2DL1022 and 2DL1026 has been to reduce the capacity of KIR2DL1 to function as an
inhibitory C2 receptor in the KhoeSan.
This effect of the KhoeSan-specific KIR2DL1 alleles is reinforced by the relatively low fre-
quency in the KhoeSan of other alleles encoding strong inhibitory C2 receptors (2DL1001,
002, 003 and 005) and relatively high frequency of alleles encoding weaker inhibitory C2
receptors. Included in the latter are the ‘blank’, the 2DL1004, 2DL1010 and 2DL1011 recep-
tors that have reduced avidity for C2 (Fig 1B and S4 Fig) and the 2DL1004 and 2DL1011 allo-
types that have reduced signaling capacity caused by the cysteine residue at position 245 [38]
(Fig 1A). In sum, the frequency of weak or inactive 2DL1 allotypes in the KhoeSan is 71.8%,
whereas the 28.2% frequency of strong 2DL1 allotypes in the KhoeSan is much lower than that
of other populations (Fig 3C).
KIR2DL1*022 and 2DL1*026 are present on conserved haplotypes that
are recently evolved
To examine the genetic background of KIR2DL1022 and KIR2DL1026, we determined struc-
tures for the KIR2DL1-containing centromeric region of KhoeSan KIR haplotypes. Extensive
diversity was observed, there being 70 different haplotypes among a total of 110 haplotypes
characterized from 55 unrelated individuals. For each KIR2DL1 allele we determined how
Binding of KIR2DL1*022-Fc and KIR2DL2/3-Fc fusion proteins to C1-bearing HLA-B and -C allotypes. For
each C1-bearing HLA-B and HLA-C allotype, the KIR2DL2/3 binding is the mean of the values obtained with
16 KIR2DL-Fc fusion proteins (2DL1*022; 2DL2*001,*003, *004, *006, 009 *011; and 2DL3*001, *005,
*008, *009, *011, *013, *015, *016, *018). The proteins were tested against microbeads coated with one of
nine C1 HLA-C or two C1 HLA-B allotypes. Each individual binding value was normalized to the binding to
that of the W6/32 antibody before calculating the average. (C) Variable cell-surface expression of KIR2DL1.
FLAG-tagged KIR2DL1 allotypes were transfected into HeLa cells. Cell-surface expression was detected
using FLAG-specific antibody and analysis by flow cytometry. MFI = median fluorescence intensity. The
experiment was performed in triplicate, error bars give the standard deviation. The difference between
2DL1*012 and 2DL1*026 is statistically significant as assessed by a two-tailed t-test.
doi:10.1371/journal.pgen.1005439.g002
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many different haplotypes have the allele and what their frequencies are in the KhoeSan.
Because the linkage disequilibrium (LD) between nine of the eleven KhoeSan 2DL1 alleles and
other genes of the centromeric region is low, there is a strong positive correlation (r2 = 0.96)
between an allele's frequency and the number of different haplotypes on which it occurs (Fig
4A). For example, a total of seven haplotypes have 2DL1001 and they are all different in their
linked KIR alleles and genes (Fig 4A). That we find numerous different haplotypes reflects the
high diversity of KhoeSan genomes [10,16]. Dramatic exceptions to this pattern are the haplo-
types containing the KhoeSan specific KIR2DL1 alleles, which are in complete LD with the
other centromeric KIR genes and alleles. Among the 23 haplotypes containing 2DL1022 only
two are unique, and they differ only in KIR3DL3 at the centromeric end of the KIR locus (Fig
4B). The six haplotypes containing 2DL1026 are all identical (Fig 4B). The high LD across
these haplotypes shows that they have not been broken and mixed by meiotic recombination,
which is consistent with their recent evolution [39] (Fig 4C).
Discussion
Our study shows how KIR2DL1 polymorphism has given rise to NK cell receptors that vary
substantially in their capacity to recognize HLA-C and propagate intracellular signals. Empha-
sizing the value of defining structural and functional KIR variation at high resolution is our dis-
covery in the KhoeSan of two unusual allotypes of KIR2DL1, the inhibitory NK cell receptor
for the C2 epitope of HLA-C. The alleles encoding these allotypes were derived by point muta-
tion from older, more widespread KIR2DL1 alleles that encode strong, inhibitory C2 receptors.
Fig 3. The KhoeSan have highKIR2DL1 diversity compared to other human populations. (A and B)
The pie charts show the number and relative frequencies of KIR2DL1 alleles in the KhoeSan of Southern
Africa (A), and four other populations representing four continents (B): the Ga-Adangbe from Ghana in
Western Africa [14], Northern Ireland Caucasians from Europe [21], Japanese from East Asia [24] and Yucpa
Amerindians from South America [20]. The 'blank' is the frequency of KIR haplotypes that lack the KIR2DL1
gene. (C) Also compared in the five populations are the frequencies of strong KIR2DL1, weak KIR2DL1,
KIR2DL1 that are not inhibitory C2 receptors (inactive) and the absence of KIR2DL1 (blank). The definition
and designation of these KIR2DL1 categories are given in S4 Fig.
doi:10.1371/journal.pgen.1005439.g003
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Fig 4. KIR2DL1*022 and 2DL1*026 are of recent origin compared to other KhoeSanKIR2DL1 alleles.
(A) For each KhoeSan KIR2DL1 allele, the number of centromeric KIR haplotypes on which the allele is
present in the KhoeSan (number observed) is plotted against the number of different (distinct) haplotypes on
which the allele is present. In total, 110 haplotypes were analyzed. Haplotypes that lack KIR2DL1 are
denoted ‘blank’. The r2 was calculated from Pearson correlation of the alleles shown in blue. This analysis
excluded 2DL1*022 and *026 (shown in red). (B) Shows the allele content of centromeric KIR haplotypes
containing either 2DL1*022 (purple) or 2DL1*026 (yellow). The observed number of each haplotype is given
on the left. Also shown (in white) are the KhoeSan haplotypes that are the putative parents (Par?) of the
derived 2DL*022-containing and 2DL1*026-containing haplotypes. The putative parents are the haplotypes
that differ from the derived haplotypes by the least number of nucleotide substitutions. (C) Plot of haplotype
frequency against linkage disequilibrium (LD). The analysis was conditioned so that 2DL2*003-bearing
haplotypes were analyzed. The figure illustrates the high level of linkage disequilibrium observed for
haplotypes containing 2DL1*022 and 2DL1*026 suggesting they appeared more recently in the KhoeSan
population than other KIR2DL1 alleles.
doi:10.1371/journal.pgen.1005439.g004
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In stark contrast to the parental allotypes, neither progeny is a strong, inhibitory C2 receptor.
KIR2DL1026 has no capacity for signal transduction and 2DL1022 recognizes C1 with speci-
ficity and avidity that exceeds that of any KIR2DL2/3 allotype, the archetypal C1 receptor. The
methionine to lysine substitution at position 44 that defines KIR2DL1022 occurs within the
HLA-C binding site of the KIR [5]. Here, residue 44 in the D1 domain of the KIR interacts
with residue 80 of the α1 domain of HLA-C. For KIR2DL1001, the parent allele of
KIR2DL1022, methionine 44 binds to lysine 80 of the C2 epitope of HLA-C [5,7]. In contrast,
lysine 44 in KIR2DL1022 binds to asparagine 80 of the C1 epitope of HLA-C.
KIR2DL1022 is the most vivid example of how genetic polymorphism can change KIR
specificity for HLA class I. For other allotypes of KIR2DL1 and KIR2DL2/3, the effects of their
defining substitutions can act to alter different functional properties: receptor avidity
[31,32,40], stability, cell-surface abundance and signal transduction [38]. Throughout the KIR
molecule are sites where natural substitutions affect receptor functions. Many of these are away
from the HLA-C binding site and likely involve conformational changes, including ones that
affect the relative orientation of the extracellular D1 and D2 domains that combine to form the
binding site [31,40]. That KIR2DL1022 and 2DL1026 have lost their parents’ capacity to
function as inhibitory C2 receptors, exemplifies a more widespread trend in the KhoeSan. That
is an accumulation of KIR2DL1 allotypes with low avidity for HLA-C2 or weakened signaling
function, as well as KIR B haplotypes lacking the KIR2DL1 gene (Fig 3C).
In human populations worldwide there is an inverse correlation between the frequency of
HLA-C allotypes carrying the C2 epitope and the frequency of the KIR A haplotypes encoding
strong KIR2DL1 allotypes. This correlation reflects the increased risk of spontaneous abortion,
preeclampsia, and low birth-weight that is associated with pregnancies in which a KIR A
homozygous mother who lacks the C2 epitope is carrying a fetus that expresses a C2 epitope of
paternal origin [41,42]. In these pregnancies, the interaction of paternal C2 on extravillous tro-
phoblast cells with maternal uterine NK cells expressing the strong KIR2DL1 encoded by KIR
A haplotypes can lead to incomplete placentation. In general, Africans have a higher frequency
of the C2 epitope than other populations and the C2 frequency of the KhoeSan is particularly
high (63.4%; Fig 5). The reasons for the high C2 frequency are unknown, but may include
Fig 5. The C2 frequency in the KhoeSan is unusually high. Each of the seven blue-shaded vertical bars
gives the number of populations, of 140 considered [34], that have a C2 frequency within the range covered
by the bar, given on the horizontal axis. The frequency data are not significantly different from a normal
distribution (grey line). The black-shaded dots on the curve give the frequencies for the KhoeSan and the four
other populations for which KIR2DL1 allele frequencies are given in Fig 3.
doi:10.1371/journal.pgen.1005439.g005
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protection against specific diseases though interaction of C2-expressing HLA-C with NK cells
or CD8 T cells. Thus the emergence of 2DL1022 and 2DL1026, as well as the general increase
of weaker inhibitory KIR2DL1 allotypes, in the KhoeSan could have acted to reduce the inci-
dence of preeclampsia. In this manner, the KhoeSan retained the ability to both fight infection
and reproduce efficiently.
In assessing the effect of a high C2 frequency on the KhoeSan, it is informative to consider
the Yucpa, an indigenous South American population that has a low frequency of C2 and a
high frequency of C1 (82.7%) [20]. Accompanying the abundance of C1 are two Yucpa-specific
KIR2DL3 alleles, both arising by point mutation of the older, widespread 2DL3001.
KIR2DL3009 has lower C1 avidity than 2DL3001 and 2DL3008N is non-functional. These
Yucpa specific 2DL3 have a frequency of 41.8% compared to 8.2% for their 2DL3001 parent.
In the Yucpa, the high C1 frequency combines with a much-reduced frequency of strong inhib-
itory C1 receptors, whereas in KhoeSan, the high C2 frequency combines with a much-reduced
frequency of strong inhibitory C2 receptors. These analogous behaviors at the two extremes of
the frequency spectrum appear to reflect a buffering mechanism that maintains a balance
between C1, C2 and their inhibitory receptors in human populations.
One possibility is that 2DL1022 and 2DL1026 increased in frequency as a consequence of
genetic drift. Thus, they would represent two of the many private alleles that are present in the
KhoeSan because of their unique demographic history [12]. Unlike other African hunter-gath-
erer groups, the KhoeSan have maintained a large effective population size and high levels of
genetic diversity [10,43]. These characteristics argue against the KhoeSan having been subject
to a classic bottleneck of the type experienced by other African hunter-gatherer populations,
such as the Tanzanian Hadza [10], or migrant modern humans who left Africa and populated
other continents [44]. An alternative interpretation is that 2DL1022 and 2DL1026 rose in fre-
quency in the KhoeSan under positive selection. Supporting this model are the distinctive func-
tional properties of the 2DL1022 and 2DL1026 proteins, the evidence for balancing selection
at the KIR locus [20,24,45,46] and the evidence for diversifying selection at position 44, where
lysine determines the unique functionality of KIR2DL1022 [9]. To establish if drift or selection
is responsible for emergence of the new, variant KIR, will require extensive demographic simu-
lations and the development of appropriate programs that simulate co-evolution between
unlinked, highly polymorphic loci.
Materials and Methods
Ethics statement
Sampling of the 6¼Khomani San in Upington, South Africa and neighboring villages occurred
in 2006. Institution Review Board (IRB) approval was obtained from Stanford University [Pro-
tocol 13829] for assessment of genetic diversity and ancestry inference. Individuals who were
still living in 2011 were re-consented (IRB approved from Stanford University and Stellenbosch
University, South Africa). 6¼Khomani N|u-speaking individuals, local community leaders, tra-
ditional leaders, non-profit organizations and a legal counselor were all consulted regarding
the aims of this research, prior to collection of DNA. All individuals consented orally to partici-
pation, with a second, local native speaker witnessing and were re-consented with written con-
sent. DNA was collected via saliva and all individuals were as described in previous studies
[10,26].
Study populations
Genomic DNA samples were isolated from saliva samples donated by 61 KhoeSan individuals
of the 6¼Khomani San population as described by Henn et al. [10]. KIR2DL1, KIR2DL2/3 and
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HLA-C allele frequencies were determined for 55 unrelated individuals. The additional six indi-
viduals comprised five additional family members of two of the 55 unrelated individuals, and a
sibling of another. The sequences and frequencies of KhoeSan KIR andHLA-C alleles were
compared to those of Ghanaians [14], Northern Irish [21] Japanese [24] and South Amerindi-
ans [20], and also to three non-KhoeSan hunter-gatherer populations. These comprised 20
Mbuti and 20 Baka Pygmies from The Democratic Republic of Congo and Cameroon, and 52
Hadza from northern Tanzania [10]. We also analyzed the KIR sequence data of 100 Zulus
from South Africa [27]. Allele frequencies for the C1 and C2 epitopes of HLA-C were deter-
mined using data deposited at www.allelefrequencies.net [34]. The 140 populations analyzed
were chosen for being anthropologically well characterized, for having minimal admixture
with other populations, and for having a size of 40 individuals or more. This panel of popula-
tions is described in Abi Rached et al. [33].
High-resolution KIR2DL1 and KIR2DL2/3 genotyping
Nucleotide sequences were determined for all exons of KIR2DL1 and KIR2DL2/3 genes from
sixteen randomly selected unrelated KhoeSan individuals as well as the seven-member family.
Sequences for two previously unknown alleles, KIR2DL1022 (GU323355) and KIR2DL1026
(JX523630) were confirmed by re-amplification, cloning and sequencing, as described [26]. A
pyrosequencing-based method for allele-level KIR2DL1 and KIR2DL2/3 genotyping [14], was
expanded to include detection of the new KhoeSan variants (S5 Fig). This method provides a
semi-quantitative measure of SNP genotypes (the peak-height ratio) that determines both allele
identity and copy-number genotype [14]. Centromeric KIR haplotypes were characterized as
described [14], with modification to accommodate the newly-discovered 3DL3038 and
2DL5B018 alleles [26]. Pyrosequencing and standard Sanger sequencing were used to deter-
mine the 2DL1 alleles present in the Pygmy and Hadza populations.
High-resolution HLA genotyping
The 61 KhoeSan individuals were HLA-C genotyped at allele-level resolution using bead-based
SSOP hybridization (One Lambda) and detection by a Luminex-100 instrument (Luminex
corp. Austin, TX).
KIR nomenclature
KIR genes and alleles were named by the KIR nomenclature committee [47] formed from
members of the WHONomenclature Committee for factors of the HLA system, and the
HUGO Genome Nomenclature Committee. A curated database is available at http://www.ebi.
ac.uk/ipd/kir/ [47].
Searching for KIR2DL1*022 and KIR2DL1*026 alleles in the 1000
Genomes and African Genome Variation Project datasets
The high-coverage exome data from the May 2013 release of the 1000 Genomes project [25]
were used to determine the frequency of KIR2DL1022 and KIR2DL1026 in populations world-
wide. All read-pairs that map to the KIR regions (Build Hg19: chr19:55,228,188–55,383,188 and
GL000209.1) were extracted using SAMtools 0.1.18 [48]. For 39 individuals the data have insuf-
ficient coverage and were excluded from the analysis, which was performed on data from 2,496
individuals representing 26 populations (S2B Fig). Individual fastq files were probed using
locus-specific and allele-specific sequence-string searches. Where required, individual fastq files
were filtered for locus-specificity using Bowtie (version 0.12.7) [49], aligned to references and
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the SNP genotypes inspected manually. As controls we included data from eight KhoeSan indi-
viduals who had previously been sequenced using Illumina whole-exome paired end technology
[26] and, independently, KIR genotyped to allele-level resolution by pyrosequencing [14]. Three
of the eight individuals have KIR2DL1022, and one other has KIR2DL1026.
We used the same method to determine the frequencies of 2DL1022 and 2DL1026 in 100
Zulus whose genomes were sequenced as part of the African Genome Variation project [27].
Zulus are a Bantu-speaking population from southern Africa, who show evidence for recent
admixture with the KhoeSan [11,18]. For each Zulu individual having either 2DL1022 or
2DL1026 we used manual inspection of sequence reads mapped to each KIR gene to infer the
likely centromeric KIR haplotype structure.
Binding assay of KIR-Fc fusion proteins to beads coated with HLA class
I
KIR-Fc fusion proteins were generated from insect cells (cabbage looper mothHi5 cells, kindly
provided by Prof. K.C. Garcia, Stanford University) infected with baculovirus as described
[50]. The KIR-Fc fusion protein corresponding to each 2DL1, 2DL2 and 2DL3 allotype was
tested for binding to a panel of microbeads, each of which is coated with one of 31 HLA-A, 50
HLA-B and 16 HLA-C allotypes (LabScreen Single-Antigen Beads, One Lambda, lot #8). To
account for differences in the amount of HLA class I protein coating each bead, the binding of
each KIR-Fc fusion protein was normalized to the binding of W6/32, a monoclonal antibody
detecting a common epitope of HLA class I. Binding values were calculated using the formula
(specific binding—bead background fluorescence)/(W6/32 binding—bead background
fluorescence).
Cell-surface expression of KIR2DL1 in transiently transfected HeLa
Recombinant cDNA encoding the extracellular, stem, transmembrane and cytoplasmic
domain (amino acids 1–336) of KIR2DL1003 with an N-terminal 3X FLAG-tag was manufac-
tured by Genscript (Piscataway, NJ) and cloned into the pcDNA3.1+ expression vector. Site-
directed mutagenesis was performed with the QuikChange Kit (Stratagene), according to the
manufacturer’s instructions, to generate nine further KIR2DL1 variants. HeLa cells (ATCC
Cell Lines, VA) were plated in 15.6mm wells at 5 x 104 cells/well in 500μl DMEMc for 24hrs
and then transfected with a pcDNA3.1+ vector encoding FLAG-tagged KIR2DL1 allotypes
using the Fugene transfection reagent (Promega). After 36h, adherent cells were dissociated
from the wells using 200μl 0.05% trypsin EDTA solution and stained with 25μl mouse poly-
clonal FITC-conjugated FLAG-specific antibody (Sigma-Aldrich) at a final concentration of
3μg/ml. Cells expressing FLAG-tagged KIR2DL1 allotypes were detected by flow cytometry
(Accuri C6 cytometer, BD Biosciences). Dead cells were identified by staining with propidium
iodide and excluded from the analysis. The median fluorescence intensity (MFI) of FITC-con-
jugated anti-FLAG antibody bound to each positively staining cell was used as a measure of the
cell-surface expression of KIR2DL1. At least 50,000 such cells were analyzed in each experi-
ment. Three independent transfections were performed for each allotype.
Population and molecular genetic analysis
The KIR locus has extensive structural and allelic polymorphism [8,51], as well as recombina-
tion hotspots that flank the centromeric KIR region [52,53]. These characteristics preclude the
use of methods that use SNP analysis and the identification of regions of extended haplotype
homozygosity as evidence for selection [54–56]. We examined the patterns of LD associated
with specific alleles, using a method designed for analysis of a polymorphic multigene family
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[39,57]. This approach was applied to the analysis of the haplotypes in centromeric region of
the KhoeSan KIR locus, the regions containing the KIR2DL1 gene.
Supporting Information
S1 Fig. Comparison of the KIR2DL1, KIR2DL2/3 andHLA-C allele frequencies in five
human populations. The KIR2DL1 (A) and KIR2DL2/3 (B) alleles of the KhoeSan are com-
pared to those of the Ga-Adangbe, a Ghanaian population, the Caucasian population of North-
ern Ireland, the Yucpa South Amerindians from Venezuela and Japanese [14,20,21,24]. (C)
Shown are the frequencies of HLA-C alleles from each of the five populations described above.
The alleles are grouped into those encoding HLA-C allotypes with the C1 epitope and those
encoding HLA-C allotypes with the C2 epitope.
(PDF)
S2 Fig. KIR2DL1022 and 2DL1026 evolved in the KhoeSan after their divergence from
other modern human populations. (A) Shown are the results from a search, of whole-exome
genome data from eight KhoeSan individuals [26], for sequence reads corresponding to
KIR2DL1 and to the 2DL1022 and 2DL1026 alleles. Shown on the left are the KIR2DL1 geno-
types of each individual as assessed by pyrosequencing. Shown on the right are the numbers of
KIR2DL1, 2DL1022 and 2DL1026 reads obtained from the exome data and the percentage of
total 2DL1-specific reads that they constitute. (B) Shown is the number of individuals from
each of 26 populations covered by the 1000 Genomes dataset [25]. (C) Shown is the number of
individuals from the 1000 Genomes project [25] and African Genome Variation project
(AGVP) [27] datasets that tested positive for 2DL1022 and 2DL1026, using the same probes
as for panel (A). For no individual in the 1000 Genomes dataset did>1% of the reads that cov-
ered the SNP location match the tested allele (2DL1022 or 2DL1026), whereas for the control
individuals the read ratio matched the expected genotype. Five Bantu-speaking Zulu individu-
als from the AGVP dataset had reads consistent with heterozygosity for either 2DL1022 or
2DL1026. Also shown are the frequencies of 3DL3, 2DL1, 2DL1022 and 2DL1026 in two
non-KhoeSan hunter-gatherer populations: the Mbuti and Baka Pygmies (central Africa) and
the Hadza (Tanzania). Genotype data for these populations were obtained by whole-exome
sequencing.
(PDF)
S3 Fig. In the Bantu-speaking Zulu population of southern Africa, 2DL1022 and
2DL1026 are present on that same KIR haplotypes as in the KhoeSan. (A) Allele content of
centromeric KIR haplotypes containing either 2DL1022 (purple) or 2DL1026 (yellow) that
were defined from analysis of 61 KhoeSan individuals. The number of haplotypes observed is
given on the left under 'N'. Also shown are KhoeSan KIR haplotypes that are putative parents
(Par?) of the haplotypes containing 2DL1022 or 2DL1026 haplotypes (white boxes). (B)
Inferred allele content of centromeric KIR haplotypes containing either 2DL1022 (purple) or
2DL1026 (yellow) that were defined from analysis of 100 Bantu-speaking Zulu individuals.
The number of haplotypes observed is given on the left under 'N'.
(PDF)
S4 Fig. KIR2DL1 allotypes can be classified into functional groups based on HLA-C2 bind-
ing and signaling capacity. (A) KIR2DL1 allotypes were classified into three functional groups
on the basis of their binding to C2 targets and their predicted signaling capacity. KIR2DL1 allo-
types were classified as strong if they had a mean binding to C2 that is greater than 50% of the
strongest known 2DL1 allotype (2DL1020). Allotypes were considered weak if they had either
a mean binding to C2 that is less than 50% of the strongest 2DL1 allotype or if they have a
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cysteine residue at position 245, which is known to reduce inhibitory signaling capacity [38].
KIR2DL1 allotypes with no detectable binding to HLA-C2 or no capacity to transduce an
inhibitory signal were classified as inactive. (B) Table showing the classification of KIR2DL1
allotypes into groups of strong, weak and inactive receptors.
(PDF)
S5 Fig. Oligonucleotide primers used to amplify single KIR2DL1 exons. An initial PCR was
performed using the amplification primers shown in the upper panel. Pyrosequencing was per-
formed following a second (nested) amplification; (o-) indicates biotin and (nnnn-) indicates
random oligonucleotides (to prevent fragment looping). The pyrosequencing reactions were
performed using the primers shown in the lower panel. When required, standard Sanger
sequencing was performed using the amplification primers.
(PDF)
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Polymorphic HLA-C Receptors Balance the Functional
Characteristics of KIR Haplotypes
Hugo G. Hilton,*,† Lisbeth A. Guethlein,*,† Ana Goyos,*,† Neda Nemat-Gorgani,*,†
David A. Bushnell,* Paul J. Norman,*,† and Peter Parham*,†
The human killer cell Ig-like receptor (KIR) locus comprises two groups of KIR haplotypes, termed A and B. These are present
in all human populations but with different relative frequencies, suggesting they have different functional properties that
underlie their balancing selection. We studied the genomic organization and functional properties of the alleles of the inhibitory
and activating HLA-C receptors encoded by KIR haplotypes. Because every HLA-C allotype functions as a ligand for KIR, the
interactions between KIR and HLA-C dominate the HLA class I–mediated regulation of human NK cells. The C2 epitope is
recognized by inhibitory KIR2DL1 and activating KIR2DS1, whereas the C1 epitope is recognized by inhibitory KIR2DL2 and
KIR2DL3. This study shows that the KIR2DL1, KIR2DS1, and KIR2DL2/3 alleles form distinctive phylogenetic clades that
associate with specific KIR haplotypes. KIR A haplotypes are characterized by KIR2DL1 alleles that encode strong inhibitory C2
receptors and KIR2DL3 alleles encoding weak inhibitory C1 receptors. In striking contrast, KIR B haplotypes are characterized
by KIR2DL1 alleles that encode weak inhibitory C2 receptors and KIR2DL2 alleles encoding strong inhibitory C1 receptors.
The wide-ranging properties of KIR allotypes arise from substitutions throughout the KIR molecule. Such substitutions can
influence cell surface expression, as well as the avidity and specificity for HLA-C ligands. Consistent with the crucial role of
inhibitory HLA-C receptors in self-recognition, as well as NK cell education and response, most KIR haplotypes have both
a functional C1 and C2 receptor, despite the considerable variation that occurs in ligand recognition and surface expression.
The Journal of Immunology, 2015, 195: 000–000.
N
atural killer cells are cytotoxic lymphocytes that kill virus
infected (1) and malignantly transformed cells without
prior sensitization (2). They also play an important role
in early pregnancy where they control the trophoblast-mediated
remodeling of maternal blood vessels during formation of the
placenta (3). Controlling the development and function of NK cells
are a wide array of activating and inhibitory cell surface receptors
(4). A common feature of these germline-encoded receptors is
their specificity for MHC class I ligands (in humans the HLA
class I molecules). In catarrhine primates (humans, apes, and Old
World monkeys) the ubiquitously expressed classical MHC class
I molecules are recognized by the killer cell Ig-like receptor
(KIR) family (5). Because both KIR and MHC class I are highly
polymorphic, these interactions diversify and individualize NK
cell responses. The functional importance of such interactions is
illustrated by the association of various combinations of KIR and
HLA class I with the outcome of viral infection (6–8), suscepti-
bility to autoimmune disease (9–11), survival following bone mar-
row transplantation (12, 13), and reproductive success (14, 15).
The catarrhine primates share four phylogenetic lineages of
KIR that have different structure and specificity for MHC class I
molecules (3, 5). Lineage I KIRs recognize HLA-G, which has
restricted expression on trophoblast cells and monocytes and is
considered to be dedicated to reproductive function (16–18).
Lineage II KIRs recognize the A3/A11 and Bw4 epitopes that
are each carried by a different subset of HLA-A and HLA-B
alleles. Lineage III KIRs, the subject of this study, recognize
HLA-C ligands. A ligand for the lineage V KIRs, represented by
KIR3DL3 in humans, has yet to be identified. In contrast to HLA-A
and HLA-B, every HLA-C allotype forms a ligand for KIRs, and
it is these interactions that dominate NK cell responses. Two
mutually exclusive HLA-C epitopes are defined by the residue
at position 80 in the a1 domain and are recognized by different
KIRs (19). Inhibitory KIR2DL1 and activating KIR2DS1 rec-
ognize the C2 epitope (lysine 80) whereas inhibitory KIR2DL3
recognizes the C1 epitope (asparagine 80) and inhibitory
KIR2DL2 principally recognizes C1 but also has some cross-
reactivity with C2 (20, 21).
The KIR gene family is diversified by both gene content vari-
ability and allelic polymorphism and is part of the leukocyte re-
ceptor complex on human chromosome 19 (22, 23). The basic
organization of the KIR locus is conserved among the catarrhine
primates, consisting of four framework genes (common to most
haplotypes) and a suite of homologous genes that are variably
present between species and individuals (24). A site of recombi-
nation at the center of the locus defines two distinct regions: one
closer to the chromosomal centromere (termed centromeric), the
other closer to the chromosomal telomere (termed telomeric) (25).
*Department of Structural Biology, Stanford University School of Medicine,
Stanford, CA 94305; and †Department of Microbiology and Immunology, Stanford
University School of Medicine, Stanford, CA 94305
ORCID: 0000-0002-6962-727X (A.G.).
Received for publication June 17, 2015. Accepted for publication July 22, 2015.
This work was supported by National Institutes of Health Grants AI22039 and
AI17892. H.G.H. was also supported by the March of Dimes Prematurity Research
Center at the Stanford University School of Medicine, Clinical and Translational
Science Awards Grant ULI RR025744, and a Stanford University School of Medi-
cine Dean’s postdoctoral fellowship.
Address correspondence and reprint requests to Prof. Peter Parham, Stanford
University School of Medicine, Sherman Fairchild Building, D157, 299 Campus Drive
West, Stanford, CA 94305. E-mail address: peropa@stanford.edu
The online version of this article contains supplemental material.
Abbreviations used in this article: BB, blocking buffer; DMEMc, DMEM supple-
mented with FBS, streptomycin, penicillin, and L-glutamine; DPBS, Dulbecco’s
PBS; KIR, killer cell Ig-like receptor.
Copyright 2015 by The American Association of Immunologists, Inc. 0022-1767/15/$25.00
www.jimmunol.org/cgi/doi/10.4049/jimmunol.1501358
 Published August 26, 2015, doi:10.4049/jimmunol.1501358












Since the time of their common ancestor, there has been species-
specific reorganization of the centromeric and telomeric regions
of the catarrhine primate KIR locus (5). Chimpanzees, orang-
utans, and gorillas expanded variable KIR genes in the centro-
meric region of the KIR locus but not in the telomeric region (26).
In contrast, macaques and other Old World monkeys expanded
variable KIR genes in the telomeric region but not in the cen-
tromeric region (27). The human species is unique in having
expanded variable KIR genes in both the centromeric and telo-
meric regions (26). Each of these regions contains different genes
and different alleles of shared genes, and it is these differences
that are the basis for the division of human KIR haplotypes into
two functional groups, A and B (28). KIR A haplotypes encode
a fixed suite of largely inhibitory receptors whereas KIR B hap-
lotypes have a variable number of inhibitory receptors and several
activating receptors. That these haplotypes are found in all human
populations but with different relative frequencies suggests they
have different functional properties that are subject to balancing
selection (29).
In addition to their accumulation of activating receptors, the
KIR B haplotypes have accumulated a particular subset of alleles
for the inhibitory receptor genes that are common to KIR A and B
haplotypes (28, 30). Furthermore, although a limited number of
KIR haplotypes have been studied in detail, there appears to be
functional differences between the inhibitory receptors encoded
by the KIR A and B haplotypes (21, 31–33). In this study we
determined the haplotypic association, phylogeny, and function
of every KIR2DL1, KIR2DL2/3, and KIR2DS1 allele defined. In
so doing we have shed light on the evolution and function of
human HLA-C receptors and their contribution to the distinct
functions of the KIR A and B haplotypes.
Materials and Methods
Genomic analyses
Sequences encoding the D1, D2, stem, transmembrane, and cytoplasmic
tail domains (amino acids 1–328) of 26 KIR2DL1, 7 KIR2DS1, and
36 KIR2DL2/3 alleles were aligned and analyzed by three methods:
neighbor joining (using the Tamura–Nei pairwise substitution) (34), maxi-
mum likelihood, and parsimony, each with 500 replicates. The bootstrap
support for each node is indicated when .50. Representative trees are
shown in Figs. 1 and 3 and Supplemental Fig. 1. Evolutionary analyses
were conducted in MEGA6 (35).
Binding assay of KIR-Fc fusion proteins to beads coated with
HLA class I
KIR-Fc fusion proteins were generated from insect cells (provided by
Prof. K.C. Garcia, Stanford University) and infected with baculovirus as
described (36). The KIR-Fc fusion protein corresponding to each
KIR2DL1, KIR2DL2, and KIR2DL3 allotype was tested for binding to
a panel of microbeads, in which each bead is coated with 1 of 97 HLA
class I allotypes (31 HLA-A, 50 HLA-B, and 16 HLA-C allotypes)
(LABScreen single-antigen beads, One Lambda, lot no. 8). To account
for differences in the amount of HLA class I protein coating each bead,
the binding of each KIR-Fc fusion protein is normalized to the binding
of W6/32, a mAb detecting a common epitope of HLA class I. Binding
values were calculated using the formula: (specific binding 2 background
bead fluorescence)/(W6/32 binding 2 background bead fluorescence).
Cell surface expression of KIR2DL1 allotypes
We examined the cell surface expression of four natural KIR2DL1
allotypes and nine KIR2DL1*003 mutants when transfected transiently
into HeLa cells. N-terminal 33 FLAG-tags were attached to each KIR2DL1
construct, so that the expression of each KIR2DL1 variant could be mea-
sured using the same anti-FLAG Ab binding to the identical FLAG epitope.
Recombinant cDNA encoding the extracellular, stem, transmembrane, and
cytoplasmic domains (amino acids 1–328) of KIR2DL1*003 with an
N-terminal 33 FLAG-tag (amino acid sequence, DYKDHDGDYKDHDI-
DYKDDDDK) was manufactured by GenScript (Piscataway, NJ) and sub-
cloned into the pcDNA3.1+ expression vector. Site-directed mutagenesis
was performed with the QuikChange kit (Stratagene), according to the
manufacturer’s instructions, to generate three other natural KIR2DL1 alleles
and nine mutants containing termination codons at different positions in
the sequence encoding the stem, transmembrane, and cytoplasmic tail
domains. HeLa cells were cultured in DMEM (Life Technologies) sup-
plemented with 10% FBS, 100 mg/ml streptomycin, 100 U/ml penicillin,
and 2 mM L-glutamine (DMEMc). Cells were plated in 15.6-mm wells at
5 3 104 cells/well in 500 ml DMEMc for 24 h and then transfected with
a pcDNA3.1+ vector encoding FLAG-tagged KIR2DL1 allotypes using the
FuGENE transfection reagent (Promega). Thirty-six hours after transfec-
tion, adherent cells were dissociated from the wells using 200 ml 0.05%
trypsin-EDTA solution and washed with flow cytometry buffer (Dulbec-
co’s PBS [DPBS] containing 2% EDTA and 1% BSA at 4˚C). Cells were
then stained with 25 ml FITC-conjugated mouse polyclonal anti-FLAG Ab
(Sigma-Aldrich) at a final concentration of 3 mg/ml. Following a further
wash, cells were suspended in 50 ml 503 propidium iodide (BD Bio-
sciences) and fixed in 50 ml 2% paraformaldehyde. Cells expressing FLAG-
tagged KIR2DL1 were detected by flow cytometry (Accuri C6 cytometer,
BD Biosciences). Expression levels of each allotype or mutant were de-
termined from the median fluorescence intensity of FITC-conjugated
anti-FLAG Ab bound to each positive staining cell. Three independent
transfections with at least 50,000 cells each were performed for each
allotype tested.
Slide preparation and microscopy
HeLa cells were plated at 5 3 105 cells/well in 500 ml DMEMc on a
12-mm round no. 1 German glass poly-D-lysine–coated glass coverslip
(BD Biosciences) and transfected with FLAG-tagged KIR2DL1 allotypes.
Forty-eight hours after transfection the cells were fixed in 4% parafor-
maldehyde (Electron Microscopy Sciences) diluted in DPBS with mag-
nesium and calcium (Life Technologies). DPBS (275 ml) containing
glycine (25 mM) was added to quench reactive aldehydes. Cells were
permeabilized with DPBS containing 0.04% saponin and blocked in
blocking buffer (BB; DPBS containing 2% heat-inactivated goat serum,
1% BSA, 0.1% cold fish skin gelatin, 0.02% SDS, 0.1% Nonidet P-40, and
0.05% sodium azide [pH 7.2]). Rabbit polyclonal IgG anti-FLAG primary
Ab (Sigma-Aldrich) was applied at 5 mg/ml in BB and incubated overnight
at 4˚C. After washing with BB, cells were incubated for 20 min at room
temperature with 1 U Alexa Fluor 555 phalloidin solution diluted in BB.
Cells were then washed with BB and incubated for 1 h at room temperature
with Alexa Fluor 488 goat anti-rabbit IgG (Life Technologies) secondary
Ab suspended in BB. Cells were washed in BB and DPBS and coverslips
were mounted for microscopy in ProLong Gold antifade reagent (Life
Technologies). Cells were analyzed by confocal laser-scanning microscopy
using an upright system (DM6000, SP5; Leica) with an oil immersion
objective (363, 1.3 numerical aperture; HCX Plan-Apochromat; Leica)
and argon (488-nm) and HeNe (543- and 633-nm) lasers. Images were
acquired using LAS AF SP5 software (Leica) in sequential scan mode with
a 400-Hz scan rate, line averages of two, and a 5123 512-pixel resolution.
Z-stacks were collected at 0.3-mm intervals. Raw images were processed
using Volocity (PerkinElmer). To improve image quality, raw images were
processed using a fine filter before any analysis was performed. The same
settings were maintained for all samples within an experiment.
Quantification of colocalization of phalloidin and anti-FLAG
channels
Quantitative colocalization analysis in three dimensions was performed
between the phalloidin and anti-FLAG channels. Colocalized voxels
were identified by performing colocalization analysis in Volocity
(PerkinElmer) and generating channels that display the product of the
differences of the mean, which were generated by calculating the product
of the difference from the mean for each voxel intensity from the two
channels analyzed. This gave a clear visual display of areas of positive
(and negative) correlation. The total volume of colocalized voxels per
cell was calculated in Volocity using eight cells for each of the six
transfections performed.
Results
KIR2DL1 and KIR2DS1 alleles form four phylogenetic clades
that segregate on different KIR haplotypes
KIRs that recognize HLA-C divide into two groups: the inhibitory
KIR2DL2/3 that recognize the C1 epitope of HLA-C, and the
inhibitory KIR2DL1 and activating KIR2DS1 that recognize the
C2 epitope of HLA-C. KIR2DL1 and KIR2DL2/3 are highly
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polymorphic, whereas KIR2DS1 is relatively conserved (37)
(http://www.ebi.ac.uk/ipd/kir/).
Phylogenetic analysis of the coding sequence of 26 KIR2DL1
and 7 KIR2DS1 alleles distinguishes four clades of KIR (Fig. 1A,
Supplemental Fig. 1). The amino acid substitutions that distin-
guish representative members of the four clades are shown in Fig.
1B. Clade 1 comprises 10 KIR2DL1*001-like alleles (Fig. 1A),
7 of which have been mapped to KIR haplotypes (29, 38–44).
Five of the seven are present in Cen A, the centromeric region of
KIR A haplotypes (Fig. 2). In contrast, KIR2DL1*022 and
KIR2DL1*026 are present in Cen B, the centromeric region of
KIR B haplotypes (44). Clade 2 comprises 10 KIR2DL1*003-like
alleles, of which 5 have been mapped to KIR haplotypes (Fig. 1A).
These alleles segregate with Cen A (Fig. 2). Clade 3 comprises six
KIR2DL1*004-like alleles, whose products are distinguished from
those of clades 1 and 2 by a 4-aa sequence motif comprising
threonine 154, asparagine 163, and arginine 182 of the D2 domain
and glutamate 216 of the stem domain (Fig. 1B, Supplemental Fig.
2). This motif is shared with KIR2DS1, suggesting that KIR2DL1
acquired this motif from KIR2DS1 by recombination (Fig. 1C)
(26). Clade 3 comprises six KIR2DL1 alleles, of which three have
been mapped to Cen B and one (KIR2DL1*011) to Cen A (Fig. 2).
Clade 4 comprises the seven KIR2DS1 alleles. KIR2DS1 is dis-
tinguished by having an additional residue in the transmembrane
region, threonine 237, as well as lysine 233 that forms a non-
covalent association with DAP12, a disulfide-bonded homodimer
that contains an ITAM (45) (Fig. 1B). KIR2DS1 alleles are all
found in the telomeric region of KIR B haplotypes (Tel B). Four of
these alleles have been identified in the course of high-resolution
KIR haplotype studies (Fig. 2).
KIR2DL2/3 alleles form four phylogenetic clades that
segregate on different KIR haplotypes
The KIR2DL2/3 gene encodes receptors that recognize HLA-C
allotypes carrying the C1 epitope. The alleles of KIR2DL2/3 form
two distinctive groups named KIR2DL2 and KIR2DL3. Phyloge-
netic analysis of 36 KIR2DL2/3 sequences identified four clades of
alleles (Fig. 3A, Supplemental Figs. 1, 2B). The amino acid sub-
stitutions that distinguish representative members of the four clades
are shown in Fig. 3B. Clades 1 and 2 comprise the 24 KIR2DL3
alleles; clades 3 and 4 comprise the 11 KIR2DL2 alleles (Fig. 3C).
Clade 1 consists of 12 KIR2DL3*001-like alleles, and clade 2 con-
sists of 12 KIR2DL3*004-like alleles. Of the 11 KIR2DL3 alleles
mapped to KIR haplotypes, 8 are in Cen A and 2 (2DL3*014 and
2DL3*018) in Cen B (Fig. 2). Although usually present in Cen A,
KIR2DL3*001 has been found in Cen B, but rarely (41).
The KIR2DL2 proteins encoded by clades 3 and 4 are distin-
guished fromKIR2DL3mainly by differences in the transmembrane
region and the cytoplasmic tail (Fig. 3B). In this carboxyl-terminal
part of the molecule, KIR2DL2 is more similar to KIR2DL1 than to
KIR2DL3, indicating that KIR2DL2 acquired this sequence from
KIR2DL1 by recombination (Fig. 3C) (21). Clade 3 comprises 10 of
the 12 KIR2DL2 alleles. Five clade 3 KIR2DL2 alleles have been
mapped to KIR haplotypes and shown to be present on Cen B
(Fig. 2). Additionally, rare examples of 2DL2*003 and 2DL2*006
on Cen A have been reported (Fig. 2) (40, 41). Clade 4 comprises
the KIR2DL2*004 and KIR2DL2*011 alleles. Their protein prod-
ucts are distinguished from other KIR2DL2/3 at positions 41, 167,
269, and 317 (Fig. 3B, Supplemental Fig. 2B). The clade 4 alleles
are both present on Cen B (Fig. 2).
FIGURE 1. KIR2DL1 and KIR2DS1 form four phylogenetic clades. (A) Shown is a phylogenetic analysis of 33 KIR2DL1 and KIR2DS1 nucleotide
sequences encoding amino acids 1–328. The phylogenetic relationships were inferred using three tree-building algorithms that showed broad consensus.
Shown is a representative tree created using the neighbor-joining method (34). The analysis identified four clades, which are color shaded for clarity. The
optimal tree, with sum of branch length of 0.071, is shown. The percentage of replicate trees in which the associated taxa clustered together in the bootstrap
test (500 replicates) is shown next to the branches when$50. The evolutionary distances were computed using the Tamura–Nei method and are in the units of
the number of base substitutions per site. All positions containing gaps and missing data were eliminated. In the final dataset there was a total of 872 positions.
Evolutionary analysis was conducted in MEGA6 (35). (B) Shown is a sequence alignment of the most common allotypes in each of the four KIR2DL1 and
KIR2DS1 clades identified by the phylogenetic analysis. Dots indicate identity with consensus (2DL1*001) and an asterisk indicates a termination codon. The
lines beneath the alignment show the structural domains: Ig-like domains (D1 and D2), stem (St), transmembrane domain (Tm), and cytoplasmic tail (Cyt).
(C) Schematic diagram indicating the likely sites of recombination that define the four phylogenetic clades of KIR2DL1 and KIR2DS1 identified in (A).
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In summary, these analyses (Figs. 1–3) show that for both
KIR2DL1 and KIR2DS1 and KIR2DL2/3 there are four phyloge-
netic clades of alleles that correlate with genomic location in the
Cen A, Cen B, or Tel B regions of KIR haplotypes.
Cen A encodes stronger C2 receptors and weaker C1 receptors
than Cen B
We investigated whether the receptors encoded by Cen A and
Cen B alleles differ in their capacity to bind to a panel of nine C1
and seven C2 allotypes. All 10 KIR2DL1 allotypes encoded by
Cen A (Fig. 2) have strong C2 specificity (Supplemental Fig. 3A).
Of the seven KIR2DL1 encoded by Cen B (Fig. 2), six are specific
for C2 (Supplemental Fig. 3A). The exception, KIR2DL1*022,
has a methionine to lysine substitution at position 44 that gives it
C1 specificity. From a synthesis of these binding data, we dem-
onstrate that KIR2DL1 encoded by Cen A alleles binds C2 with
greater avidity than does Cen B–encoded KIR2DL1, and the dif-
ference is statistically significant (two-tailed t test, p, 0.01) (Fig. 4,
FIGURE 2. KIR2DL1, KIR2DS1, and KIR2DL2/3 segregate on distinct KIR haplotypes. Shown is a listing of the published associations of KIR2DL1 and
KIR2DS1 and KIR2DL2/3 alleles with the centromeric KIR A (Cen A, red), centromeric KIR B (Cen B, light blue), and telomeric KIR B (Tel B) haplotypes (29,
38–44). Alleles with a dual association are listed under both haplotypes with bold type indicating the more frequent association. Alleles that associate differently
from the other alleles in their phylogenetic clade are highlighted with either light blue (phylogenetically Cen B but segregate with Cen A) or light red
(phylogenetically Cen A but segregate with Cen B) shading. Alleles are grouped according to their clade that is shown in parentheses to the right of each allele.
FIGURE 3. KIR2DL2 and KIR2DL3 form four phylogenetic clades. (A) Shown is a phylogenetic analysis of 36 KIR2DL2/3 nucleotide sequences
representing the domains encoding amino acids 1–328. The phylogenetic relationships were inferred using three tree-building algorithms that showed broad
consensus. Shown is a representative tree created using the neighbor-joining method (34). The analysis identified four clades that have been color shaded for
clarity. The optimal tree with sum of branch length of 0.079 is shown. The percentage of replicate trees in which the associated taxa clustered together in the
bootstrap test (500 replicates) is shown next to the branches when$50. The evolutionary distances were computed using the Tamura–Nei method and are in
the units of the number of base substitutions per site. All positions containing gaps and missing data were eliminated. In the final dataset there was a total of
952 positions. Evolutionary analysis was conducted in MEGA6 (35). (B) Shown is an alignment of four KIR2DL2/3 allotypes representing the four clades
identified using phylogenetic analysis. Dots indicate identity with the consensus (2DL3*001) and an asterisk indicates a termination codon. The lines
beneath the alignment show the structural domains: Ig-like domains (D1 and D2), stem (St), transmembrane domain (Tm), and cytoplasmic tail (Cyt). (C)
Schematic diagram indicating the likely sites of recombination that define the four phylogenetic clades identified in (A).
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left panel). Receptor function of three Cen B–associated
KIR2DL1 allotypes is further weakened by substitutions in the
transmembrane or cytoplasmic domain. The presence of cysteine
245 in KIR2DL1*004 and *007 (Supplemental Fig. 2A) reduces
their signaling capacity (31), and that of KIR2DL1*026 is abro-
gated as a result of premature termination at codon 246 that
eliminates the cytoplasmic tail (44, 46). Consistent with a persis-
tent selection pressure to reduce the functionality of Cen B–
encoded KIR2DL1, some allotypes are weakened by substitutions
in both the ligand binding and signaling domains (Table I).
We performed similar analyses of the KIR2DL2/3 allotypes
encoded by Cen A and Cen B. The seven KIR2DL2 alleles gen-
erally associate with Cen B, although rare examples of 2DL2*003
and 2DL2*006 on Cen A have been reported (Fig. 2) (40, 41). Of
these, KIR2DL2*004 is inactivated (47) and does not encode
a functional C1 receptor (44). The eight KIR2DL3 alleles with
defined haplotype association are all on Cen A. Among these is
KIR2DL3*008N that does not encode a functional receptor (29).
KIR2DL3*014 and 2DL3*018 are associated with Cen B and display
strong binding to C1 and cross-reactivity with C2 (Supplemental
Fig. 3B). These binding properties are more like KIR2DL2 allo-
types than the Cen A–encoded KIR2DL3 allotypes. The Cen A–
encoded KIR2DL2 and KIR2DL3 receptors have lower avidity for
C1 than do the Cen B–encoded KIR2DL2 and KIR2DL3 recep-
tors, and this is statistically significant (two-tailed t test, p ,
0.0001) (Fig. 4, right panel). Thus, Cen B–associated KIR2DL2/3
have higher avidity for C2 than do Cen A–associated KIR2DL2/3
(two-tailed t test, p , 0.0001) (Fig. 4, center panel). This pattern
is the opposite of that seen for KIR2DL1, where the Cen A–encoded
allotypes have higher avidity for C2 than do those encoded by
Cen B.
Four D2 domain substitutions give Cen A–associated
KIR2DL1*003 and Cen B–associated KIR2DL1*004 different
C2 avidity
To determine the basis for the weaker C2 avidity of Cen B–en-
coded KIR2DL1, we compared KIR2DL1*003 and KIR2DL1*004,
respectively, the most common Cen A– and Cen B–associated
alleles (29, 38–44). In the D1 and D2 domains that form the
ligand-binding site, KIR2DL1*003 and KIR2DL1*004 differ only
in D2, at positions 114, 154, 163, and 182 (Fig. 5A). We made
KIR-Fc fusion proteins from KIR2DL1*003, KIR2DL1*004, and
the set of 14 KIR2DL1 mutants that represents all possible com-
binations of the four dimorphic positions. These 16 KIR-Fc fusion
proteins were tested for binding to the panel of 97 HLA class I
allotypes.
The 16 KIR2DL1-Fc bound only to the seven C2 allotypes,
with the mean values being shown in Fig. 5B. Substitution at all
four positions affects receptor avidity for C2. Single mutation
at three of the positions (154, 163, and 182) showed that the
KIR2DL1*003 residue increases and the KIR2DL1*004 residue
decreases avidity. For position 114 the opposite effect was seen;
that is, the KIR2DL1*003 leucine decreases avidity and the
KIR2DL1*004 proline increases avidity. Receptors with higher
C2 avidity than any natural KIR2DL1 allotype were made by
introducing proline 114 into KIR2DL1*003 and histidine 182 into
KIR2DL1*004, whereas the weakest of all the mutants tested is the
KIR2DL1*004 mutant with leucine 114. In contrast to the striking
differences seen among the single mutations, the mutants that
differ by two substitutions from KIR2DL1*003 and KIR2DL1*004
are less varied and are all weaker C2 receptors than KIR2DL1*003.
Notably, the combination of histidine 182 and proline 114, which
individually give the strongest receptors, is a weaker receptor than
KIR2DL1*003.
Each of the residues that contributes to the difference between
KIR2DL1*003 and KIR2DL1*004 is present in 8 of the 16
KIR-Fc tested. By averaging the binding of the eight receptors
FIGURE 4. KIR Cen A encodes stronger C2 and weaker C1 receptors
than does Cen B. KIR2DL1 alleles that segregate on the Cen A haplotype
encode receptors that bind to HLA-C2 targets with significantly greater
avidity than those that segregate on the Cen B haplotype (two-tailed t test,
p , 0.01) (left panel). In contrast, KIR2DL2/3 alleles that segregate on the
Cen A haplotype encode receptors that bind to HLA-C2 targets with sig-
nificantly lower avidity than those on the Cen B haplotype (two-tailed
t test, p , 0.001) (center panel). KIR2DL2/3 alleles that segregate on the
Cen A haplotype encode receptors that bind to HLA-C1 targets with sig-
nificantly lower avidity than those on the Cen B haplotype (two-tailed
t test, p , 0.001) (right panel). The binding avidity of each allotype was
assessed using the binding of KIR-Fc fusion proteins to microbeads, each
coated with one of nine HLA-C1 and seven HLA-C2 allotypes (Supplemental
Fig. 3). Binding values are normalized to that of the W6/32 Ab that binds
to all HLA class I allotypes with equal avidity.
Table I. Single nucleotide polymorphisms inactivate six inhibitory lineage III KIR allotypes
Allele Haplotype Linked HLA-C Receptor Mutation Inactivation Mechanism References
2DL1*013N — — E35Ter Truncated protein (38)
2DL1*014 — — G179S Misfolded protein and intracellular retention (44)
2DL1*022 Cen B 2DL2*003 M44K Specificity change to HLA-C1 (44)
2DL1*026 Cen B 2DL2*003 W246Ter Truncated protein (44)
2DL1 blank Cen B 2DL2*003 NA Gene absent (38–44)
2DL2*001
2DL2*005
2DL2*004 Cen B — H41T Misfolded protein and intracellular retention (47)
2DL3*008N Cen A 2DL1*003 Ins86/Ter124 Truncated protein (29)
Haplotype association and identity of known linked HLA-C receptors for five HLA-C receptors that are unable to effect an inhibitory signal via engagement with HLA class I
are shown. Also included is KIR2DL1*022, an allele that encodes a receptor that recognizes C1 but not C2 (44), and 2DL1 blank (the absence of the 2DL1 gene). The amino acid
mutation, termination (Ter) or insertion (Ins), and mechanism by which each allele encodes an inactivated protein is listed to the right with the reference that identified it. —, the
allele listed has no known published association; NA; not applicable, indicates that the listed allele is not defined by an amino acid mutation.
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containing a particular residue we see that the mean values are
very similar, except for that between the groups of receptors
having leucine or proline at position 114 (Fig. 5C). These results
are consistent with all four positions contributing to the binding
and being affected by the particular residues present at the other
positions. Thus, the four dimorphic sites have not coevolved to
produce the strongest and weakest C2 receptors possible. Instead,
there exists a more moderate balance between a stronger and a
weaker C2 receptor. The dimorphism of arginine (KIR2DL1*003)
and cysteine (KIR2DL1*004) at position 245 at the end of the
transmembrane domain (Fig. 1B) also adds to the functional
difference between KIR2DL1*003 and KIR2DL1*004. The cyste-
ine 245 reduces the capacity of KIR2DL1*004 to develop inhibitory
signals (31) and educate NK cells (33).
The N-terminal half of the KIR2DL1 transmembrane domain is
essential for cell surface expression
KIR2DL1*004 is one example of a Cen B–associated allotype
that is functionally affected by polymorphism at the junction
between the transmembrane and cytoplasmic domains. Another is
KIR2DL1*026 that has a termination codon at position 246
(Supplemental Fig. 2A). This substitution has two effects. First, it
eliminates the cytoplasmic tail with its ITIMs that mediate inhib-
itory signaling function (46). Second, it reduces the cell surface
expression of KIR2DL1*026, which is 32% that of KIR2DL1*012,
the progenitor of KIR2DL1*026 (44). This observation raised the
question: How much of the transmembrane domain is necessary for
KIR2DL1 to become cell surface associated?
To address this question we introduced termination codons at five
evenly spaced positions within the sequence encoding the trans-
membrane domain (residues 225–245) of KIR2DL1*003, as well as
at position 224 in the stem domain and positions 246, 250, and
256 in the cytoplasmic tail (Fig. 6A). After incorporation of
N-terminal 33 FLAG-tags, the 12 mutant constructs and wild-
type KIR2DL1*003 were transiently transfected into HeLa cells.
After 48 h of culture the amounts of KIR2DL1 on the surface of
the transfected HeLa cells were measured using anti-FLAG Ab
and flow cytometry.
Termination in the N-terminal half of the transmembrane region
(residues 225–235) completely abrogated cell surface expression
of the mutant KIR2DL1*003. In contrast, termination in the
carboxyl-terminal half of the transmembrane (residues 236–245)
permitted cell surface expression of mutant KIR2DL1*003, with
levels corresponding to 53–72% of the wild-type (Fig. 6A). These
results show that the N-terminal half of the transmembrane do-
main is required for membrane association and cell surface ex-
pression of KIR2DL1. Mutants that terminate at positions 238,
242, and 246, and that lack a cytoplasmic tail, were expressed at
slightly higher levels than mutants 250 and 256 that have a short,
truncated cytoplasmic tail (p = 0.0317). Terminating at position
246, KIR2DL1*026 is in the former category.
KIR2DL1*014 folds inefficiently and is retained inside the cell
KIR2DL1*014 differs from KIR2DL1*003 by substitution of glycine
for serine at position 179 in the D2 domain (Supplemental Fig. 2A).
Serine 179 prevents cell surface expression of KIR2DL1*014 and
the binding of KIR2DL1*014-Fc to HLA class I (44). These
properties suggest that serine 179 prevents KIR2DL1*014 from
folding properly, thereby leading to a denatured protein and its
intracellular retention.
To test this hypothesis, confocal microscopy was used to ex-
amine the cellular localization of FLAG-tagged KIR2DL1*014 in
FIGURE 5. Variation at positions 154, 163, and 182 in the D2 domain reduces the avidity of KIR2DL1*004 for HLA-C2. (A) Structural representation of
KIR2DL1 (PDB: 1NKR) (48) mapping the location of the four residues at which 2DL1*003 and 2DL1*004 differ. The protein backbone is shown in gray with
the four positions of substitution highlighted in yellow. (B) Mean binding of 16 KIR2DL1-Fc fusion proteins to microbeads, each coated with one of seven
C2 HLA-C allotypes. Shown is a sequential mutation analysis in which every possible residue or combination of residues at which 2DL1*003 and 2DL1*004
differ is tested for binding to HLA-C2. The alignment to the left shows the identity of the residues in each KIR-Fc mutant. Binding values are normalized to
that of the W6/32 Ab that binds to all HLA class I allotypes with equal avidity. Broken vertical lines indicate the binding of 2DL1*003 (dark blue) and
2DL1*004 (light blue) for comparison. (C) Shown is the mean binding to HLA-C2 of every mutant KIR-Fc containing the listed amino acid residue at positions
114, 154, 163, and 182. KIR-Fc with leucine 114 bound to HLA-C2 with a significantly lower avidity than those with proline 114 (two-tailed t test, p, 0.01).
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transiently transfected HeLa cells (Fig. 6B). KIR2DL1*012, an
allotype expressed highly at the cell surface, served as the control.
Phalloidin, which binds to intracellular actin, was used as an in-
dependent marker of the underside of the cell surface (Fig. 6Bb).
In cells expressing FLAG-tagged KIR2DL1*012, the distribution
of the anti-FLAG Ab (Fig. 6Bc, upper) overlapped with that of
phalloidin. This is further seen in a merge of the two images
(Fig. 6Bd, upper) and determination of the extent of colocalization
(Fig. 6Be, upper). In the cells expressing KIR2DL1*014 the anti-
FLAG Ab was detected inside the transfected cells (Fig. 6Bc,
lower) but not at the cell surface similar to phalloidin (Fig. 6Bb,
lower). On merging the two images (Fig. 6Bd, lower) there was
no detectable colocalization (Fig. 6Be, lower). Quantification
of the extent of the colocalization of phalloidin and anti-FLAG
Ab in transfected HeLa cells expressing KIR2DL1*012 and
KIR2DL1*014 is shown in Fig. 6C. This analysis demonstrates
that transfected cells expressing KIR2DL1*014 make the protein
but do not transport it to the cell surface. These data are consistent
with KIR2DL1*014 not folding properly.
Analysis of the three-dimensional structure of KIR2DL1*001
(PDB:1NKR) (48) showed that position 179 of the D2 domain is
buried beneath the binding site for HLA-C (Fig. 6D, left panel). We
modeled the effect of replacing glycine 179 of KIR2DL1*001
with the serine 179 of KIR2DL1*014. In this model, the side chain
substitution of a hydrogen atom for a methyl group displaces the
tyrosine at position 134 (Fig. 6D, right panels). We hypothesize that
this displacement is incompatible with proper folding of the KIR2D
molecule. Supporting this interpretation, tyrosine 134 and glycine
179 are conserved in hominoid lineage III KIR (Supplemental Fig. 4).
Variation at positions 16 and 148 diversifies the recognition of
HLA-C by KIR2DL2/3
Analysis of hominoid KIR sequences demonstrated that positions
16 (D1 domain) and 148 (D2 domain) have been subject to positive
selection during hominoid evolution (26). These residues juxtapose
within the hinge region that connects the D1 and D2 domains
(Fig. 7A) (49). Polymorphism at residues 16 and 148 of KIR2DL2/3
has been proposed to vary the angle between the D1 and D2
domains and account for KIR2DL2*001 and KIR2DL3*001 having
different avidity and specificity for HLA-C (21, 50). Having proline
16 and arginine 148, KIR2DL3*001 is a C1-specific receptor of
moderate avidity. In contrast, arginine 16 and cysteine 148 give
KIR2DL2*001 high avidity for C1 and cross-reactivity with C2
(21, 32).
Sequence comparison of 61 KIR2DL1, KIR2DL2, and KIR2DL3
variants showed that arginine and proline are the only residues
present at position 16, whereas arginine, proline, and cysteine can
occur at position 148 (Fig. 7B). Five of the six possible combi-
nations of these residues are present in human lineage III KIR.
Absent is the combination of arginine 16 with proline 148
(Supplemental Fig. 4). The other five combinations are repre-
sented in the 36 KIR2DL2/3 allotypes, but only two combinations
are represented in the 33 KIR2DL1 and 2DS1 allotypes (Fig. 7C).
To see how the variability at positions 16 and 148 influence avidity
FIGURE 6. The N-terminal half of the KIR2DL1 transmembrane domain is essential for cell surface expression. (A) Cell surface expression of natural and
mutant KIR2DL1. Constructs encoding FLAG-tagged KIR2DL1 were transiently transfected into HeLa cells. The binding of anti-FLAG Ab to the transfected
cells was measured. Shown are median fluorescence intensity (MFI) values for the KIR2DL1*012, KIR2DL1*026, KIR2DL1*003, and KIR2DL1*014
natural allotypes and for nine KIR2DL1 mutants, each containing a termination codon at the listed residue. Termination codons were placed at position 224 in
the stem region (brown), positions 228, 231, 235, 238, and 242 in the transmembrane region (gray) and positions 246, 250, and 256 in the cytoplasmic tail
(pale yellow). Error bars give the SD for three separate experiments. Statistically significant differences are denoted by brackets. Shown below is the amino
acid sequence at positions 220–258 in KIR2DL1*003. This sequence encompasses the stem region (brown), the transmembrane region (gray), and the
cytoplasmic tail (yellow). Residues at which termination codons were introduced are shown in red. (B) Shown are confocal microscopy images of HeLa cells
48 h after transfection with FLAG-tagged KIR2DL1*012 (upper panels) and KIR2DL1*014 (lower panels). Columns a–e show the bright field image,
staining with phalloidin–Alexa Fluor 555 to identify the area near the cell surface, staining with FITC-conjugated anti-FLAG Ab, a merged image of columns
b and c, and the colocalization of anti-FLAG and phalloidin. (C) Shown is the quantitative colocalization analysis in three dimensions performed between the
phalloidin and anti-FLAG channels. The total volume of colocalized voxels per cell was calculated in Volocity (PerkinElmer) using eight cells for each of the
six transfections performed. (D) Structural representation of KIR2DL1 (PDB: 1NKR) (48) showing the location of glycine 179 (yellow) buried in the interior
of the receptor architecture (left panel). As seen in the enlargement in the right panels, structural analysis showed that substitution of glycine for serine at
position 179 is predicted to disrupt protein folding as a result of a side chain interaction between serine 179 and tyrosine 134.
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for HLA-C, we made 18 KIR-Fc fusion proteins in which all six
combinations of the natural residues at positions 16 and 148 were
introduced into KIR2DL1*003, KIR2DL2*001, and KIR2DL3*001.
These KIR-Fc fusion proteins were tested for binding to HLA
class I.
KIR2DL1*003 and four of the five KIR2DL1 mutants have
similarly high avidity and specificity for HLA-C, exhibiting ,15%
variability in the binding to any HLA-C allotype (Fig. 7D). In
contrast, the mutant combining proline 16 with proline 148 retained
high specificity for C2 but its avidity was reduced to 60% that of
KIR2DL1*003.
In comparison with the relative insensitivity of KIR2DL1*003
to mutation, all the KIR2DL2 and KIR2DL3 mutants exhibit
detectable differences (Fig. 7D). For KIR2DL2 the major effect
of mutation was to change the avidity, whereas the specificity, of
stronger binding to C1 and weaker binding to C2, was less af-
fected. Arginine residues correlate with the highest binding.
Thus, the mutant with arginine 16 and arginine 148 binds more
strongly to HLA-C than does the wild-type KIR2DL2*001 that
combines arginine 16 with cysteine 148. Alternatively, lower
binding correlates with the presence of proline at positions 16
and 148, with the weakest receptor having proline 16 and pro-
line 148. The effect of cysteine at position 148 is intermediate
between that of arginine and proline. These general effects of
arginine and proline are seen for KIR2DL1, KIR2DL2, and
KIR2DL3 (Fig. 7E).
Three of the KIR2DL3 mutants have higher avidity for
HLA-C than does wild-type KIR2DL3*001. What distinguishes
KIR2DL3*001 from the five mutants is its minimal cross-reactivity
with C2. It therefore appears that KIR2DL3*001 evolved under
selection for C1 specificity, with avidity being of secondary im-
portance. In contrast, the evolution of KIR2DL1*003 resulted in
a receptor having both high avidity and high specificity for C2.
The properties of KIR2DL2 are different again. KIR2DL2 rec-
ognizes both C1 and C2, making it a stronger C1 receptor than
KIR2DL3 and a weaker C2 receptor than KIR2DL1. Thus, KIR2DL2
appears as an evolutionary compromise, or intermediate, between
KIR2DL1 and KIR2DL3.
KIR2DS1 allotypes bind HLA-C2 with different avidity
KIR2DS1 has specificity for C2 (20), similar to KIR2DL1, but is
less polymorphic. KIR2DS1 alleles encoding seven KIR2DS1 al-
lotypes have been described (37). KIR2DS1*002 is by far the most
frequent allele, being present in every population that has been KIR
typed at allele-level resolution (29, 38–44). To study the avidity
and specificity of KIR2DS1, we constructed KIR-Fc fusion proteins
for the four KIR2DS1 allotypes that differ in the amino acid se-
quences of the D1 and D2 domains that bind HLA class I (Fig. 8A).
The four KIR2DS1 allotypes all bound to the seven C2-bearing
HLA-C allotypes (Fig. 8B) but did not bind to the nine C1-bearing
HLA-C allotypes (data not shown). KIR2DS1*001 has the highest
avidity for C2, which correlates with arginine at position 70,
where the other KIR2DS1 allotypes have lysine. KIR2DS1*008
has the lowest avidity for C2, which correlates with serine 123,
where the other KIR2DS1 allotypes have tryptophan. Having
a similar intermediate avidity for C2 are KIR2DS1*002 and
KIR2DS1*004. They differ at position 90, where the valine–leucine
dimorphism has little effect on the receptors’ avidity. Thus, the
FIGURE 7. Residues at positions 16 and 148 diversify the binding of two-domain KIR to HLA-C. (A) Structural representation of a two-domain
KIR (green) bound to HLA-C (blue) (PDB: 1EFX) (49). Shown in red and enlarged in the right panel is the position of residues 16 and 148 that
occupy the hinge region of the receptor. (B) Alignment showing the amino acid variation at positions 16 and 148 in 61 KIR2DL1 and KIR2DL2/3
allotypes. One representative allele with a unique combination of residues is shown for KIR2DL1 and KIR2DL2/3. The allotypes listed differ at
residues other than 16 and 148 (Supplemental Fig. 2). (C) For each unique combination of residues at positions 16 and 148, the number of
KIR2DL1, KIR2DS1, KIR2DL2, and KIR2DL3 allotypes that encode that combination are listed. A dash (-) indicates the combination is not present
in the listed gene. (D) Shown is the binding of six 2DL1-Fc, six 2DL2-Fc, and six 2DL3-Fc fusion proteins to nine HLA-C1 allotypes (s) and 7
HLA-C2 allotypes (▴). The residues at positions 16 and 148 were mutated to those listed below each KIR-Fc. The prototypical allotypes of each
KIR (KIR2DL1*003, KIR2DL2*001, and KIR2DL3*001, respectively) are indicated with red lettering and gray shading. Binding values are
normalized to that of the W6/32 Ab that binds to all HLA class I allotypes with equal avidity. (E) Shown is the mean binding to HLA-C2 and HLA-
C1 of every KIR containing arginine at either position 16 or 148 (R), cysteine at either position (C), or proline at either position (P). KIR2DL3-Fc
containing either R16 or R148 bound to C1-bearing allotypes with significantly greater avidity than those containing either P16 or P148 (two-tailed
t test, p , 0.01).
8 FUNCTIONAL VARIATION IN KIR HAPLOTYPES












observed differences in avidity can be attributed to the dimor-
phisms at position 70 in the D1 domain and 123 in the D2 domain.
Position 70 has been subject to positive selection in hominoid KIR
and has a dominant effect in modifying the avidity of KIR2DL1
and KIR2DL3 (51). Arginine at position 70 improves recognition
of HLA-C as shown in this study for KIR2DS1 and previously for
KIR2DL3 (51). Although, overall, KIR2DS1 allotypes are not as
avid HLA-C2 receptors as KIR2DL1, there are KIR2DL1 allo-
types that have similar HLA-C2 avidity to each of the KIR2DS1
allotypes (Fig. 8B).
Discussion
This study investigated the genetic and functional diversity of human
HLA-C receptors. We showed that the inhibitory KIR2DL1, acti-
vating KIR2DS1, and inhibitory KIR2DL2/3 alleles form distinctive
phylogenetic clades that associate with specific KIR haplotypes.
Typifying KIR Cen A haplotypes are KIR2DL1 alleles that encode
strong inhibitory C2 receptors and KIR2DL2/3 alleles encoding
weak inhibitory C1 receptors. In striking contrast, Cen B haplotypes
combine KIR2DL1 alleles that encode weak inhibitory C2 receptors
with KIR2DL2/3 alleles encoding strong inhibitory C1 receptors.
Our results are in accordance with the first descriptions of the
genomic organization of KIR haplotypes (28, 52, 53). These
studies identified the segregation of KIR2DL3 with KIR A hap-
lotypes and KIR2DL2 with KIR B haplotypes. Subsequent work
highlighted the functional differences between the receptors
encoded by these allelic variants (21, 32). High-resolution KIR
analysis of white populations consistently associated KIR2DL1*004
with the KIR B haplotype, and in positive linkage disequilibrium
with KIR2DL2 (30). Functional differences between the KIR2DL1
alleles of KIR A and B haplotypes were likewise discovered when
NK cells expressing KIR2DL1*004 were found to be hypores-
ponsive in comparison with NK cells expressing KIR2DL1*003
(33). Dimorphism at position 245 in the transmembrane region of
KIR2DL1 was demonstrated to be one mechanism that causes
such functional differences (31).
We show that such attenuated function is not limited to
KIR2DL1*004, or even to the group of KIR2DL1 allotypes having
cysteine 245, but it is a defining characteristic of the KIR2DL1
encoded by Cen B–associated alleles. A variety of mechanisms
cause functional attenuation, with mutations in the ligand-binding
domains regulating the avidity and specificity of KIR2DL1 for
HLA-C. Such changes can synergize with those in the trans-
membrane domain (which predominantly regulate cell surface
expression and signaling function) to produce a broad range of
functionally distinct receptors that share the common feature of
being weakened in comparison with the KIR2DL1 allotypes as-
sociated with the KIR A haplotype.
Examination of KIR2DL2/3 allotypes revealed a range of
functional properties, similar to those seen for KIR2DL1. In
contrast to KIR2DL1, the weaker C1 receptors are associated with
KIR A haplotypes and the stronger receptors are associated with
KIR B haplotypes. Additionally, the weaker KIR A–associated
receptors are more specific C1 receptors than the KIR B–associated
receptors, which to varying degree exhibit cross-reactivity for
C2. Unlike KIR2DL1, most functional differences between
KIR2DL2/3 allotypes arise from amino acid substitutions in the
ligand-binding domains.
Of interest in this regard are KIR2DL2*008 and KIR2DL2*010,
two alleles for which haplotype associations have yet to be de-
termined. The ligand-binding domains are identical to those of the
KIR2DL2*001 prototype. Where they differ from KIR2DL2*001,
and all other KIR2DL2/3 allotypes, is in the transmembrane
domain. They have cysteine instead of arginine at position
245. Given the functional attenuation caused by cysteine 245 in
KIR2DL1 (31), it is likely that cysteine 245 in KIR2DL2*008 and
KIR2DL1*010 weakens their function by reducing cell surface
expression and inhibitory signaling. Supporting this hypothesis,
KIR2DL2 and KIR2DL1 have almost identical transmembrane
and cytoplasmic domains (21). We further predict that KIR2DL2*008
and KIR2DL2*010 associate with Cen A haplotypes, not Cen B
haplotypes, similar to other KIR2DL2 alleles. A precedent for
such “haplotype infidelity” is that KIR2DL3*014 and KIR2DL3*018
are strong C1 receptors that cross-react with C2 and associate with
Cen B.
Our results indicate that polymorphisms in all of the structural
domains of the mature protein can impact the function of KIR with
respect to the initiation and propagation of inhibitory or activating
signals. Substitutions that change the avidity of KIR2DL1 for
HLA-C are usually in the D2 domain, whereas substitutions that
change the avidity of KIR2DL2/3 for HLA-C are usually in the
hinge region connecting the D1 and D2 domains. The only site
where substitution has significant impact on the specificity of
KIR2DL1 for C2, or KIR2DL2/3 for C1, is position 44 in the D1
domain. Substitutions that affect the cell surface expression of
KIR2DL are more often in the transmembrane or the cytoplasmic
domain, but there are also substitutions in the extracellular domains
that affect receptor function in this way. An extreme example is
KIR2DL1*014, which is completely retained inside the cell as
a consequence of having serine, rather than glycine, at position
179 in the D2 domain. We suspect that this substitution prevents
proper folding of KIR2DL1*014.
FIGURE 8. Substitutions in the extracellular binding domains regulate the avidity of KIR2DS1 allotypes for HLA-C2. (A) Shown is an alignment of the
Ig-like domains (D1 and D2) of four allotypes of KIR2DS1 and four allotypes of KIR2DL1. Dots indicate identity with consensus. The position of the
structural domain (D1 or D2) is indicated by a line below the alignment. (B) Binding of four naturally occurring KIR2DS1-Fc and KIR2DL1-Fc fusion
proteins to microbeads coated with seven C2 HLA-C allotypes. Binding values are normalized to that of the W6/32 Ab that binds to all HLA class I
allotypes with equal avidity.
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Similar to KIR2DL1*014, KIR2DL1*013N, KIR2DL1*026,
KIR2DL2*004, and KIR2DL3*008N are inhibitory lineage III
KIR that are unlikely to be functional receptors (Table I). We
examined the extent to which inactivation of these receptors af-
fected the capacity of their haplotypes to provide inhibitory
receptors that recognize C1 and C2. From the initial description of
KIR A and B haplotypes it was appreciated that they both encode
inhibitory receptors that recognize C1 and C2 (28, 52). Subsequent
studies established the combination of KIR2DL1 and KIR2DL3 on
Cen A and of KIR2DL1 and KIR2DL2 on Cen B (25, 30, 40–42).
Overlaying our functional binding data onto the high-resolution
KIR haplotypes of seven populations, we find that every KIR2DL1
allotype encoded by Cen A recognizes C2 and that every KIR2DL3
allotype encoded by Cen A recognizes C1. The exception is a KIR A
haplotype of Yucpa Amerindians, which has a frequency of 7.4%
and combines a strong, C2-specific receptor with the nonfunc-
tional KIR2DL3*008N allele (29). Consequently, the receptors
encoded by this haplotype cannot recognize C1, although the
frequency of the haplotypes is such that ,1% of individuals in the
population would be deficient in C1 recognition.
Cen B haplotypes that encode KIR2DL1*022 and KIR2DL1*026
(neither of which can mediate inhibition via engagement with
C2) are in strong linkage disequilibrium with KIR2DL2*003 and
are specific to the KhoeSan and immediately neighboring pop-
ulations in southern Africa (44). Cen B haplotypes that lack the
KIR2DL1 gene (KIR2DL1 blank) are widespread and associated
with KIR2DL2*003, KIR2DL2*001 and KIR2DL2*005 (Table I)
(38–44). These Cen B haplotypes retain some capacity to recog-
nize C2 because their associated KIR2DL2 allotypes cross-react
with C2 (Supplemental Fig. 3B). The functional importance of
these cross-reactions needs to be assessed in cellular assays of NK
cell education and effector response.
Although the relative frequency of KIR A and B haplotypes
varies substantially across the world, as do C1 and C2 frequencies,
there is a strong correlation between C2 and KIR B and a corre-
sponding inverse correlation between C2 and KIR A (14). Thus, it
appears that in populations with high C2 frequency, such as those
in Africa, there has been selection for weak C2 receptors and
strong C1 receptors (found on KIR B haplotypes) whereas in
populations with high C1 frequency, such as those in Asia and the
Americas, there has been selection for weak C1 receptors but
strong C2 receptors (found on KIR A haplotypes). Underlying
these observations, and implicating a strong inhibitory C2 receptor–
ligand interaction in their pathogenesis, are correlations with
pregnancy syndromes. Thus, women who are pregnant with a fetus
expressing C2 are at increased risk of pre-eclampsia (14, 15).
Those same strong inhibitory KIR–ligand interactions are, how-
ever, vital for the development of well-educated NK cells that are
both self-tolerant and responsive to virally infected and malig-
nantly transformed cells. Thus, a pattern emerges in which KIR
haplotypes with contrasting functional properties are subject to
selection in response to the relative abundance of HLA-C ligand.
In this way, the KIR system may be considered a buffering mecha-
nism by which optimal NK cell function is preserved, despite
fluctuations in the frequency of available ligand.
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Soluble recombinant proteins that comprise the extracellular part of a surface expressed receptor attached to the
Fc region of an IgG antibodyhave facilitated the determination of ligand specificity for an array of immune system
receptors. Among such receptors is the family of killer cell immunoglobulin-like receptors (KIR) that recognize
HLA class I ligands. These receptors, expressed on natural killer (NK) cells and T cells, play important roles in
both immune defense and placental development in early pregnancy. Herewe describe amethod for the produc-
tion of two domain KIR–Fc fusion proteins using baculovirus infected insect cells. This method is more scalable
than traditional mammalian cell expression systems and produces efficiently folded proteins that carry post-
translational modifications found in native KIR. We also describe a multiplex binding assay using the Luminex
platform that determines the avidity and specificity of two domain KIR–Fc for a panel of microbeads, each coated
with one of 97 HLA class I allotypes. This assay is simple to perform, and represents a major improvement over
the assays used previously, which were limited in the number of KIR and HLA class I combinations that could
be assayed at any one time. The results obtained from this assay can be used to predict the response of NK cell
and T cells when their KIR recognize HLA class I.
© 2015 Elsevier B.V. All rights reserved.
1. Introduction
Killer-cell immunoglobulin like receptors (KIR) are a family of germ-
line encoded cell surface receptors that regulate the activity of natural
killer (NK) cells and T cells in immunity and reproduction through inter-
action with HLA class I molecules (Parham andMoffett, 2013). Both KIR
and HLA are encoded by polymorphic genes, which have numerous al-
leles encoding unique KIR and HLA class I proteins, which are known
as allotypes. HLA class I proteins are expressed on the surface of most
cell types and present a diverse repertoire of peptides that furnish li-
gands for KIR and other immune system receptors (Bjorkman et al.,
1987; Colonna et al., 1992; Colonna and Samaridis, 1995; Moretta
et al., 1993). The HLA class I locus contains three highly polymorphic
genes, called HLA-A, B and C. HLA-C is the most recently evolved and
the only one for which all the variant forms are KIR ligands (Guethlein
et al., 2007; Older Aguilar et al., 2010, 2011). Dimorphism at position
80 in HLA-C defines two epitopes, C1 (asparagine 80) and C2 (lysine
80), which are ligands for two different forms of two-domain KIR
(Mandelboim et al., 1996; Winter and Long, 1997). KIR2DL1 encodes
methionine at position 44 and binds to C2 bearingHLA-C, KIR2DL2/3 en-
codes lysine at position 44 and binds to C1 bearing HLA-C allotypes.
Because the genes encoding KIR and HLA class I are on different
chromosomes, their independent segregation during meiosis produces
diversity in the number and type of KIR–HLA gene combinations
inherited by individuals (Norman et al., 2013; Wilson et al., 2000). Fur-
ther, NK cells can express more than one KIR at a time (Lanier, 1997;
Valiante et al., 1997). This inherent diversity has complicated the inves-
tigation of the specific KIR–HLA class I interactions that modulate
immune response. Development of soluble KIR proteins for which the
reactivity for single HLA class I molecules was determined by direct
binding assay, facilitated understanding of how particular receptor–
ligand combinations contributed to NK cell reactivity (Winter et al.,
1998). These recombinant proteins were made in a mammalian cell ex-
pression system by fusing the extracellular domains of a two-domain
KIR with two Fc domains of a human IgG1 to form a soluble homodimer
(Winter and Long, 2000).
We have adapted this method for the production of soluble KIR–Fc
fusion proteins by usingbaculovirus-infected insect cells. The advantage
of this approach is that insect cells are simple to culture. They have short
doubling times that facilitate scaling and they are capable of higher pro-
tein yields thanmammalian cell systems of expression. Because of these
advantages, the baculovirus–insect cell system is now one of the most
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widely used methods for the production of recombinant proteins
(Hitchman et al., 2009). Although not equivalent to higher eukaryotic
cells, most post-translational modifications are made correctly in insect
cells, and proteins unable to be expressed in E. coli have been successful-
ly expressed in the insect cell system (Victor et al., 2010). The
baculovirus family are species-specific double-stranded DNA viruses
that infect insects as their natural host (Kost and Condreay, 1999).
Once inserted into the host nucleus, the baculovirus is packaged into
flexible nucleocapsids, into which foreign DNAmay readily be inserted.
The target gene, in this case the KIR–Fc fusion construct, is inserted into
a transfer vector and positioned between sequences that are homolo-
gous to the ones in the baculoviral genome. When the viral genome
and transfer vector are transfected into insect cells, recombination
occurs, and produces intact viral genomes harboring the target gene
sequence. The target gene replaces the non-essential baculoviral
polyhedrin gene. The strong promoter of the polyhedrin gene is co-
opted for production of recombinant target protein.
We have also developed a multiplex assay that tests the binding of
soluble KIR–Fc to 97 HLA class I allotypes. This assay uses the Luminex
platform, in which the antigenic targets are microbeads, each coated
with a definedHLA class I allotype. Such beadswere developed original-
ly for studying the specificity of human alloantibodies (Pei et al., 1998,
2003), but our group has successfully adapted this platform for use
with recombinant two-domain KIR–Fc fusion proteins and monoclonal
antibodies (Hilton and Parham, 2013; Moesta et al., 2008). By adjusting
the relative concentration of two fluorescent dyes, a set of 100 individ-
ually identifiable beads is generated. Each bead is then coatedwith a dif-
ferent HLA class I allotype, allowing the results of the immunoassay to
be correlated with HLA class I specificity.
The goal of the KIR–Fc HLA-bead binding assay is to determine the
strength and specificity of the interactions between HLA class I and
KIR using defined purified proteins. The results can be used to predict
the reactivity of KIR expressing NK cells and T cells when their KIR rec-
ognize cognate HLA class I ligands. This assay represents a major ad-
vance from the cell-based direct binding assay in which the reactivity
of only a few KIR and HLA class I combinations could be determined at
any one time (Winter and Long, 2000). Moreover, the KIR–Fc HLA
bead-binding assay is designed to inform cellular assays of lymphocyte
function in which receptor deficient effector NK cells transfected with a
specific KIR are incubated with ligand-deficient target cells transfected
with a specific HLA class I molecule (Moesta et al., 2008).
The HLA class I specificity of several KIR allotypes has been investi-
gated using various assays. Our initial study with the multiplex bead-
binding assay showed that KIR2DL2*001–Fc recognized HLA-C2 allo-
types with higher avidity than its allotypic variant KIR2DL3*001–Fc
(Moesta et al., 2008). A cellular cytotoxicity assay subsequently showed
that KIR2DL2*001, but not KIR2DL3*001 effectively inhibited lysis
when incubated with HLA class I deficient 221 cells transfected with
the HLA-C2 allotype, HLA-C*04:01 (Moesta et al., 2008). Another
group investigated a second allotypic variant, KIR2DL3*005 (Frazier
et al., 2013) using a similar multiplex assay. They showed that
KIR2DL3*005–Fc bound HLA-C1 allotypes with higher avidity than
KIR2DL3*001–Fc. This result was concordant with a cellular assay in
which NK cells expressing either 2DL3*005 or 2DL3*001 respectively
were incubated with 221 cells expressing the C1 bearing allotype
HLA-C*03:04. Natural killer cells expressing 2DL3*005 exhibited a
more potent inhibitory signal than those transfected with 2DL3*001
(Frazier et al., 2013). A third type of assay, surface plasmon resonance,
confirmed that the 2DL3*005 variant bound with greater avidity than
the 2DL3*001 variant to the HLA-C1 allotype HLA-C*03:04 (Frazier
et al., 2013).
In summary,we have developed a simplifiedmethod for the produc-
tion of KIR–Fc and designed an assay that tests their binding to 97 HLA
class I allotypes simultaneously. The assay is easy to perform and corre-
lates well with more complicated experimental techniques such as cel-
lular cytotoxicity and surface plasmon resonance that have traditionally
been used to determine the avidity and specificity of KIR for HLA class I
ligands.
2. Materials and methods
KIR–Fc fusion protein generation.
This section describes the generation of a DNA insert, flanked by re-
striction sites, that encodes the first 224 amino acids of the KIR2D of in-
terest and the Fc region of human IgG1 (Fig. 1A). This insert is first
cloned into the pAcGP67a transfer vector (Fig. 1B). Subsequently it is
co-transfected with linearized baculovirus into insect cells.
2.1. KIR–Fc fusion construct generation
Amplify the sequences encoding the D1, D2 and stem region of the
selected KIR2D molecule by PCR (primers from Fig. 1D, upper panel).
The forward primer annealing site is immediately downstream of the
KIR signal sequence cleavage site and should contain a BamHI (New En-
gland BioLabs, Cat. #R0136) site. The reverse primer annealing site is
immediately upstream of the transmembrane region and contains an
XbaI (New England Biolabs, Cat. #R0145s) site.
Add a mix consisting of 20.2 μl PCR grade sterile water, 2.5 μl 10×
cloned Pfu buffer, 0.5 μl forward primer (10 mM), 0.5 μl reverse primer
(10 mM), 0.2 μl dNTP mix (40 mM) and 0.25 μl HotStart TAQ polymer-
ase (Kit from Qiagen, Cat. #203203) to 1 μl of template DNA (10 ng/μl)
and perform PCR using the following conditions: (5 min at 95 °C) × 1,
(30 s at 94 °C, 1 min 25 s at 62 °C, 40 s at 72 °C) × 35, (10 min at
72 °C) × 1, and hold at 4 °C. Digest the amplification products with
BamHI and XbaI and ligate into the BamH1 and XbaI digested pAcGP67a
vector (BD Pharmigen, Cat. #554758). Amplify the sequences encoding
the hinge, CH2 and CH3 regions of human IgG1 using a forward primer
containing an XbaI site and a reverse primer containing a NotI (New
England Biolabs, Cat. #R0189) site (primers from Fig. 1D, upper
panel). Digest the amplification products with XbaI and NotI and li-
gate into the XbaI and NotI digested pAcGP67a vector. Transform
the ligation products into E. coli competent cells (Kit from Invitrogen, Cat.
#K4510-20). Following overnight incubation select individual E. coli
colonies, clonally amplify and prepare transfection quality DNA using
Qiagen columns (Kit from Qiagen, Cat. #27104). Sequence each clone to
confirm that the desired KIR–Fc fusion gene is inserted in frame behind
the GP67 secretion signal sequence (primers from Fig. 1D, lower panel).
2.2. Site-directed mutagenesis of KIR–Fc constructs
Site-directed mutagenesis can be used to introduce non-
synonymous mutations into the newly generated KIR–Fc fusion gene.
This technique is useful for making comparisons of closely related
KIR2D–Fc allotypes or to investigate the effect of alternative amino
acids at a particular position on HLA class I recognition. Mutagenesis
primers should have a melting temperature of at least 78 °C and the de-
sired mutation should be situated in the center of the primer sequence.
The website www.bioinformatics.org/primerx was used to design mu-
tagenesis primers. Add a mix consisting of 40 μl PCR grade sterile
water, 5 μl 10× cloned Pfu buffer (Agilent Technologies, Cat. #600153-
82), 1 μl forward primer (10 mM), 1 μl reverse primer (10 mM), 1 μl
dNTP mix (40 mM) and 1 μl Turbo polymerase (Agilent Technologies,
Cat. #600252-52) to 1 μl of template DNA (50 ng/μl) and perform PCR
using the following conditions: (30 s at 95 °C) × 1, (30 s at 95 °C, 60 s
at 55 °C, 15 min at 68 °C) × 20, (7 min at 72 °C) × 1, and hold at 4 °C.
A 15 min extension time is recommended, because of the large size of
the pAcGP67a vector (9761 bp). Following the PCR, add 1 μl DpnI
(New England BioLabs, Cat. #R0167S) to the reactionmixture and incu-
bate for 30min at 37 °C. DpnI digests themethylated template DNA and
effectively increases the efficiency of mutated DNA transformation into
competent E. coli cells. Following overnight incubation select individual
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E. coli colonies and then clonally amplify and prepare transfection qual-
ity DNAusingQiagen columns (Kit fromQiagen, Cat. #27104). Sequence
each clone to confirm that the desired KIR–Fc fusion gene is inserted in
frame with the GP67 secretion signal (primers from Fig. 1D, lower
panel).
2.3. Co-transfection of KIR–Fc containing transfer vector and baculovirus
into insect cells
Having constructed the KIR-Fc gene, cloned it into the pAcGP67a
transfer vector and mutated it when required, the construct must now
be combined with linearized baculovirus and transfected into insect
cells. For the initial transfection, the insect cells derived from Spodoptera
frugiperda (Sf9) (Invitrogen, Cat. #11496-015) are used. Both the Sf9 in-
sect cells and baculovirus should be handled in a sterile laminar flow
hood. The Sf9 cells should be cultured in Sf-900 II media (Invitrogen,
Cat. #10902-096) supplemented with 10% heat inactivated fetal bovine
serum (FBS), 1% Penicillin–Streptomycin and 1% L-Glutamine, shaking
at 120 rpm at 27 °C. The Sf9 cells should be maintained at between
4 × 105 and 2 × 106 cells/ml. When maintained at this density, Sf9
cells have an approximate doubling time of 24 h; a slower doubling
time may signify unhealthy cells (see Section 2.11). For each KIR–Fc
transfection, seed one well of a sterile six-well plate (BD Falcon, Cat.
#353046) with 2 ml Sf9 cells at a density of 1 × 106 cells/ml and incu-
bate for 60 min at 27 °C to allow adherence of Sf9 cells. Concurrently,
mix (gently using a pipette) 2 μg of purified transfer vector DNA with
KIR–Fc insert from step 2.1 with 0.5 μg of linearized baculovirus DNA
(Expression Systems, Cat. #91-002) in a sterile 2 ml microcentrifuge
tube and incubate for 5 min at room temperature. This specific
baculovirus has the chitinase and cathepsin loci deleted to remove a
detrimental protease and reduce competition for resources for protein
synthesis during late gene expression.Meanwhile, for each transfectant,
mix 10 μl Cellfectin II (Invitrogen, Cat. #10362-100) with 100 μl un-
supplemented Sf-900 II media (Invitrogen, Cat. #10902-096) and pi-
pette to mix them together. Add this to the baculovirus/KIR–Fc con-
struct mixture (immediately following the 5 min incubation), mix
Fig. 1. (A) Schematic diagram showing the configuration of a recombinantKIR–Fc fusion gene. The recombinant fusion gene consisting of theD1, D2 and stemdomains of a KIR2Dmolecule
(gray box) and the Fc region of a human IgG1 antibody (white box) is cloned using BamH1 and Not1 restriction sites into the multiple cloning site (MCS) of the pAcGP67a vector (B) in
frame behind the GP67 secretion signal sequence. Transfection into insect cells produces a soluble recombinant KIR–Fc dimer (C) consisting of the D1, D2 and stem regions (extracellular
domain— ECD) of the KIR molecule (gray ovals) and the Fc region (white ovals) of the IgG1 antibody. (S–S) shows the location of the di-sulfide bonds that lead to formation of a dimer.
(D) Table listing the primers for amplification and sequencing of KIR–Fc fusion genes representing inhibitory KIR2DL1, 2DL2/3 and activating KIR2DS1, 2DS2, 2DS3, 2DS4 and 2DS5. The
properties of each primer, including the GC content, melting temperature (Tm) and length are listed to the right. Restriction sites are shown in bold when present in a primer sequence.
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gently using a pipette and incubate for a further 30 min at room
temperature. Following the 30 min incubation, add 1.8 ml un-
supplemented Sf-900 II media to complete each KIR–Fc transfection
mixture. In summary, each KIR–Fc transfection mixture should contain
Sf9 cells,KIR–Fc fusion geneDNA in pAcGP67a transfer vector, linearized
baculovirus DNA, Cellfectin and un-supplemented Sf-900 II media.
Remove the 6-well plate from incubation and replace the medium
covering the adherent cells with the KIR–Fc transfection mixture. Incu-
bate, covered but not shaking, for 3–5 h at 27 °C. Remove the superna-
tant from each well and replace with 3 ml Sf-900 II media (warmed to
27 °C and supplemented with 10% heat inactivated FBS, 1% Penicillin–
Streptomycin and 1% L-Glutamine). Incubate, cover and seal, with labo-
ratory film (Pechiney, Cat. #PM996), for 7 days at 27 °C. Remove the su-
pernatant from each well and transfer to a sterile 15 ml tube. Separate
the cells by centrifugation (1000 g for 10 min), discard the pellet and
transfer the supernatant to a sterile 15 ml tube and store in the dark
at 4 °C. This first transfectant, termed P0, and each subsequent Sf9 am-
plification supernatant (P1–P3) may be placed without further modifi-
cation at−80 °C for long-term storage.
2.4. Amplification of baculovirus in Sf9 cells — P1–3 production
Successive rounds of Sf9 cell amplification are now used to amplify
the baculovirus (now containing the KIR–Fc gene added in step 2.3).
Add 30 ml Sf9 cells at a density of 1 × 106 cells/ml to a 125 ml vented
sterile Erlenmeyer flask (Thermo-Scientific, Cat. #4116-0125) and
leave shaking at 115 rpm overnight at 27 °C. The following day, add
500 μl of P0 virus stock to the flask and incubate for 4–5 days shaking
at 120 rpm at 27 °C. Collect 14ml suspension from each flask and trans-
fer to a sterile 15 ml tube. Separate the cells by centrifugation (1000 g
for 5 min) and transfer each supernatant to a new sterile 15 ml tube.
Discard the pellet and store in the dark at 4 °C. This forms the P1 viral
stock. A second (P2) or third (P3) round of amplification in which
each round is seededwith 50 μl of the preceding amplified supernatant,
may be required to produce Sf9 supernatant with a sufficiently high
baculoviral titre for adequate protein production.
Quantification of baculovirus amplification in Sf9 supernatant.
Before proceeding it is necessary to quantify the amount of
baculovirus generated from the amplification of the Sf9 cells in
Sections 2.3 and 2.4. The amount of baculovirus generated is critical, as
insufficient baculoviral amplification will result in low or absent protein
yield. An estimation of viral titre can bemade in twoways: directly, using
small-scale protein production (protein mini-prep) (see Section 2.5)
or indirectly, by flow cytometry, assessing baculoviral-induced up-
regulation of surface glycoprotein 64 (GP64) (see Section 2.6).
2.5. KIR–Fc fusion protein— mini-prep
This small-scale protein production tests the capacity of the
baculoviral infected Sf9 supernatant from steps 2.3 and 2.4 to produce
protein from Trichopulsia ni (Hi5) (Invitrogen, Cat. #B855-02) insect
cells. Hi5 cells are similar to Sf9 cells but are optimized for recombinant
protein production rather than baculoviral amplification. Hi5 cells
should be cultured, shaking at 27 °C in Express Five serum free media
(Invitrogen, Cat. #10486-025) supplemented with 1% L-Glutamine. The
cell density should be kept at between 4 × 105 and 3 × 106 cells/ml.
Aggregation of cells, which is more likely to occur at densities higher
than 3 × 106 cells/ml, is a sign of unhealthy cells and will reduce the
possible protein yield from any preparation in which they are used
(see Section 2.11). Seed each well of a sterile 6-well tissue culture
plate with 2 ml Hi5 cells at a density of 1 × 106 cells/ml. Add 100 μl of
the viral stock under test (P1, P2 or P3) to each well, seal the plate
with laboratory film and incubate for 48 h (covered, shaking at
120 rpm, at 27 °C). To serve as a negative control, one well should con-
tain Hi5 cells but no Sf9 supernatant. To serve as a positive control, one
well should be transfected with an Sf9 supernatant previously used to
produce KIR–Fc protein. Transfer the contents of each well to a 2 ml
microcentrifuge tube and separate the cells by centrifugation (1000 g
for 5 min). Discard the pellet and transfer 1.5 ml of the supernatant to
a clean 2mlmicrocentrifuge tube, add 150 μl 10×Hepes Buffered Saline
(HBS), pH 7.2 and 10 μl protein A Sepharose bead slurry (Invitrogen, Cat.
#101142). Rotate the mixture overnight at 4 °C.
Separate the beads by centrifugation (2500 g, 15 min, 4 °C) and dis-
card the supernatant. Add 20 μl Laemmli sample buffer (Bio-Rad, Cat.
#161-0737) with 5% β-mercaptoethanol (Bio-Rad, Cat. #161-0710)
and incubate the sample at 95 °C for 10 min. Load the sample onto a
12% SDS-PAGE gel (Bio-Rad, Cat. #456-1043) and run at 150 V for 1 h.
Stain with Coomassie reagent (Bio-Rad, Cat. #161-0786) to identify
an appropriately sized band. Although each KIR–Fc exists as a
102 kDa homodimer in native format (Fig. 1C), they run as a band
of 51 kDamonomers (Fig. 3A) on an SDS gel. The reducing conditions
in the sample application buffer disrupt the disulfide bonds that link
the twomonomers. The bands produced from successive Sf9 amplifi-
cations of the same KIR–Fc construct should show increasing intensi-
ty. Amplification is considered sufficient when successive rounds of
amplification produce bands of similar intensity. This indicates that
the amplification of baculovirus from Sf9 cells has reached capacity
on SDS-PAGE.
2.6. Identification of baculovirus-infected Hi5 cells by flow cytometry
GP64 is a baculovirus encoded glycoprotein that is expressed on in-
sect cells upon infection with baculovirus (Blissard and Rohrmann,
1989). Because the titre of the transfecting supernatant corresponds to
the degree of cell-surface expression of GP64, this can be used as a
proxy to assess viral amplification in Sf9 supernatant. Seed an appropri-
ate number of wells of a sterile six-well tissue culture plate with 2 ml
Hi5 cells at a density of 1 × 106 cells/ml. Add 100 μl of P1, P2 or P3
viral stock to each well, seal the plate with laboratory film and incubate
for 24 h (covered, shaking at 120 rpm, at 27 °C). To serve as a negative
control, one well should contain Hi5 cells but no Sf9 supernatant. To
serve as a positive control for the ability of the Hi5 cells to express
GP64, onewell should be transfectedwith a high baculoviral titre Sf9 su-
pernatant. Mix the cells and add 250 μl of the contents of the well to a
2 ml microcentrifuge tube and separate the cells via centrifugation
(50 g for 2 min). In the following steps, all wash solutions should be at
4 °C. Resuspend the cells in flow cytometry buffer (FCB) (1× phosphate
buffered saline [PBS — Cellgro, Cat. #21-031-CV] supplemented with
0.5% EDTA and 1% BSA) andwash twice. Following the secondwash, re-
suspend the cells in 25 μl FCB and stain the cells with 1 μl anti-
baculovirus GP64 antibody (eBioscience, Cat. #14-6995-81). Incubate
for 30 min at 4 °C. Wash the cells a further three times in FCB,
resuspending in 1 ml FCB after the final wash. Flow cytometry is then
used to detect the presence of the PE-conjugated antibody bound to
cell surface GP64. Hi5 cells transfected with low viral titre P0 or P1
viral stocks show low or absent levels of surface GP64. Successive Sf9
amplifications of the same KIR–Fc construct should show increasing
levels of cell-surface GP64 (Fig. 2). Amplification is considered complete
when successive rounds of amplification result in similar levels of cell-
surface GP64. This indicates that the amplification of baculovirus from
Sf9 cells has reached capacity and typically occurs at the P2 stage.
2.7. Harvest and purification of soluble KIR–Fc fusion proteins from
baculovirus infected Hi5 cells
Once a suitable baculoviral Sf9 stock has been produced and assessed
for viral titre, a full-scale experiment to produce recombinant KIR–Fc
protein can be performed. Grow a 1 l Hi5 cell culture to a density of
2 × 106 cells/ml. Add 1 ml of high-titre P2 or P3 viral stock and incubate
for 60 h (covered, shaking at 120 rpm, 27 °C). Separate cells by centrifu-
gation (2500 g for 15 min, 4 °C). Discard the pellet and pass the
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Fig. 2. (A) GP64 is up-regulated on the surface ofHi5 cells following transfectionwith baculovirus infected Sf9 supernatant. Shown is the gating strategy and representative flow cytometry plots fromHi5 cells transfectedwith Sf9 supernatant from P0,
P1, P2 and P3 viral stocks and stained with PE conjugated anti-GP64 antibody. P0 viral stocks do not induce up-regulation of GP64 on the surface ofHi5 cells. Transfection ofHi5 cells with P1 viral stocks induces partial up-regulation of GP64whereas













supernatant through a 0.2 μm filter (Nalgene, Cat. #450-0020) into a
sterile container. Add 100 ml 10× HBS, pH 7.2 per 900 ml filtered Hi5
supernatant. Add 1 ml protein A Sepharose bead slurry and rotate bot-
tles slowly overnight at 4 °C.
In the following steps, all wash solutions should be at 4 °C. Separate
the protein A Sepharose beads from the Hi5 supernatant by filtration
using gravity flow through a Buchner funnel with fritted glass disk
(Pyrex, Cat. #36060). Care should be taken to avoid the Sepharose
beads running dry. Wash the beads with approximately 500 ml of 1×
PBS and transfer to an empty 13 ml PD-10 column with a 20–85 μm
frit filter (GE Healthcare, Cat. #17-0435-01) using a serological pipette.
The beads should collect on the frit filter as the wash solution passes
through by gravity flow.
Elute the KIR–Fc fusion protein from the collected beads in the
PD-10 column using 100 mM glycine, pH 2.7 in 8 fractions of 800 μl
each, neutralizing by elution into 8 separate microcentrifuge tubes,
each containing 200 μl 1 M Tris, pH 9.0. The protein content of each elu-
tion fraction should be determined by Bradford assay (Kit from Bio-Rad,
Cat. #500-0001).
Wash a Sephadex G-25 desalting column (GE Healthcare, Cat. #17-
0851-01) with 25 ml 1× PBS. Load 2.5 ml of the fractions having the
highest protein concentration onto the desalting column. Add 3.5 ml
1× PBS to the desalting column in 0.5 ml aliquots and collect seven
0.5 ml fractions in separate microcentrifuge tubes. Determine the pro-
tein content of each fraction by Bradford assay.
At this stage, it is best to estimate the purity of each eluted protein
fraction by gel electrophoresis. Add 10 μl of each KIR–Fc eluent to an
equal volume of Laemmli sample buffer with 5% β-mercaptoethanol
and incubate the sample at 95 °C for 10 min. Transfer the sample onto
a 15% SDS-PAGE gel and electrophorese at 150 V for 1 h. Stain with
Coomassie reagent to identify the appropriately sized band (Fig. 3A).
2.8. Assessment of KIR–Fc integrity by flow cytometry
Having produced recombinant KIR–Fc protein from the full-scale
prep as described in Section 2.7, it is now necessary to determine the
integrity (i.e. correct protein folding) of the protein. This is achieved
by flow-cytometry, using monoclonal antibodies specific for KIR. In
the following steps, all wash solutions should be kept at 4 °C. Add
20 μl of anti-human IgG-coated beads (Bangs Laboratories, Cat.
#BM562) to 500 μl KIR–Fc fusion protein (diluted in 1× PBS to
100 μg/ml). Ensure that the beads are vortexed gently to resuspend
them prior to their use. Incubate, shaking gently for 30min at 4 °C. Col-
lect the beads by centrifugation (50 g for 2 min) and wash twice with
FCB. Following the second wash, resuspend the beads in 25 μl FCB and
add 2 μl PE-conjugated mouse anti-human KIR antibody (KIR2DL1:
Beckman Coulter, Cat # EB6-PE; KIR2DL2/3, Beckman Coulter, Cat #
DX27-PE; Lineage III KIR: AbD Serotec, Cat #NKVFS1). Incubate, shaking
gently for 30 min at 4 °C. Collect the beads by centrifugation (50 g for
2 min) and wash a further two times with FCB. Resuspend the beads
in 150 μl FCB. Flow cytometry is then used to detect the presence of
the PE conjugated anti-KIR antibody bound to individual IgG coated
beads (Fig. 3B).
2.9. Multiplex assay to detect binding of soluble KIR proteins to HLA class I
single antigen beads
The purified, functional KIR–Fc fusion proteins are now ready to be
tested for their capacity to recognize HLA class I allotypes. Each KIR–Fc
protein is first incubated with approximately 10,000 individual beads,
each coated with one of 97 HLA class I allotypes; the goal being to test
the binding of the KIR–Fc to each HLA class I allotype approximately
100 times. In the second step of the assay, a secondary antibody
is added that binds to the Fc portion of the KIR–Fc. The Luminex reader
is able to simultaneously detect the identity of the bead (which
correlates with a specific HLA class I) and the fluorescence of the anti-
body, which indicates the amount of KIR–Fc bound to the bead.
For each KIR–Fc protein to be tested, pre-wet one well of a 96-well
0.65 μm filter plate (Millipore, Cat. #MSDVN6510) with 200 μl 1× PBS.
Remove the PBS from the wells by vacuum aspiration (manifold from
Qiagen, Cat. #19504). Add 50 μl of soluble KIR protein (100 μg/ml)
and 3 μl LABscreen microbeads (One Lambda, Cat. #LS1A04) to each
pre-wettedwell. Ensure that the beads are vortexed gently to resuspend
them prior to aliquoting into each well. For each assay, 50 μl W6/32
antibody (Biolegend, Cat. #311402) (50 μg/ml) should be added to
one well to control for antigen density on individual beads (see
Section 2.10). Incubate the KIR–Fc proteins and W6/32 with the beads
for 60 min, shaking gently and covered at 4 °C.
In the following steps, all wash and resuspension solutions should be
at 4 °C. Wash the beads in each well four times with 1× Luminex wash
buffer (One Lambda, Cat. #LS1A04). For each wash, add 200 μL of wash
buffer to each well and gently pipette up and down several times. If
more than one protein is being tested use amulti-channel pipette to en-
sure even washing of each KIR–Fc protein being tested. Care should be
taken to avoid introducing air bubbles into the wells. Following each
wash, aspirate the wash solution using a vacuum manifold, ensuring
that thewell does not become dry. The vacuumpressure should not ex-
ceed 100 mm Hg.
Following the first complete wash cycle (4 individual washes),
resuspend the KIR–Fc fusion proteins in 100 μl PBS with 1% PE-
conjugated goat anti-human IgG-Fc antibody (One Lambda, Cat. #LS-
AB2). Suspend the beads incubated with W6/32 in 100 μl PBS with 1%
PE-conjugated goat anti-mouse IgG-Fc antibody (BD Pharmigen, Cat.
#550589). Incubate both KIR–Fc andW6/32 for a further 60 min, shak-
ing gently and covered at 4 °C. Following the second incubation, wash
the beads a further four timeswith 1× Luminex wash buffer, resuspend
in 100 μl 1× PBS and transfer into a 96-well, 250 μl ‘V’ bottom micro-
plate (Whatman, Cat. #7701-3250). The test plate should be transferred
immediately into the Luminex reader (with pre-warmed lasers and
beadset template entered to avoid delay in starting the assay).
2.10. Calculating fluorescence relative to HLA class I antigen density
To correct for differences in the absolute amount of HLA class I
annealed to each microbead, the binding of KIR–Fc fusion proteins to a
specific HLA class I should be calculated relative to the amount of HLA
class I as determined by binding of W6/32, an antibody that recognizes
an epitope common to all HLA class I allotypes. The relativefluorescence
ratio of a given KIR–Fc is calculated using the formula (KIR–Fc
binding− negative control bead binding) / (W6/32 binding− negative
control bead binding).
2.11. Common problems and their solutions
Themost common problem encountered in the protocol is failure of
amplification of baculovirus in Sf9 cell preps and failure of protein pro-
duction from Hi5 cell preps. We have introduced several steps to test
baculoviral amplification, the goal being to identify insufficient
baculoviral amplification early and take steps to correct it to minimize
lost time. A common cause of amplification failure is unhealthy Sf9 or
Hi5 cells. The following steps can be used to ensure healthy cells and de-
tect unhealthy cells should they occur.
Sf9 cells should have a doubling time of between 24 and 30 h. Hi5
cells should have a doubling time of between 18 and 24 h. Slow dou-
bling times usually indicate that Sf9 or Hi5 cell cultures are unhealthy.
Unhealthy cells will not amplify baculovirus successfully or produce
adequate recombinant protein. Cell viability for both Sf9 and Hi5 cells,
as determined by trypan blue staining, should be greater than 95% at
all times. Both bacterial and fungal infections in the insect cell culture
will reduce cell viability and doubling times. These can be prevented
with good cell culture technique and the addition of antibiotics (1%
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Fig. 3. (A) Shown is a reducing (SDS) gel stainedwith Coomasie Bluewith a protein ladder in the left column (Precision plus Protein Kaleidoscope Standards, Bio-Rad, Cat # 1610375) and a
band corresponding to KIR2DL3–Fc at 50.7 kDa in the right column. The gel was loaded with 10 μl of KIR2DL3–Fc protein (100 μg/ml). (B) KIR2D–Fc bound to IgG coated beads (Bangs
Laboratories) are stained with KIR specific antibodies to assess their integrity. Representative flow cytometry plots showing staining of KIR2DL1 (left panel, red) and KIR2DL3–Fc (right
panel, blue) fusion proteinswith EB6 and DX27 antibodies respectively. (C) Titrations of the binding of KIR2D to beads coatedwith HLA class I molecules. Each of three KIR2DL1–Fc fusion
proteins distinguished by substitutions at residue 70 bind to HLA-C*06:02 with different avidities. Both mutant and wild type KIR2DL1 show saturated binding at concentrations greater
than 100 μg/ml. KIR2DL3–Fc binds to three HLA class I allotypes (HLA-B*73:01, HLA-C*03:04 and HLA-C*16:01) with different avidities. The binding of KIR2DL3–Fc to each allotype be-
comes saturated at concentrations above 100 μg/ml. (D) KIR2DL1–Fc binds to HLA-C2 bearing allotypes but not to HLA-C1, HLA-A or HLA-B allotypes. KIR2DL3–Fc binds to HLA-C1 allo-
types and to HLA-C2 allotypeswith lower avidity. KIR2DL3–Fc also binds to two HLA-B allotypes that encode the C1 epitope. (E) KIR–Fc fusion proteins are amenable to long-term storage
at−80 °C. The binding of KIR2DL1–Fc stored at−80 °C for 12 months is compared to 2DL1–Fc stored at 4 °C.
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Penicillin–Streptomycin) and/or anti-fungals (0.25 μg/ml Amphotericin
B) to the culture medium. Cultures should be discarded immediately if
there is evidence of microorganism contamination. A second reason
for slow doubling is oxygen restriction. If the cell culture does not
have sufficient surface area exposed to the air, cell growth will be re-
tarded. This can be prevented by ensuring that flasks are filled no
more than one-third (by volume) with culture medium. Ensuring that
the flasks are shaken at between 120 and 150 rpm also ensures ade-
quate oxygenation. Shaking at a higher rpm leads to cell damaging
shearing stress and should be avoided. Further information on the cul-
ture of insect cells is available (Shrestha et al., 2008).
For the formation of intact baculovirus it is essential that transfer
vector and linearized baculoviral DNA recombine during initial co-
transfection of Sf9 cells. We have obtained the best results with freshly
isolated transfer vector and baculoviral DNA that has not been stored
at 4 °C for more than two weeks. Additionally, freeze/thaw cycles of
the transfer vector should be avoided where possible. Because the line-
arized baculovirus is a large DNA fragment (~130 kb), it is particularly
susceptible to shear stress; over-zealous pipetting during transfection
should therefore be avoided to minimize DNA and maximize transfec-
tion success.
The most common problems associated with the Luminex assay are
high background and inter-assay variability.We have found that the fol-
lowing precautions minimize these problems. In this context we define
high background readings as those in which the negative control bead
binding is greater than 1% of the highest positive reading obtained. Dur-
ing the wash and incubation phases of the protocol, care should be
taken to minimize any warming of the reagents. All wash reagents
should be chilled to 4 °C andwash steps should be completed as quickly
as possible to avoid unnecessary warming of the samples. This may
mean reducing the number of KIR–Fc proteins under test in any one
assay to expedite this phase.
Although not always the case, some KIR–Fc are not stable when
stored at 4 °C and their use in the assay can lead to high background
readings. To control for this issue, divide each batch of protein into
100 μl aliquots and store them at −80 °C. Similarly, HLA class I beads
that have been thawed and stored at 4 °C are not typically stable for
more than 3 months. The beads should also be divided into 10 μl ali-
quots and frozen at −80 °C if they are unlikely to be used within this
time frame. Each of these precautions also helps to reduce both high
background and inter-assay variability. Additionally, we include well
characterized HLA-C1 and HLA-C2 receptors (e.g., KIR2DL3*001–Fc
and KIR2DL1*003–Fc respectively) in every assay as positive controls.
Changes in the avidity and specificity of the KIR–Fc under test can
then be related not only to W6/32, but also to these KIR–Fc controls.
In addition to the failure of baculoviral amplification described
above, a further limitation of this system is that we have, as yet, been
unable to produce functional three domain KIR using the Fc fusion sys-
tem. Although the KIR3D protein is expressed by insect cells, it does not
fold into a tertiary structure that binds to KIR-specific antibody or to
HLA class I. As such, the HLA class I reactivity of these receptors remains
under investigation.
3. Results and discussion
The purpose of this protocol is to provide a simplified method with
which to produce and test the reactivity of soluble two-domain KIR–Fc
fusion proteins. We chose to use an insect cell expression system be-
causemost post-translationalmodifications aremade correctly in insect
cells and the system is scalable, allowing production of large quantities
of soluble recombinant protein in a comparatively short time. We have
sought to reduce variability in final protein yield by implementing a se-
ries of quality controls at points during the baculoviral amplification
phase. These methodological improvements allow us to better track
baculoviral amplification in Sf9 cells and prevent the Hi5 preparations
having insufficient protein yield.
We have also designed a novel assay that tests the binding of KIR–Fc
to HLA class I allotypes. This assay simultaneously detects the binding of
KIR to 97HLA class I allotypes. As a result it holds a clear advantage over
previous cell-based binding assays that allowed examination of only a
few KIR–HLA class I interactions at any one time. The assay is sensitive
over a two-log range, permitting both strong and weak reactions to be
interpreted with confidence and correlated with structural polymor-
phisms in both KIR and HLA class I (Frazier et al., 2013; Gendzekhadze
et al., 2009; Graef et al., 2009; Hilton et al., 2012; Moesta et al., 2008).
The KIR–Fc HLA-bead binding assay has also been used to explore
the binding characteristics of KIR in simian primates. The HLA class I
specificity of primate KIR has been difficult to determine because of a
comparative lack of cellular reagents. As such, the combination of
methods described in this paper has led to a number of critical discover-
ies on the immunologic function and co-evolution of KIR andMHC class
I. In OldWorld Monkeys, the lineage III KIR (precursor to theMHC-C re-
ceptors of higher primates) is represented by a single gene (Sambrook
et al., 2005) while lineage II KIR genes have expanded and diversified.
To identify their MHC epitope-specificity and avidity, a panel of rhesus
macaque lineage II KIR–Fc was assayed using the methods present
here (Older Aguilar et al., 2011). Although MHC-C is not present in ma-
caques, their KIR recognize HLA-C epitopes more effectively than they
recognize HLA-A and HLA-B, suggesting that MHC-C evolved to become
a stronger ligand for KIR thanHLA-A and -B. The emergence ofMHC-C in
the orangutan was accompanied by an expansion of lineage III KIR and
their evolution as MHC-C receptors (Guethlein et al., 2007). All orangu-
tan MHC-C allotypes have asparagine at position 80 and display the C1
epitope. Correspondingly, results from the KIR–Fc HLA bead binding
assay showed that the orangutan has C1-specific KIR but no C2-
specific KIR (Older Aguilar et al., 2010). In chimpanzees the MHC-C
gene became fixed and the C2 epitope emerged. As a consequence, out
of nine chimpanzee lineage III KIR genes (Abi-Rached et al., 2010),
eight encode receptors with high avidity for HLA-C, comprising three
C1-specific receptors and 5 C2-specific receptors (Moesta et al., 2009).
Thus, results from the multiplex binding assay show that changes in
the character of the KIR locus correlate with change in the MHC class I
genes, suggesting co-evolution between these receptors and ligands
and uncovering a progression in which the complexity of the KIR locus
gets increasingly sophisticated across higher primate species.
3.1. Flow cytometry can be used to confirm baculoviral transfection
Surface glycoprotein GP64 is a baculovirus encoded glycoprotein
that can be used as a marker for successful transfection and amplifica-
tion of baculovirus in Hi5 insect cells (Blissard and Rohrmann, 1989;
Volkman and Goldsmith, 1988). Fig. 2 shows that GP64 expression is
not detected on un-transfected Hi5 cells but is expressed following
transfection with high viral titre Sf9 supernatant. P0 viral stock was
not sufficient to induce GP64 surface expression whereas surface ex-
pression was typically detected after transfection with P1 viral stock
andwith each subsequent amplified viral stock (P2 and P3) (Fig. 2). Sur-
face expression of GP64 was sensitive to the baculoviral titre with P2
transfected Hi5 cells showing a 40% increase in surface expression of
GP64 as compared to Hi5 cells transfected with P1 viral stocks. That P3
stocks induced only marginally greater GP64 surface expression than
P2 viral stocks suggests that GP64 is either maximally up-regulated by
a given viral titre or Sf9 cells reachmaximal viral amplification between
the second and third amplification rounds.
3.2. Confirmation of KIR–Fc integrity by flow cytometry
Both EB6 antibody, which recognizes KIR2DL1, and DX27 antibody,
which recognizes KIR2DL2/3, bound to KIR–Fc immobilized on anti-
human IgG flow cytometry beads (Fig. 3B). This test provides a cost-
effective way to test the integrity of both the KIR region and Fc region
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of the final fusion protein, as both are required to have folded correctly
to produce a positive result in the Luminex binding assay.
3.3. Titration of KIR2D–Fc fusion proteins against HLA class I shows that
100 μg/ml is an appropriate concentration to use in the binding assay
The binding of KIR–Fc fusion proteins to HLA class I increaseswith an
increasing concentration of KIR–Fc fusion protein until binding becomes
saturated at approximately 100 μg/ml. Use of KIR–Fc at greater concen-
trations (100–400 μg/ml) does not increase binding to HLA class I and
avidity differences between individual allotypes are found to be consis-
tent at this concentration. Additionally, this saturation point applies to
between different HLA class I allotypes and for different naturally occur-
ring and mutant KIR2D (Fig. 3C).
3.4. Multiplex Luminex assay comparing the binding ofW6/32, KIR2DL1–Fc
and KIR2DL3–Fc to HLA class I coated microbeads
KIR2DL1–Fc binds specifically and with high avidity to HLA-C2 but
not HLA-C1 or anyHLA-A or HLA-B allotypes (Fig. 3D). HLA-C2 allotypes
display a range of avidity for KIR2DL1 with HLA-C*15:02 and HLA-
C*04:01 having the highest and lowest avidities respectively (Fig. 3D).
KIR2DL3–Fc binds specifically to HLA-C1 but does not bind to HLA-C2
or any HLA-A allotype. Unlike KIR2DL1, KIR2DL3 does bind to two un-
usual HLA-B allotypes (HLA-B*46:01 and HLA-B*73:01) that have the
C1 epitope (Fig. 3D). HLA-C1 allotypes have a range of avidity for
KIR2DL3 with HLA-C*03:04 and HLA-C*16:01 having the highest and
lowest avidities, respectively. Both HLA-B*46:01 and HLA*73:01 bind
with high avidity to KIR2DL3.
3.5. KIR–Fc fusion proteins remain functional following long-term storage
at−80 °C
Each 1 l prep of Hi5 cells yields between 2 and 4 mg of KIR–Fc pro-
tein. Given that the KIR–Fc are used at a dilution of 100 μg/ml in the
multiplex binding assay, there is typically an excess of KIR–Fc reagent.
KIR–Fc remain stable at 4 °C for 1–6 months, however, to allow repeti-
tion of a particular experiment over longer time periods and to provide
stable positive controls, we investigated the storage of KIR–Fc aliquots
at−80 °C (Fig. 3E). KIR–Fc show similar binding in the multiplex bind-
ing assay up to 12months following initial freezing. Freezing the KIR–Fc
is assumed to prevent the protein degradation, aggregation and
misfolding that occurs at an unpredictable rate when stored at 4 °C.
4. Conclusions
Wehave described the production of KIR–Fc fusion proteins in an in-
sect cell expression system and their interaction in a multiplex binding
assay with a panel of 97 HLA class I allotypes. KIR–Fc production in in-
sect cells is relatively simple, allowing production of large amounts of
recombinant protein in around 20 days. The assay is sensitive enough
to discriminate between single amino acid substitutions in the extracel-
lular domains of the KIRmolecule and has, as a result, greatly facilitated
investigation of even closely related KIR allotypes. Furthermore, the re-
sults of this direct binding assay appear to correlatewell with the results
obtained in the limited cellular assays thatwere used to discover theKIR
and first investigate their specificity for HLA class I.
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Monoclonal antibodies with specificity for human leukocyte antigen (HLA) class I
determinants of HLA were originally characterized using serological assays in which
the targets were cells expressing three to six HLA class I variants. Because of this
complexity, the specificities of the antibodies were defined indirectly by correlation.
Here we use a direct binding assay, in which the targets are synthetic beads coated
with 1 of 111 HLA class I variants, representing the full range of HLA-A, -B and
-C variation. We studied one monoclonal antibody with monomorphic specificity
(W6/32) and four with polymorphic specificity (MA2.1, PA2.1, BB7.2 and BB7.1)
and compared the results with those obtained previously. W6/32 reacted with all HLA
class I variants. MA2.1 not only exhibits high specificity for HLA-A*02 , -B*57 and
-B*58 , but also exhibited cross-reactivity with HLA-A*11 and -B*15:16 . At low
concentration (1 μg/ml), PA2.1 and BB7.2 were both specific for HLA-A*02 and -
A*69 , and at high concentration (50 μg/ml) exhibited significant cross-reactions with
HLA-A*68 , -A*23 and -A*24 . BB7.1 exhibits specificity for HLA-B*07 and -B*42 ,
as previously described, but reacts equally well with HLA-B*81, a rare allotype
defined some 16 years after the description of BB7.1. The results obtained with cell-
based and bead-based assays are consistent and, in combination with amino acid
sequence comparison, increase understanding of the polymorphic epitopes recognized
by the MA2.1, PA2.1, BB7.2 and BB7.1 antibodies. Comparison of two overlapping
but distinctive bead sets from two sources gave similar results, but the overall levels
of binding were significantly different. Several weaker reactions were observed with
only one of the bead sets.
Introduction
Since first being reported in 1978 (1), monoclonal antibodies
with specificity for human leukocyte antigen (HLA) class
I molecules have been invaluable tools for both basic and
clinical research in human immunology. These antibodies can
be divided into two groups according to the types of epitope
they recognize (2). Monomorphic antibodies, such as W6/32,
the antibody described by Barnstable et al. (1), recognize
monomorphic determinants that are common to all HLA class
I variants, whereas polymorphic antibodies recognize deter-
minants carried by a subset of such variants. Well-studied
examples of polymorphic antibodies are PA2.1, BB7.1,
BB7.2 and MA2.1. Originally, PA2.1 and BB7.2 were seen
to be specific for HLA-A2 (2–4), but with more extensive
characterization they were also shown to recognize and define
HLA-A*69 , a variant that is a recombinant of HLA-A*02 and
HLA-A*68 (5). In a similar fashion, BB7.1 was originally seen
to be specific for HLA-B*07 (2) but was subsequently shown
to recognize HLA-B*42 (6), a recombinant of HLA-B*07 and
HLA-B*08 (7) that is characteristic of African populations
(8). MA2.1, which was originally described as recognizing
HLA-A2 and HLA-B17 antigens (9), has been shown to react
with both the B*57 and B*58 components of the HLA-B17
(10), but no additional reactivities have been reported.
In large part, the HLA class I specificity of monoclonal
antibodies has been determined using panels of cells each of
which minimally expresses one HLA-A, one HLA-B and one
HLA-C allotype and more commonly express two allotypes
for HLA-A, -B and -C. This complexity means that binding
reactions cannot be directly attributed to particular HLA
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class I variants but must be inferred through various types
of correlation. As a consequence, there are limitations in
the extent to which data can be interpreted and thus in the
resolution and accuracy of the data. An initial approach to
address these limitations was the use of mutant cell lines
that lacked endogenous HLA class I expression and could be
transfected to express a single HLA class I allotype of choice
(11). A more recent approach has been to replace cells as the
target antigen with synthetic beads each of which is coated
with a single HLA class I allotype (12, 13). Elimination of
cells from the assay facilitated the commercial development
of panels of >90 different beads that provide a representation
of the range of HLA-A, -B and -C diversity. By using such
beads to determine the HLA class I specificities of Fc-fusion
proteins made from killer-cell immunoglobulin-like receptors
(KIRs), we have achieved results of higher resolution that
are more reproducible and insightful than was possible with
cell-based assays (14, 15). Here we have re-examined the
HLA class I specificities of the MA2.1, PA2.1, BB7.2 and
BB7.1 monoclonal antibodies using two panels of beads
coated with HLA class I molecules.
Materials and methods
Binding of MA2.1, PA2.1, BB7.2 and BB7.1 antibodies to
beads, each coated with a representative range of HLA-A, -
B and -C allotypes was assessed in a multiplex assay on the
Luminex platform (Luminex, Austin, TX). The bead panels
tested were (a) LabScreen single-antigen beads (One Lambda,
Canoga Park, CA) and (b) LifeCodes single-antigen beads
(Gen-Probe, San Diego, CA). Antibodies (1 and 50 μg/ml)
were incubated with each set of beads for 60 min at 4◦C,
washed four times and then labeled with anti-mouse Fc anti-
body conjugated with phycoerythrin and incubated for a fur-
ther 60 min at 4◦C. The fluorescent intensity and identification
of individual labels of the beads were visualized on a Luminex
100 reader. In each experiment, data were collected from a
minimum of 100 antigen-coated beads for each combination
of bead and monoclonal antibody. The results presented are
the mean fluorescence relative to the fluorescence intensity
obtained with the W6/32 antibody obtained from three repli-
cate experiments performed for each monoclonal antibody.
Results
Figure 1 provides a distillation of the results obtained from
previous work using cell-based assays to study the HLA
class I specificities of the MA2.1, PA2.1, BB7.2 and BB7.1
mouse monoclonal antibodies and the epitopes of HLA class I
molecules that these antibodies recognize. In this study, these
four antibodies were tested for binding to beads coated with
single HLA-A, -B or -C allotypes. Two sets of commercially
available beads (from One Lambda and Gen-Probe) were
tested and compared. Together the two bead sets allowed us
to test a total of 111 HLA class I allotypes (33 HLA-A, 66
HLA-B and 21 HLA-C allotypes). The HLA class I allotypes
represented in each bead set are shown in Figure 2A.
The assay used to measure the binding of the monoclonal
antibodies is essentially the same as the one that we designed
and have used for measuring the binding of KIR-Fc fusion
products to beads coated with HLA class I (14). In this
assay, the binding of the antibodies recognizing polymorphic
epitopes was normalized to that of the W6/32 monoclonal
antibody that recognizes an epitope common to all HLA class
I epitopes (1, 31). This normalization corrects for differences
in the absolute amount of HLA class I on the various beads. As
measured by the binding of W6/32, the amount of HLA class I
on the beads varied with allotypes, but a more general property
was that the One Lambda Labscreen beads consistently bound
more W6/32 than the Gen-Probe LifeCodes beads (Figure 2B).
Gen-Probe beads showed a mean reduction in W6/32 binding
of 54% (range: 35%–69%), 52% (range: 20%–71%) and
50% (range: 23%–75%) for HLA-A, -B and -C allotypes,
respectively as compared with One Lambda beads.
Specificity of the MA2.1 monoclonal antibody
The MA2.1 antibody bound strongly to the five HLA-A*02
subtypes tested (A*02:01, :02, :03, :05 and :06 ) and also to
HLA-B*57:01 , B*57:03 and B*58:01 (corresponding to the
serological HLA-B17 antigen; Figure 3A). These results are
consistent with the previously defined specificity of MA2.1 for
the HLA-A2 and -B17 antigens (9). In addition, we observed
a weak reactivity of MA2.1 with HLA-B*15:16 and an even
weaker one with HLA-A*11 . These weak cross-reactions were
detected only with the One Lambda beads.
Results from several groups of investigators are consistent
with the GETR motif at residues 62–65 in the helix of the
α1 domains of HLA-A*02 , B*57 and B*58 being critical
for forming the epitope recognized by MA2.1 (Figure 1).
Within this motif, glycine 62 is the only residue that is not
found in any of the other 89 HLA-A, -B and -C allotypes
tested. HLA-B*15:16 and HLA-A*11 differ only at position
62, having the RETR and QETR motifs, respectively, which
correlates with them having some avidity for MA2.1. The
replacement of glycine 62 with arginine in B*15:16 is seen
to be more favorable for binding MA2.1 than the glutamine
residue at this position in A*11 (Figure 3B). Other HLA class
I allotypes having the QETR motif (e.g. HLA-A*03 , A*30 and
A*36 ) are not recognized by MA2.1, suggesting that further
residues, away from this motif in the α1 domain also influence
recognition of HLA class I by MA2.1.
In addition to the GETR motif at residues 62–65 in the α1
domain, mutation at several positions in the α2 domain (149,
152, 170, 174, 175 and 181) has been shown to influence
MA2.1 binding (20, 22, 16, 24), as has the residue at position
8 in the peptide bound to HLA-A2 (20) (Figure 3C). These
influences could involve direct contact with the antibody or be
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Figure 1 Summary of studies investigating the polymorphic antibodies MA2.1, PA2.1, BB7.2 (top panel) and BB7.1 (bottom panel). Listed is the main
finding from each study, the study’s first author and year of publication. The specific reference as listed in the current publication is noted to the right.
a consequence of indirect effects that alter the conformation
of residues 62–65.
Specificity of the PA2.1 and BB7.2 monoclonal
antibodies
When used at a concentration of 1 μg/ml, the PA2.1 and
BB7.2 antibodies gave similarly strong reactions with five
subtypes of HLA-A*02 and with HLA-A*69:01 (Figure 4A).
For each of these reactions, the Gen-Probe beads gave weaker
reactions than the One Lambda beads, the difference being
greatest for HLA-A*02:01 , as was also the case for MA2.1
(Figure 3A). These results are consistent with those obtained
with the W6/32 antibody (Figure 2B).
When a much higher concentration of antibody was
used (50 μg/ml), cross-reactions of the PA2.1 and BB7.2
antibodies were observed with HLA-A*23:01 , A*24:02 ,
A*24:03 , A*68:01 , A*68:02 and A*69:01 (Figure 4B). These
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Figure 2 (A) Human leukocyte antigen (HLA) class I allotypes represented by the One Lambda LabScreen and Gen-Probe LifeCodes bead sets. (B)
Binding of the monomorphic HLA class I antibody W6/32 to beads from One Lambda LabScreen (gray bars) and Gen-Probe LifeCodes (orange bars).
The binding reactions shown are to the allotypes that are common to both bead sets.
cross-reactions correspond well with the cross-reactivity first
described in the 1960s (32) between the serological A2, A28
(A*68 and A*69 ) and A9 (A*23 and A*24 ) antigens and
more recently described for cell-binding assays with the I-
145 monoclonal antibody (33). These cross-reactions were
stronger for BB7.2 than PA2.1, a feature observed for both
sets of HLA class I coated beads. The cross-reactivity was
much stronger for A*24:03 than either A*24:02 or A*23:01 .
This must be due to the two substitutions that distinguish
A*24:03 from both A*24:02 and A*23:01 (34) and which
are at positions 166 and 167 in the α2 domain (Figure 3C).
Consistent with the relative binding to PA2.1 and BB7.2, HLA-
A*24:03 shares the glutamate 166 and tryptophan 167 motif
with HLA-A*02 , whereas HLA-A*24:02 and A*23:01 share
the aspartate 166 and glycine 167 motif with HLA-A*01:01 ,
which binds neither PA2.1 nor BB7.2.
The combination of sequence comparisons (2, 4, 5, 10)
and site-directed mutagenesis (18, 19, 23) has shown that
tryptophan 107 in the α2 domain is a critical factor in forming
the epitope recognized by PA2.1 and BB7.2 (Figures 1 and
4B). In addition, mutations at positions 161, 163, 166, 167 and
169 can lead to loss of binding by PA2.1 and BB7.2, showing
that these residues also contribute to forming the epitope (16,
23) (Figure 4C).
Specificity of the BB7.1 monoclonal antibody
As previously reported, we found that BB7.1 reacts with
HLA-B*07:02 and HLA-B*42:01 (Figure 5A). In addition,
we found that HLA-B*81:01 , an African allotype (35, 36),
also reacts strongly with BB7.1, which fits with both HLA-
B*81:01 , B*42:01 and B*07:01 having α1 domains with
identical sequence (Figure 5B) and residues 63–70 of the α1
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Figure 3 (A) Binding of MA2.1 (1 μg/ml) to beads coated with human leukocyte antigen (HLA) class I allotypes from the One Lambda LabScreen (left
panel) and Gen-Probe LifeCodes (right panel) bead sets. (B) Alignment of HLA class I allotypes showing selected residues in the α1 and α2 domains.
Residues from allotypes that form the epitope recognized by MA2.1 are shaded in gray. (C) Space-filling model of the binding surface of HLA-A*02
(gray) with associated peptide (cyan). Residues highlighted in yellow fall within the footprint recognized by MA2.1. Residues 62–65 are critical for
formation of the epitope recognized by MA2.1 and are highlighted in red.
domain being critical for the BB7.1 epitope (2, 6, 30, 28,
25, 27, 26, 21) (Figure 1). Comparably strong reactions for
HLA-B*07:02 , B*42:01 and B*81:01 were observed with the
One Lambda beads, but the binding of BB7.1 to the Gen-
Probe B*42:01 bead was relatively weak. Even weaker was
the binding to the B*07:03 bead, which likely reflects an
inherent difference between B*07:02 and B*07:03 in their
avidities for BB7.1. That B*07:03 differs from B*07:02 by
nonconservative substitutions at positions 69, 70 and 71 also
provides evidence that favors this interpretation (37).
Both HLA-B*56:01 and B*82:01 have α1 domains with
identical sequence to that of HLA-B*07:02 , B*42:01 and
B*81:01 but these allotypes are not bound by BB7.1
suggesting that residues in the α2 domain abrogate their
recognition. HLA-B*07:02 , B*42:01 and B*81:01 encode
arginine at position 131 whereas B*56:01 and B*82:01
encode serine at this position. Similarly, both B*56:01 and
B*82:01 encode leucine at position 163 whereas HLA-
B*07:02 and B*81:01 both have glutamic acid. Interestingly,
HLA-B*42:01 has a threonine at position 131 which may
explain its weaker recognition by BB7.1 as detected on both
the One Lambda and Gen-Probe beads. That BB7.1 interacts
with residues in the α2 domain is further supported by the
observation that mutation at positions 166 and 169 of HLA-
B*07 eliminates the BB7.1 epitope (29).
Therefore, whilst the α1 domain residues between positions
63–71 likely form the dominant epitope for recognition by
BB7.1, binding is influenced by polymorphism in the α2
domain, suggesting that this antibody binds both the α1 and
α2 regions of HLA class I. Given that this footprint would
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Figure 4 (A) Binding of PA2.1 (1 μg/ml) and BB7.2 (1 μg/ml) to beads coated with human leukocyte antigen (HLA) class I allotypes from the One
Lambda LabScreen (left panel) and Gen-Probe LifeCodes (right panel) bead sets. (B) Binding of PA2.1 (50 μg/ml) and BB7.2 (50 μg/ml) to beads coated
with HLA class I allotypes from the One Lambda LabScreen (left panel) and Gen-Probe LifeCodes (right panel) bead sets. (C) Alignment of HLA class
I allotypes showing selected residues in the α2 domain. Residues from allotypes that form the epitope recognized by PA2.1 and BB7.2 are shaded
in gray. (D) Space-filling model of HLA-A*02 (gray) with associated peptide (cyan). Residues highlighted in yellow fall within the footprint recognized
by PA2.1 and BB7.2. Tryptophan at position 107 is considered critical for formation of the epitope recognized by PA2.1 and BB7.2 and is highlighted
in red.
span the peptide-binding cleft, peptide variability is likely to
influence BB7.1 recognition of HLA class I.
In summary, we find that the patterns of antibody reactivity
observed here are entirely consistent with those obtained
previously, and extend those results by being able to detect
and distinguish reactions and cross-reactions in a quantitative
manner. All the observed reactions are with HLA-A and
-B variants, with no cross-reactivity for HLA-C, further
emphasizing the distinctive properties of HLA-C (38).
Discussion
Consistent with previous studies we showed that MA2.1
bound to HLA-A*02 subtypes and to HLA-B*57 and HLA-
B*58 allotypes (9, 23). Experimental data and sequence
analysis suggest that the α1 residues GETR at positions
62–65 are critical in forming the epitope recognized by
MA2.1 (23, 17). In this study, we showed weak interactions
with MA2.1 are also formed when glycine at position 62 is
substituted for arginine, as in HLA-B*15:16 and glutamine
as in HLA-A*11:02 . This finding contrasts with results of a
cellular assay in which substitution of glycine for arginine at
position 62 abrogated recognition of HLA-A*02 by MA2.1
(23). HLA-B*15:16 has a high degree of sequence homology
with HLA-B*57 , which appears sufficient to confer reactivity
with MA2.1 despite the introduction of a residue apparently
less favorable for recognition by MA2.1 at position 62. That
glutamine at position 62 results in weak binding to HLA-A*11
and no detectable binding to other HLA-A allotypes with
glutamine at this position (e.g. HLA-A*03 , A*30 and A*36 )
would suggest that this residue is less favorable for binding
than both glycine and arginine. An alternative explanation is
that a few of the peptides presented by either HLA-B*15:16
and HLA-A*11 form an epitope with a high affinity for
MA2.1, sufficient to overcome the reduction in affinity
incurred by the presence of either arginine or glutamine at
position 62.
Several lines of evidence suggest that peptide variability
influences recognition of HLA class I by MA2.1. Although
© 2013 John Wiley & Sons A/S 217
Tissue Antigens, 2013, 81, 212–220
Refining monoclonal antibody specificity H. G. Hilton & P. Parham
Figure 5 (A) Binding of BB7.1 (1 μg/ml) to beads coated with human leukocyte antigen (HLA) class I allotypes from the One Lambda LabScreen (left
panel) and Gen-Probe LifeCodes (right panel) bead sets. (B) Alignment of HLA class I allotypes showing selected residues in the α1 and α2 domains.
Residues from allotypes that form the epitope recognized by BB7.1 are shaded in gray. (C) Space-filling model of the binding surface of HLA-B*07
(gray) with associated peptide (cyan). Residues highlighted in yellow fall within the footprint recognized by BB7.1. Residues 63–71 in the α1 domain
and position 131 in the α2 domain are critical for formation of the epitope recognized by BB7.1 and are highlighted in red.
the residues critical for formation of the epitope recognized by
MA2.1 are located in the α1 domain, mutational experiments
indicate that the binding footprint extends to residues in the
α2 domain of the HLA class I molecule (20, 22). This is
supported by the finding that MA2.1 recognition of HLA-
A2 is prevented in a competitive binding assay with PA2.1
(10), an antibody whose epitope is formed exclusively by
residues in the α2 domain. Together these studies suggest that
MA2.1 binds to an area spanning the peptide-binding groove
on the face of HLA class I molecule. Direct evidence of the
effect of peptide variability is provided from the observation
that MA2.1 recognizes HLA-A2 complexed with the HIV-1
p17 epitope (SLYNTVATL) at least 30 times more strongly
than all other complexes studied, and this enhanced reactivity
was sensitive to point mutation of threonine to alanine at
position 8 in the peptide (24). Therefore there exist two
possible explanations for the ability of the bound peptide
to influence MA2.1 reactivity. Either MA2.1 is sensitive to
peptide-induced conformational changes of the helices, or
it directly contacts certain peptides in the groove of HLA
class I. The identity of the bound peptides presented by
HLA class I on beads manufactured by One Lambda and
Gen-Probe is unknown, but we presume they are highly
heterogeneous.
The weaker interactions between MA2.1 and HLA-B*15:16
and A*11:02 were evident only in the One Lambda LabScreen
bead set. Similarly, weak interactions between BB7.1 and
HLA-B*48:01 and B*67:01 were identified with the One
Lambda beads but these interactions were not observed in the
Gen-Probe bead set. Our data and those of others suggests that
the residues critical for formation of the epitope recognized
by BB7.1 are found in the α1 and α2 domains suggesting that,
like MA2.1, the identity of the peptide might play a role in
the recognition of HLA class I by this antibody. Therefore,
the weak interactions observed with BB7.1 might reflect the
different peptide pools found in the One Lambda and Gen-
Probe bead sets, with those from One Lambda collectively
having higher binding affinity than those found in the Gen-
Probe bead set. Such weak interactions were not evident
for either PA2.1 or BB7.2, antibodies thought to recognize
an epitope formed exclusively by residues found in the α2
domain and as such they are unlikely to be subject to the
same changes in peptide pool that we have hypothesized to
influence recognition of MA2.1 and BB7.1.
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An alternative explanation for the lower affinity of MA2.1
and BB7.1 for HLA class I allotypes presented on the Gen-
Probe bead set is the lower antigen density present on these
beads. We have shown that the antigen density present on
the Gen-Probe bead set is approximately 50% of that present
on the One Lambda bead set as evidenced by binding of the
monomorphic HLA class I antibody W6/32. As a result the
weak interactions noted on the One Lambda bead set might
not reach the lower level of detection of the assay with the
Gen-Probe bead set.
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A Distinctive Cytoplasmic Tail Contributes to Low Surface
Expression and Intracellular Retention of the Patr-AL MHC
Class I Molecule
Ana Goyos,*,†,‡ Lisbeth A. Guethlein,* Amir Horowitz,*,†,‡ Hugo G. Hilton,*
Michael Gleimer,*,†,‡,1 Frances M. Brodsky,x,{,‖,2 and Peter Parham*,†,‡
Chimpanzees have orthologs of the six fixed, functional human MHC class I genes. But, in addition, the chimpanzee has a seventh
functional gene, Patr-AL, which is not polymorphic but contributes substantially to population diversity by its presence on only
50% ofMHC haplotypes. The ancestral AL gene emerged long before the separation of human and chimpanzee ancestors and then
subsequently and specifically lost function during human evolution, but was maintained in chimpanzees. Patr-AL is an alloantigen
that participates in negative and positive selection of the T cell repertoire. The three-dimensional structure and the peptide-
binding repertoire of Patr-AL and HLA-A*02 are surprisingly similar. In contrast, the expression of these two molecules is very
different, as shown using specific mAbs and polyclonal Abs made against Patr-AL. Peripheral blood cells and B cell lines express
low levels of Patr-AL at the cell surface. Higher levels are seen for 221-cell transfectants expressing Patr-AL, but in these cells
a large majority of Patr-AL molecules are retained in the early compartments of the secretory pathway: mainly the endoplasmic
reticulum, but also cis-Golgi. Replacing the cytoplasmic tail of Patr-AL with that of HLA-A*02 increased the cell-surface
expression of Patr-AL substantially. Four substitutions distinguish the Patr-AL and HLA-A*02 cytoplasmic tails. Systematic
mutagenesis showed that each substitution contributes changes in cell-surface expression. The combination of residues present
in Patr-AL appears unique, but each individual residue is present in other primate MHC class I molecules, notably MHC-E, the
most ancient of the functional human MHC class I molecules. The Journal of Immunology, 2015, 195: 3725–3736.
T
he selective pressures imposed by diverse, fast-evolving
pathogens cause the MHC class I genes of their mam-
malian hosts also to evolve rapidly (1). As a consequence,
there is considerable species-specific character to MHC class I
gene families. Characteristics shared by most mammalian species
are highly polymorphic classical MHC class I molecules that
engage highly variable types of lymphocyte receptors and con-
served nonclassical MHC class I molecules that engage conserved
types of lymphocyte receptors. Of the six human MHC class I
genes that are functional, HLA-A, -B, and -C are highly poly-
morphic and provide ligands for the ab TCRs of CD8 T cells and
for the killer cell Ig-like receptors (KIR) of NK cells. In contrast,
the HLA-E, -F, and -G genes exhibit little variation. HLA-E is the
ligand for the CD94:NKG2A and CD94:NKG2C receptors of NK
cells (2), which complement and collaborate with the KIR. By
comparison, the function of HLA-F is poorly understood, but it
could serve as a chaperone that transports unfolded HLA class I
molecules back from the cell surface to the cell’s interior (3).
HLA-G is the most specialized, being expressed only by extra-
villous trophoblast during pregnancy (4) and monocytes (5). Co-
operative interactions between HLA-G and the KIR2DL4 and
LILRB1 receptors of uterine NK cells are necessary for the de-
velopment of the placenta and the success of reproduction (6).
Counterparts to the HLA class I genes are restricted to simian
primates, and the chimpanzee (Pan troglodytes) has orthologs of
all six expressed HLA class I genes (7). For some 50% of chim-
panzee MHC haplotypes, these genes (Patr-A, -B, -C, -E, -F, and -G)
are the only expressed MHC class I genes, but the other 50%
of haplotypes have a seventh expressed gene, Patr-AL, that is
within an additional ∼125-kb block of genomic DNA that is next
to the 80-kb block containing the Patr-A gene (8). More closely
related to Patr-A than the other expressed genes, Patr-AL is one of
a group of A-related genes (hence the name A-like) that includes
the nonfunctionalMHC-H andMHC-J genes (9). Although not yet
proved, there is evidence for the existence of two forms of human
MHC haplotype that correspond to the Patr-AL+ and Patr-AL2
chimpanzee haplotypes (8). Called HLA-Y, the human equivalent
of Patr-AL is nonfunctional and contains a 59 region of high se-
quence similarity with Patr-AL that is recombined with a 39 region
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from another A-related gene (8). Neither Patr-AL nor HLA-Y ex-
hibit significant polymorphism. Patr-AL originated long before the
separation of human and chimpanzee ancestors (8, 9) and was
specifically inactivated during human evolution. Such inactivation
could have been driven by selection or by the demographic factors
of population bottleneck and genetic drift. Study of Patr-AL will
therefore define an immune system component that humans have
lost.
Patr-AL forms a heterotrimeric complex with b2-microglobulin
(b2m) and nonamer peptides to give a three-dimensional structure
in which the Ca traces of the H chain and b2m superimpose with
their counterparts in other HLA class I structures (8). The peptide-
binding specificity of Patr-AL is essentially the same as that of
HLA-A*02, although the two molecules differ by .40 aa sub-
stitutions, of which 30 are in the a1 and a2 domains and 13 are
predicted to contact peptide (8). These properties suggest that
Patr-AL, like HLA-A and Patr-A, presents peptide Ags to ab
TCRs. Supporting this hypothesis, Patr-AL is an alloantigen
recognized by the highly specific cytotoxic CD8 abT cells that
are present in chimpanzees lacking Patr-AL (8). This implies
that Patr-AL is expressed in the thymus and mediates negative
selection.
The major structural difference between Patr-AL and other
human and chimpanzee MHC class I molecules is the upper face of
the a helix of the a2 domain, which is unusually electropositive
and makes Patr-AL exceptional in having a basic isoelectric point
(8). Previous preliminary analysis of mRNA levels indicated that
the expression of Patr-AL was either very low or restricted to
a minority of PBMCs (9). In the investigation reported in this
article, we made Abs against Patr-AL and used them to study both
endogenous Patr-AL protein expression and recombinant Patr-AL
stably expressed in an MHC class I–deficient cell line and com-




Expression vectors were constructed by using PCR to amplify exons 1–8 of
Patr-AL*01:01:01 and HLA-A*02:07 from plasmids (8, 9) and cloning the
amplicons into the HindIII and XbaI sites of the mammalian expression
vector pcDNA3.1+ (Invitrogen Life Technologies, Grand Island, NY),
which drives expression via the CMV promoter. Patr-AL contains a me-
thionine at the second position of the leader sequence peptide. A mutated
construct was generated to express a threonine at that position (P2T). This
mutation causes unstable binding of the leader peptide to HLA-E, resulting
in poor cell-surface expression of HLA-E, preventing binding to CD94:
NKG2A/C.
Vectors containing FLAG-tagged Patr-AL and HLA-A*02 were gen-
erated by inserting a modified 3xFLAG tag (DYKDHDGDYKDHDI-
DYKDDDDK) between the signal sequence (encoded by exon 1) and the
a1 domain (encoded by exon 2) by a three-step PCR approach. All
amplifications were with 0.2 mM of each primer, 0.2 mM total dNTPs, 13
enzyme buffer, 1.5 mM MgCl2, 2.5 U HotStarTaq Plus DNA polymerase
(Qiagen, Venlo, the Netherlands). An exon 1 and the first half of the
3xFLAG tag fragment (with 59 HindIII site) was amplified from a cDNA
clone by using primers HindIII-AL-L-KZ-F or HindIII-A0207-L-KZ-F and
3xFLAG-ALL-R (primers listed in Supplemental Fig. 1) with amplifica-
tion conditions of 5 min at 95˚C, 35 cycles of 30 sec at 94˚C, 30 sec at
62˚C, and 40 sec at 72˚C followed by a final 10-min extension at 72˚C. A
second fragment consisting of the second half of the 3xFLAG and exons
2–8 (with 39 XbaI site) was amplified from a cDNA clone by using primers
3xFLAG-AL-F or 3xFLAG-A-F and XbaI_AL-A_Cyt_R with amplifica-
tion conditions of 5 min at 95˚C, 35 cycles of 30 sec at 94˚C, 30 sec at
62˚C, and 1 min 10 sec at 72˚C followed by a final 10-min extension at
72˚C. The 3xFLAG primers were designed with a 22-bp overlap allowing
them to join during the third PCR step. The two amplified fragments were
purified by gel extraction (Qiagen). These two fragments were joined and
amplified from 1 ml each of gel-purified PCR product by using primers
HindIII-AL-L-KZ-F or HindIII-A0207-L-KZ-F and XbaI_AL-A_Cyt_R
with amplification conditions of 5 min at 95˚C, 35 cycles of 30 sec at
94˚C, 1 min 25sec at 62˚C, and 40 sec at 72˚C followed by a final 10-min
extension at 72˚C. Purified PCR products consisting of exon1-3xFLAG-
exons2–8 were digested with HindIII and XbaI, cloned into pcDNA3.1+,
and the sequence determined (MCLAB, South San Francisco, CA).
To mutate specific residues in the transmembrane and cytoplasmic tails
of 3xFLAG-tagged-Patr-AL or -HLA-A*02, we performed site-directed
mutagenesis (QuikChange Lightning Multi Site-Directed Mutagenesis
Kit; Agilent Technologies, Santa Clara, CA) following the manufacturer’s
protocol. Mutagenesis primers (Supplemental Fig. 2) were designed using
Agilent Technologies QuikChange Primer Design Web site (http://www.
genomics.agilent.com/primerDesignProgram.jsp) and synthesized by the
Protein and Nucleic Acid Core Facility (Stanford University). All con-
structs were sequenced (MCLAB), using T7 forward and BGH reverse
primers, to assess the accuracy of the insert.
Preparation of a mAb specific for native Patr-AL
Patr-AL–specific Abs were generated by immunizing 10 BALB/c mice
with soluble complexes of recombinant Patr-AL extracellular domains,
b2m, and the ALDKATVLL peptide. Mice were primed at day 0 i.p. with
100 mg recombinant Patr-AL complexes in CFA (Sigma-Aldrich, St.
Louis, MO) and boosted similarly with Ag in IFA (Sigma-Aldrich) on days
14, 28, and 56. Serum Ab titers were measured by ELISA using immo-
bilized recombinant Patr-AL as Ag. The spleen from the mouse having the
highest titer of Abs was harvested on day 62, and fusion of splenocytes
with FOX-NY myeloma cells (ATCC, Manassas, VA) was performed for
5 min at a 5:1 ratio in PEG-3350 (Roche, Nutley, NJ). Hybridoma cells
were cloned by limiting dilution or by single-cell sorting into 96-well
plates on a FACSVantage Diva instrument (Becton-Dickinson, Santa Clara,
CA) at the Stanford Core FACS facility. Clones were grown in the presence
of BALB/c feeder splenocytes in Advanced DMEM (Invitrogen, Carlsbad,
CA) supplemented with 20% FetalClone I HyClone (GE Healthcare,
Logan, UT), pyruvate (Invitrogen), and L-glutamine (Invitrogen). Hy-
bridoma clones were selected using the hypoxanthine/aminopterin/
thymidine supplement (Invitrogen). Seven days after fusion, hybridoma
supernatants were screened by ELISA using soluble recombinant Patr-AL–
covered plates. The 96 hybridomas giving strongest binding to Patr-AL
were chosen for expansion and screening by flow cytometry. In screening,
the hybridoma supernatants were tested for binding to HLA class I–defi-
cient 221 cells and to a panel of 221 cell transfectants, each expressing
a single human or chimpanzee MHC-A allotype. These comprised human
HLA-A*01:01, A*02:01, A*02:07, and A*03:01, and chimpanzee Patr-
A*0:402, A*05:01, A*06:01, A*10:01, A*11:01, A*13:01, A*16:01, and
A*20:01. mAb 10A5 was found to be the most specific and most sensitive,
and was of the IgG1 H chain isotype and the k L chain isotype. All
experiments were approved by Stanford’s Administrative Panel on Labo-
ratory Animal Care.
The specificity of the 10A5 mAb was further assessed using the Lab-
Screen Group 1 Luminex assay (One Lambda, Canoga Park, CA) as de-
scribed previously (10). In this assay, 97 beads, each coated with a different
HLA-A, -B, or -C allotype, were tested for binding to 10A5. This panel of
HLA allotypes represents a broad range of HLA-A, -B, and -C variants.
Although all the bead-coated HLA allotypes bound to W6/32, an Ab that
reacts with all HLA class I molecules, none of the 97 HLA-A and -B
allotypes bound to 10A5.
Preparation of a polyclonal Ab specific for unfolded Patr-AL
A Patr-AL–specific rabbit polyclonal antiserum (ALpoly) was raised
(Anaspec, Fremont, CA) against the synthetic peptide QETQISK-
VYAQNDRVN, corresponding to residues 86–101 of Patr-AL. This se-
quence has the highest divergence from both Patr-A and HLA-A
sequences. A cysteine was added to the C terminus of the peptide, which
enabled peptide conjugates to be made with keyhole limpet hemocyanin
and BSA using hydroxysuccinimide. Antisera were raised in two rabbits
according to approved company protocols. The antisera were assayed by
ELISA using immobilized peptide as the Ag. The rabbit with higher serum
titer was bled and Patr-AL–specific Abs affinity-purified from the serum
using immobilized peptide. On Western blots, the resulting polyclonal Ab
was shown to be highly specific for Patr-AL, failing to recognize Patr-A.
Cells, cell lines, and transfections
EBV-transformed chimpanzee B cell lines from both Patr-AL+ and Patr-
AL2 individuals were generated in our laboratory as described previously
(9). Blood samples were obtained from common chimpanzees housed at
Yerkes Regional Primate Center (Atlanta, GA). PBMCs were isolated by
Ficoll density gradient separation (Ficoll–Paque PLUS; GE Healthcare)
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and cryopreserved in 90% heat-inactivated FBS (HI-FBS; Gemini Bio-
Products) + 10% DMSO (EMD Millipore, Billerica, MA). Cryopre-
served PBMCs were thawed and washed once in complete RPMI me-
dium, resuspended at a concentration of 2 3 106 cells/ml, and allowed
to recover overnight (15 h) at 37˚C before performing any in vitro
experiments.
Individual Patr-AL, HLA-A*02, and mutant cDNAs in the pcDNA3.1+
vector were stably transfected into the MHC-A–, -B–, and -C–deficient cell
line 721.221 (subsequently referred to as 221 cells). A total of 23 106 221
cells were transfected in 100 ml Cell Line Nucleofector Kit V (Lonza
Group, Basel, Switzerland) using program A-024 in a Nucleofector 2b
Device (Lonza Group) with 2 mg linearized DNA. Transfected 221 cells
were mixed with 500 ml complete RPMI [RPMI 1640 (Gibco; Life
Technologies, Grand Island, NY) + 10% HI-FBS, 2 mM L-glutamine, and
antibiotics (penicillin 100 U/ml and streptomycin 100 mg/ml; Gibco; Life
Technologies)] and 200 ml was plated into 3 wells of a 96-well round-
bottom plate. Four weeks later, successfully transfected 221 were ex-
panded and sorted for positive MHC cell-surface expression using the class
I–specific Ab W6/32.
HeLa cells (ATCC Cell Lines) were plated in 24-well plates at 5 3 104
cells/well in 500 ml complete DMEM (Gibco; Life Technologies; + 10%
HI-FBS, 2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml strep-
tomycin) for 24 h. Cells were then transfected with 1 mg of a pcDNA3.1+
vector encoding FLAG-tagged Patr-AL, HLA-A, or mutant allotypes and
3 ml of the FuGENE 6 transfection reagent (Promega, Madison, WI) in 25 ml
Opti-MEM (Gibco; Life Technologies) per well. Forty-eight hours after
transfection, adherent cells were dissociated from the wells using 200 ml
0.05% trypsin EDTA solution (Gibco; Life Technologies) for staining
using a 3xFLAG-specific, FITC-conjugated mAb (M2-FITC; Sigma-
Aldrich) and analysis by flow cytometry.
Immunoprecipitation and endoglycosidase H treatment
Patr-AL was immunoprecipitated from stable 221-Patr-AL transfectants
with the mAb 10A5, using the Dynabeads Co-Immunoprecipitation Kit
(Invitrogen) and the manufacturer’s protocol. In brief, 10 mg 10A5 was
coupled overnight to 1 mg Dynabeads M-270 Epoxy. For each immuno-
precipitation (IP) experiment, 1.5 mg Ab-coupled beads were used to im-
munoprecipitate Patr-AL from Nonidet P-40 (NP-40) cell lysates of 150 mg
cells. Following the recommended washes, samples were subjected to
Endoglycosidase H (New England Biolabs, Ipswich, MA) treatment. One
thousand units of Endoglycosidase H in G5 buffer was used to digest 5 ml
immunoprecipitate at 37˚C for 1 h. For protein blotting, samples were
heated at 95˚C for 5 min, then separated by SDS-PAGE (Bio-Rad, Her-
cules, CA) and analyzed by Western blot using ALpoly at a concentration
of 0.5 mg/ml.
Immunofluorescence and confocal microscopy
221-Patr-AL cells plated at 3.53 105 cells/well of a 24-well plate in 500 ml
complete RPMI on a 12-mm Round No. 1 German Glass Poly-D-Lysine–
coated glass coverslip (BD Biosciences, San Jose, CA) were allowed to
attach for 1 h at 37˚C. Cells were then fixed with a mixture of 70%
methanol and 30% acetone for 10 min on ice followed by permeabilization
for 1 min with cold acetone. After washing wells three times with DPBS
(containing calcium chloride and magnesium chloride; Life Technologies),
cells were blocked for 15 min with cold blocking buffer (DPBS containing
2% heat-inactivated goat serum, 1% BSA, 0.1% cold fish skin gelatin,
0.02% SDS, 0.1% NP-40, and 0.05% sodium azide, pH 7.2). Cells were
then stained with 5 mg/ml primary Abs against Patr-AL (ALpoly), In-
variant chain (PIN.1; Abcam, Cambridge, U.K.), cis-Golgi (GM130; BD
Biosciences), or HLA-DR (L243; BD Biosciences) diluted in blocking
buffer and incubated overnight at 4˚C with gentle agitation. After washing
with blocking buffer, cells were incubated with 4 mg/ml goat anti-rabbit
IgG Alexa Fluor 488, goat anti-mouse IgG1 Alexa Fluor 555, or goat anti-
mouse IgG2a Alexa Fluor 647 (Molecular Probes, Eugene, OR) secondary
Abs in blocking buffer for 1 h at 4˚C with gentle shaking. Cells were then
washed in blocking buffer, followed by DPBS, and coverslips were
mounted for microscopy in ProLong Gold antifade reagent (Life Tech-
nologies). Secondary Ab specificity was assessed by controls in which
primary Ab was omitted.
Cells processed for immunofluorescence were analyzed by confocal
laser-scanning microscopy using an upright system (DM6000, SP5; Leica)
with an oil immersion objective (633, 1.3NA; HCX Plan Apochromat;
Leica, Solms, Germany) and argon (488) and HeNe (543 and 633) lasers.
Images were acquired using LAS AF SP5 software (Leica) in sequential
scan mode with a 400-Hz scan rate, line averages of 2, and a 512 3 512–
pixel resolution. Z-stacks were collected at 0.3-mm intervals. The same
settings were maintained for all samples within an experiment. Raw
images were processed using Volocity (PerkinElmer, Waltham, MA) by
applying a fine filter to improve image quality. Quantitative colocalization
analysis was performed on processed images by calculating the Pearson’s
correlation coefficient using the staining intensity of voxels falling
within the region of interest identified using the Lasso tool in Volocity.
The automatically selected region of interest from individual channels
was then overlaid and analyzed. A value of 0 represents no colocaliza-
tion, whereas 21 represents negative colocalization, and 1 represents
positive colocalization.
Flow cytometry
Patr-AL and HLA-A*02 were detected on the surface of stably transfected
221 cells by staining with mAbs 10A5 and BB7.2 (BD Biosciences), re-
spectively, at 5 mg/ml in 50 ml FACS buffer (1 mM EDTA, 1% BSA, and
0.04% azide in PBS). W6/32 (purified in our laboratory) was used at 5 mg/
ml as a pan-MHC class I Ab. After three washes with FACS buffer, a goat
anti-mouse IgG Alexa Fluor 488 (Molecular Probes) secondary Ab, at
a concentration of 4 mg/ml, was used to stain the cells. After three more
washes with FACS buffer, cells were resuspended in FACS buffer con-
taining 2 mM propidium iodide (BD Biosciences) and fluorescence
measurements were acquired using an Accuri C6 cytometer (BD Bio-
sciences).
To detect intracellular Patr-AL, we fixed 221 transfectants with a mixture
of 70% methanol and 30% acetone for 10 min on ice, washed three times
with intracellular FACS buffer (IFB: 1% BSA, 2% heat-inactivated goat
serum, 0.1% cold fish skin gelatin, and 0.05% sodium azide in PBS at pH
7.2), after which one aliquot of cells was permeabilized for 10 min on ice
using IFB supplemented with 0.02% SDS and 0.1% NP-40, and another
aliquot was not permeabilized. From this point on, the permeabilized cells
were washed with IFB containing NP-40 and SDS, whereas the unper-
meabilized cells were washed with IFB only. Fixed and permeabilized cells
were then stained with 100 ml 10A5 primary Ab at 5 mg/ml in IFB, washed
three times, and subsequently stained with goat anti-mouse IgG Alexa
Fluor 488 at 4 mg/ml. After three more washes with IFB, cells were
resuspended in IFB containing 2 mM propidium iodide (BD Biosciences)
and fluorescence measurements using an Accuri C6 cytometer.
We examined the cell-surface expression of 36 3xFLAG-tagged Patr-AL,
HLA-A*02, and individual transmembrane and cytoplasmic tail mutants in
HeLa cells (ATCC Cell Lines). Transiently transfected HeLa cells were
detached from the wells using 200 ml 0.05% trypsin EDTA solution
(Invitrogen), and the reaction was quenched with 1 ml complete RPMI.
Detached cells were washed with blocking buffer and stained with 50 ml
FITC-conjugated anti-FLAG mouse monoclonal IgG1, M2-FITC (Sigma-
Aldrich) at a final concentration of 3 mg/ml in FACS buffer. After Ab
staining, cells were washed three times with FB and finally resuspended in
FB containing 2 mM propidium iodide and 2% paraformaldehyde. Cells
expressing the FLAG-tagged mutants were detected by flow cytometry
using an Accuri C6 cytometer (BD Biosciences). Expression levels of each
mutant allotype were determined from the average median fluorescence
intensity (mfi) of M2-FITC Ab-reactive cells. A minimum of three
experiments was performed for each MHC allotype.
Results
Most Patr-AL molecules made by B lymphoblastoid cells do not
reach the cell surface
Previously we showed that the Patr-AL protein can be detected in
chimpanzee PBMCs and B lymphoblastoid cell lines (BLCL), but
at a much lower level than classical MHC class I molecules (9). To
facilitate further study of Patr-AL expression, we made mAbs
from the B cells of mice immunized with soluble, recombinant
Patr-AL. This Ag comprised the extracellular domains of Patr-AL,
b2m, and the nonamer Patr-AL binding peptide ALDKATVLL
(8). Of many mAbs obtained, the 10A5 Ab was selected for use in
this study because it binds strongly to Patr-AL and exhibits no
detectable interaction with other MHC class I (Fig. 1). Thus, 10A5
binds to HLA-A–, -B–, and -C–deficient 221 cells transfected with
Patr-AL, but not to untransfected 221 cells or to 221 cells trans-
fected with either HLA-A or Patr-A (Fig. 1A).
The W6/32 Ab recognizes an epitope shared by all human and
chimpanzee MHC class I molecules (11). It thus binds to the small
amount of HLA-E expressed on the surface of 221 cells (12). Trans-
fection of 221 cells with wild-type Patr-AL, Patr-AL expressing
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a modified Leader peptide to prevent increased cell-surface
HLA-E expression (P2T), Patr-A, or HLA-A causes cell-surface
expression of these MHC class I molecules (Fig. 1B). Transfection
of 221 cells with either version of Patr-AL induces an increase in
W6/32 binding that is about a third of that seen for Patr-A or
HLA-A (Fig. 1B). Binding of these same cell lines with an Ab
specific to HLA-E (Fig. 1C) demonstrates that there is not a sig-
nificant difference of cell-surface HLA-E expression between the
two Patr-AL–expressing cell lines. This result shows that unlike
HLA-A and Patr-A, the majority of Patr-AL molecules made by
the transfected 221 cells do not reach the cell surface. This could
arise from intracellular retention, intracellular degradation, or
a combination of these factors.
The exquisite specificity of the 10A5 Ab for Patr-AL is
demonstrated by analysis to measure the binding of 10A5 to 97
HLA-A, -B, and -C variants and comparing the results with the
binding achieved by W6/32. This analysis was performed by
using a panel of Luminex beads, in which each bead is coated with
a different HLA class I molecule (13). Whereas the binding of
W6/32 to the 97 beads varied between a fluorescence intensity of
17,715 and 28,136, the binding of 10A5 varied between 9 and 77
(Fig. 1D). Thus, none of the 31 HLA-A, 50 HLA-B, and 16
HLA-C allotypes is bound significantly by the anti-Patr-AL
mouse mAb 10A5.
Chimpanzee cells and cell lines differ in their expression of
cell-surface Patr-AL
Because the Patr-AL gene is carried by ∼50% of chimpanzee MHC
haplotypes, individual chimpanzees can have 0, 1, or 2 copies of the
Patr-AL gene. B cell lines made from the lymphocytes of four Patr-
AL2 chimpanzees and six Patr-AL+ chimpanzees were analyzed by
flow cytometry for their capacity to bind the 10A5 Ab (Fig. 2A).
Cell lines from the Patr-AL2 chimpanzees did not bind 10A5,
whereas a variable but reproducible binding was observed for the
cell lines from Patr-AL+ chimpanzees (Fig. 2A). We measured the
frequency of 10A5+ cells because the fluorescence staining intensity
of the bulk populations were similar. Only a minority of cells bound
the 10A5 Ab, the number varying between 1 and 13% of cells. Both
Miss Eve and Ericka have two copies of Patr-AL, Miss Eve being
homozygous and Ericka being heterozygous (9). Because this in-
formation is not known for the other chimpanzee BLCL used in this
study, we cannot exclude the possibility of a Patr-AL gene dosage
effect in augmenting the expression of Patr-AL in Miss Eve and
Ericka B cell lines.
Analogous results were obtained when PBMCs from 8 Patr-AL2
chimpanzees and 16 Patr-AL+ chimpanzees were similarly ana-
lyzed, but the fraction of cells from Patr-AL+ chimpanzees that
stain with 10A5 is,3% (Fig. 2C). In fact, most of the bulk PBMC
populations we analyzed contained ,1% of cells staining positive
for 10A5, a value that is well within the background of the gating
strategy used for this analysis. To test the possibility that Patr-AL
was enriched in a particular subset of PBMCs, we performed
immunophenotyping experiments where we identified T cells,
B cells, NK cells, monocytes, and granulocytes, but did not ob-
serve such enrichment (data not shown). Chimpanzee PBMCs
were also stimulated in vitro with the cytokine IFN-g, a compound
known to upregulate MHC class I expression, and with a potent
polyclonal T cell stimulator, the superantigen staphylococcal en-
terotoxin A, to determine whether an upregulation of cell-surface
Patr-AL could be detected. In vitro stimulation of chimpanzee
PBMCs with IFN-g or staphylococcal enterotoxin A at different
concentrations for 48 h did not result in an increase in cell-surface
Patr-AL (data not shown). Despite the reduced levels of cell-
surface Patr-AL on chimpanzee BLCL and PBMCs, these cells
do express a constitutive level of classical class I molecules on
their cell surface (Fig. 2B, 2D), as expected. These results clearly
show that Patr-AL, unlike classical MHC class I, is not constitu-
tively expressed at cell surfaces.
FIGURE 1. Cell-surface expression of Patr-AL is very low compared
with HLA-A and Patr-A. (A–C) Surface staining, with anti–Patr-AL mAb
10A5 (A), anti–MHC class I mAb W6/32 (B), or anti–HLA-E mAb 3D12
(C), of 221 cells (221, shaded gray), and 221 cells transfected with Patr-AL
expressing its native Leader peptide (AL, orange), Patr-AL expressing
a mutated Leader that abrogates expression of HLA-E (AL [P2T], blue),
HLA-A*02:07 (HLA-A, green), and Patr-A*04:02 (Patr-A, purple). Bar
graph on the left shows the mfi values obtained for the histograms shown
on the right. Error bars indicate SD between two replicates within an
experiment. Histograms show staining intensity for intact, live cells. One
representative experiment is shown from the three total performed. Not
shown are data for 221 transfectants expressing other human (HLA-
A*01:01, -A*02:01, -A*02:07, and -A*03:01) and chimpanzee (Patr-
A*04:02, -A*05:01, -A*06:01, -A*10:01, -A*11:01, -A*13:01, -A*16:01,
and -A*20:01) MHC-A allotypes that have expression levels comparable
with the HLA-A*02:07 and Patr-A*24:02 transfectants. (D) Summary of
the binding reactions of 10A5 and W6/32 Abs to microbeads, individually
coated with 1 of 31 HLA-A, 50 HLA-B, and 16 HLA-C allotypes. Ab
10A5 bound to none of the HLA class I allotypes, whereas W6/32 bound to
all of them and to similar extent (,15% variation between the beads). Data
from at least 100 beads were obtained for each HLA class I allotype.
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To determine whether endogenous Patr-AL could be detected
intracellularly, we used immunofluorescence staining and high-
resolution confocal microscopy to detect Patr-AL in chimpanzee
BLCL derived from Miss Eve (Fig. 2E) or Faye (Fig. 2F). In these
experiments, Patr-AL was detected using ALpoly. This Ab, which
was raised against a synthetic peptide corresponding to residues
86–101 of the Patr-AL a1 and a2 domains, recognizes both native
and denatured Patr-AL (see Materials and Methods). As a marker
of the endoplasmic reticulum (ER), we used an Ab specific for the
cytoplasmic tail of the MHC class II invariant chain. This Ab
marks the ER and early secretory pathway, because the cyto-
plasmic tail becomes degraded when the invariant chain traffics
from the secretory pathway to an endosomal compartment (14). A
signal specific for Patr-AL is detected intracellularly in BLCL
from a Patr-AL+ donor, whereas no signal is detected in the BLCL
derived from the Patr-AL2. These results suggest that Patr-AL is
intracellularly localized.
Patr-AL is synthesized and sequestered inside B
lymphoblastoid cells
For Patr-AL and HLA-A*02, which have remarkably similar
structures and peptide-binding specificities (8), we compared the
distribution of molecules between the cell surface and intracellular
compartments (Fig. 3). Transfected 221 cells expressing Patr-AL
or HLA-A*02, under the control of the same promoter, were
tested for binding 10A5 (Fig. 3A) and the HLA-A*02–specific Ab
BB7.2 (Fig. 3B). Consistent with these specificities, the Patr-AL
transfectant bound 10A5, but not BB7.2, whereas the HLA-A*02
transfectant bound BB7.2, but not Patr-AL. Furthermore, the cell-
surface binding to Patr-AL by 10A5 (Fig. 3A) was only 6% that of
HLA-A*02 to BB7.2 (Fig. 3B). Aliquots of transfected 221 cells
were either fixed or first fixed and then permeabilized before
staining with the 10A5 and BB7.2 Abs, to assess the relative
amounts of intracellular Patr-AL and HLA-A*02. Permeabilization
dramatically increased the specific binding of 10A5 to the Patr-AL–
transfected cells (Fig. 3C), but did not similarly affect the binding of
BB7.2 to HLA-A*02 (Fig. 3D). Thus, although similar amounts of
Patr-AL and HLA-A*02 are made by the transfectants, because
both are generated by expression under the control of the strong
CMV promoter, .90% of HLA-A*02 is delivered to the cell sur-
face, whereas .90% of Patr-AL is sequestered within the cell.
Patr-AL is retained within cells at an early stage in the
secretory pathway
To identify the intracellular sites where Patr-AL is sequestered, we
used immunofluorescence staining and high-resolution confocal
microscopy to compare the intracellular distribution of Patr-AL
with those of well-characterized intracellular markers. A signifi-
cant colocalization of Patr-AL with the invariant chain was ob-
served (Fig. 4A), showing a retention of Patr-AL in the ER and
early secretory pathway. In contrast, there was little colocalization
of Patr-AL with the mature MHC class II molecules detected by
the L243 mAb (Fig. 4B), most of which are not associated with
the invariant chain (Fig. 4C). Also observed was colocalization of
Patr-AL with the Golgi matrix protein GM130, a cis-Golgi marker
(Fig. 4D), but to lesser extent (∼45%) than the colocalization of
Patr-AL with invariant chain (Fig. 4A), suggesting that most of the
intracellular Patr-AL is localized to the ER. Consistent with the
results of flow cytometry (Fig. 1A), a small amount of Patr-AL
was visualized on the cell surface in analysis of transient HeLa
transfectants by microscopy (Supplemental Fig. 3). These results
therefore show that, whereas small amounts of Patr-AL are observed
on cell surfaces, most of the cellular Patr-AL is retained within the
cell, mostly in the ER and to a lesser degree in the cis-Golgi.
FIGURE 2. Patr-AL is not expressed constitutively on cell surfaces. (A
and B) Cell-surface staining and flow-cytometric analysis of 10 BLCL
derived from chimpanzee peripheral blood B cells. Cells were stained with
Patr-AL–specific Ab 10A5 (A) and pan MHC class I–specific Ab W6/32
(B). For 10A5 staining (A), the bars show the frequency of Ab-binding
intact, live cells. For W6/32 staining (B), the bars show mfi staining of the
intact, live cells. Light gray shaded bars denote BLCL derived from
chimpanzees that lack the Patr-AL gene; dark gray shaded bars denote
BLCL derived from chimpanzees that carry the Patr-AL gene. (C and D)
Shown are analyses comparable with those depicted in the upper panels but
performed on samples of PBMCs obtained from 24 chimpanzees. (C)
Frequency of cells staining for Patr-AL with the 10A5 Ab. (D) The mfi of
staining for MHC class I as detected with the W6/32 Ab. (E and F)
Multicolor immunofluorescence staining and confocal microscopy of
chimpanzee BLCL derived from a Patr-AL+ individual, Miss Eve (E) and
a Patr-AL2 individual, Faye (F) fixed with 70% methanol 30% acetone and
stained with various Abs. Patr-AL was stained with ALpoly (green). The
specificity of ALpoly was confirmed by the negative staining of 221 cells
(data not shown) and BLCL derived from a Patr-AL2 donor. Invariant
chain was stained with the PIN.1 mAb, which identifies the ER and early
ER-derived vesicles of the endolysosomal system (red). TOTO-3 (blue) is
used as a nuclear counterstain. Original magnification 363.
The Journal of Immunology 3729













To confirm the results of the microscopy experiments, we ex-
amined the maturity of the oligosaccharide attached to N86 of Patr-
AL, and hence whether Patr-AL has undergone posttranslational
modification upon trafficking through the Golgi apparatus. IP of
Patr-AL with the 10A5 Ab was performed on lysates prepared from
221 cells and 221 cells transfected with Patr-AL. The precipitates
were treated with endoglycosidase H, which removes immature,
but not mature, N-linked oligosaccharides and then subjected to
SDS-PAGE and Western blotting using ALpoly. Analysis of the
immunoprecipitates (Fig. 4E, left panel), as well as whole cell
lysates (Fig. 4E, right panel), show that Patr-AL was detected, as
expected, only in the Patr-AL–transfected cells. On treatment with
endoglycosidase H, most, but not all, of the Patr-AL H chains
were reduced in m.w. and were thus sensitive to the enzyme
(Fig. 4E, left panel). This, in turn, shows that most, but not all,
Patr-AL molecules carry an immature N-linked oligosaccharide.
This result is consistent with intracellular Patr-AL molecules be-
ing sequestered principally in the ER and secondarily in the cis-
Golgi.
To determine whether Patr-AL molecules travel to endolyso-
somal compartments, we examined lysosomes, late endosomes,
and compartments containing matureMHC class II for the presence
of Patr-AL. Patr-AL–transfected 221 cells were stained with
ALpoly, monoclonal MHC class II–specific L243, and an mAb
specific for Lamp-1, a marker of late endosomes and lysosomes
(Fig. 4F). The extent of the colocalization among the three
markers was quantified. A good correlation was observed between
the presence of Lamp-1 and HLA-DR, but no correlation between
the presence of Patr-AL and either Lamp-1 or HLA-DR (Fig. 4G).
As is well established (15), we find that mature MHC class II
molecules do travel to endolysosomal compartments. In contrast,
we find no evidence for the movement of Patr-AL molecules from
the ER to endolysosomal compartments during steady-state con-
ditions. In conclusion, these experiments (Fig. 4) demonstrate that
Patr-AL is actively retained at an early stage of the secretory
pathway, which is predominantly in the ER but also includes the
cis-Golgi.
In some circumstances, proteins that are retained in the ER can
be brought to the cell surface by reducing the temperature to,37˚C
(16, 17). To test this possibility for Patr-AL, we subjected 221
transfectants expressing Patr-AL or HLA-A*02 to overnight cul-
ture at temperatures ranging from 21 to 37˚C. The expression of
Patr-AL and HLA-A*02 was then determined by flow cytometry
using the 10A5 and BB7.2 Abs, respectively. Over this tempera-
ture range, there was no difference in the cell-surface expression
of HLA-A*02. In contrast, for Patr-AL we observed a trend in
which there was an increase by 31% of cell-surface expression as
the temperature was lowered from 37 to 27˚C, which then reversed
as the temperature was further lowered to 21˚C (Fig. 5).
The distinctive cytoplasmic tail of Patr-AL is a cause of
intracellular retention
One mechanism used to retain transmembrane proteins inside cells
involves sequence motifs in the cytoplasmic tail that are bound by
tethering or adaptor proteins (18–20). In examining the sequence
of the Patr-AL cytoplasmic tail, we found a modified tyrosine-
based sorting signal, YFQA at positions 320–323, which would
potentially affect endocytosis or trans-Golgi network sorting, but
no dileucine-based endocytic protein sorting motifs, none of
which would be relevant to the localization of Patr-AL in the early
secretory pathway. Comparing the cytoplasmic tail sequences of
MHC class I molecules from different species identified four
residues (F321, N326, S329, and E333) that appear unique to Patr-
AL (Fig. 6A, Supplemental Fig. 4). Moreover, these are the only
four residues that distinguish the cytoplasmic tails of Patr-AL and
HLA-A*02. Remarkably, this combination of residues found in
Patr-AL’s cytoplasmic tail is unique to Patr-AL and not found in
cytoplasmic tail sequences of the known Patr-AL orthologs (8),
HLA-Y, Gogo-OKO, and Popy-A, nor in any other characterized
MHC class I molecule (Supplemental Fig. 4). We therefore hy-
pothesized that one or more of these four residues contribute to the
intracellular retention and low cell-surface expression of Patr-AL.
To test this hypothesis, we made Patr-AL and HLA-A*02
mutants in which their cytoplasmic tails were swapped, the pre-
diction being that mutant Patr-AL with the HLA-A*02 tail would
have higher cell-surface expression, whereas mutant HLA-A*02
with the Patr-AL tail would have lower cell-surface expression.
Stable 221 transfectants expressing the two recombinant mutants
and the two parental molecules were tested for their capacity to
bind Patr-AL–specific 10A5 and HLA-A*02–specific BB7.2.
Expression of the Patr-AL mutant with the HLA-A*02 tail was
5.0-fold higher than that of Patr-AL (Fig. 6B). Similarly, the cell-
surface expression of HLA-A*02 was 4.5-fold that of the HLA-
A*02 mutant with the Patr-AL tail (Fig. 6C). These results were
recapitulated by high-resolution confocal microscopy analysis of
transient HeLa transfectants (Supplemental Fig. 3). These results
demonstrate that one or more of the four substitutions that dis-
tinguish the cytoplasmic tails of Patr-AL and HLA-A*02 con-
tribute to the differential cell-surface expression of these two
MHC class I molecules. However, these differences can account
for only approximately one third of the 13.4-fold difference in
the expression of HLA-A*02 and Patr-AL in 221 transfectants
FIGURE 3. Transfected cells make comparable amounts of Patr-AL and
HLA-A*02, but Patr-AL mainly stays inside the cell, whereas HLA-A*02
goes to the surface. Flow-cytometric analysis of 221 cells (221), 221
transfectants expressing Patr-AL (AL), and 221 transfectants expressing
HLA-A*02:07 (A*02) after staining with anti–Patr-AL (10A5) and anti–
HLA-A*02 (BB7.2) mAbs. (A) and (B) show cell-surface staining for Patr-
AL (A) and HLA-A*02 (B). Bars give the mfi values of positively staining
intact, live cells. Error bars represent SD between mfi shown for the data
from three replicate experiments. (C) and (D) compare the amounts of Patr-
AL (C) and HLA-A*02 (D) that are at intracellular and cell-surface
locations. Because of the different physicochemical properties of the 10A5
and BB7.2 Abs, different protocols were used to detect their epitopes. For
10A5 staining (C), cells were fixed with 70% methanol 30% acetone, after
which one aliquot of cells was permeabilized with cold acetone and the
other was not. The cells were then stained with 10A5 and analyzed by flow
cytometry. For BB7.2 staining (D), transfectants were fixed with 4%
paraformaldehyde, after which one aliquot of cells was permeabilized with
0.04% saponin in FACS buffer and the other was not. The cells were then
stained with the BB7.2 Ab and analyzed by flow cytometry. (C and D) Gray
bars give the staining of nonpermeabilized cells, and black bars show the
staining of the permeabilized cells. Error bars show the SD in mfi for data
from three replicate experiments.
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(Fig. 1C). Thus, substitutions in other domains of the Patr-AL and
HLA-A*02 proteins are also implicated in altering cell-surface
expression.
The four residues that distinguish the cytoplasmic tail of
Patr-AL all act to reduce cell-surface expression
To determine the effects of the four substitutions that distinguish
the cytoplasmic tails of Patr-AL and HLA-A*02, we made sets of
16 Patr-AL and 16 HLA-A*02 mutants that represent all possible
combinations of the dimorphisms at positions 321, 326, 329, and
333. To facilitate comparison of the cell-surface expression of
these mutants, we included 3xFLAG epitopes at the N terminus of
each mutant and parental allotype. These constructs were tran-
siently transfected into HeLa cells and their cell-surface expres-
sion assessed by flow cytometry using the M2 mAb that recog-
nizes the 3xFLAG epitope (Fig. 7).
FIGURE 4. Patr-AL concentrates in the ER and the cis-Golgi. (A–D) Multicolor immunofluorescence staining and confocal microscopy of 221-Patr-AL
transfectants (left panels) fixed with 70% methanol 30% acetone and stained with various Abs. Patr-AL was stained with ALpoly. The specificity of ALpoly
was confirmed by the negative staining of 221 cells (data not shown). HLA-DR is stained with the L243 mAb, which recognizes mature class II molecules
that lack the invariant chain. Invariant chain is stained with the PIN.1 mAb. Golgi matrix protein of 130 kDa is stained with the GM130 mAb. The right
panels are scattergrams showing the quantitative colocalization analysis of pairs of markers. Numbers in the scattergram are Pearson’s correlation coef-
ficient values for the indicated channels (1 = perfect colocalization, 0 = no colocalization, 21 = negative colocalization) as averaged from analysis of 50
cells. Scale bar, 5 mm. For (A)–(D), blue represents DNA. (E) Patr-AL was immunoprecipitated from Patr-AL–transfected 221 cells (221-AL) using the
10A5 Ab and the Dynabeads Co-Immunoprecipitation Kit (Invitrogen). 221 cells served as the negative control. Immunoprecipitates were treated with
Endoglycosidase H (1000U) (+) or not (2), and analyzed by SDS-PAGE on a 4–15% gradient gel. Western blotting was performed using ALpoly to detect
Patr-AL (left panel). For comparison, total lysates of 221 and 221-AL cells were similarly analyzed by SDS-PAGE and Western blotting (right panels). (F)
Multicolor immunofluorescence staining and confocal microscopy of 221 cells transfected with Patr-AL. Cells were fixed (as described earlier) and si-
multaneously stained with ALpoly (green), anti-lysosomal and anti-late endosomal marker, Lamp-1 (red), and HLA-DR (blue). The Lamp-1+ and HLA-
DR+ compartments within each cell were analyzed by quantitative colocalization analysis of pairwise comparisons for each of the three channels imaged.
Pink color shows overlap of red and blue staining. (G) From the data illustrated in (F), mean values for Pearson’s correlation coefficient were calculated
from pairwise comparisons of fluorescence intensity measurements, of 20 cells, from each of the 3 channels imaged. Error bars represent SD between
average Pearson’s correlation coefficient values for the 20 cells sampled. ***p , 0.0001.
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The cytoplasmic tail of Patr-AL is distinguished by F321, N326,
S329, and E333. We compared the expression levels of Patr-AL
cytoplasmic tail mutants upon stepwise mutagenesis from an
HLA-A*02 (right of each panel in Fig. 7) with a Patr-AL cyto-
plasmic tail (middle of each panel in Fig. 7). The results from the
subset of Patr-AL mutants shown in Fig. 7A allow us to assess
how each individual residue influences the cell-surface expression
of Patr-AL. F321 has the strongest impact, accounting for ∼50%
of the effect in reduced surface expression of the Patr-AL tail. The
other 50% is due to lesser contributions from the residues at
positions 326, 329, and 333. Among the six combinations of two-
residue mutants, F321 and E333 give the greatest effect (Fig. 7B),
whereas among the four possible mutants combining three of the
residues, it is the combination of F321, S329, and E333 that is
most effective (Fig. 7C). However, none of these mutants is as
effective as the combination of all four residues present in the
cytoplasmic tail of Patr-AL. Thus, for Patr-AL, although phenyl-
alanine at position 321 plays a dominant role in the decrease of
Patr-AL surface expression, each of the four Patr-AL cytoplasmic
tail–specific residues have all made contributions in reducing the
cell-surface expression of Patr-AL.
In similar analysis of the four substitutions that distinguish the
HLA-A*02 cytoplasmic tail from that of Patr-AL, the presence of
either S321, A329, or D333 is sufficient to restore cell-surface
expression to a level that is greater or equal to that of HLA-
A*02. Also, the presence of S326 achieves 92% of wild-type
HLA-A*02 expression (Fig. 7C). Although individually the four
residues have positive effects, in combinations they have more
varied effects. Thus, the combination of S321, S326, and D333
causes little increase of HLA-A*02 cell-surface expression over
that seen with the full Patr-AL cytoplasmic tail mutant of HLA-
A*02 (Fig. 7A), and the combinations of either S326 or A329 with
D333 also have small effects (Fig. 7B). In contrast, several
combinations of residues raise the level of cell-surface expression
much more than that of HLA-A*02 (Fig. 7A). Thus, there are
antagonistic and synergistic effects between the residues at posi-
tions 321, 326, 329, and 333 in HLA-A*02. These results suggest
that for both Patr-AL and HLA-A, whereas polymorphisms in
cytoplasmic tail residues contribute to differences in cell-surface
expression, other factors simultaneously regulate their surface
expression.
Natural sequence variation in the transmembrane domain
influences cell-surface expression
Because multiple factors are implicated in reducing cell-surface
expression of Patr-AL, we investigated the effect of the single
amino acid difference that distinguishes the transmembrane domains
FIGURE 5. Cell-surface expression of Patr-AL, but not HLA-A*02, is
temperature sensitive. 221 cells transfected with Patr-AL (upper panel)
and HLA-A*02 (lower panel) were cultured in complete RPMI medium
and incubated for 16 h at various temperatures from 21 to 37˚C. Cell-
surface expression of Patr-AL (10A5) and HLA-A*02 (BB7.2) were
subsequently assayed by Ab staining and flow cytometry. The average mfi
values for positively staining, live cells are plotted. Error bars represent SD
between mfi shown for the data from three replicate experiments.
FIGURE 6. Unique features in the cytoplasmic tail contribute to the intracellular retention of Patr-AL. (A) Amino acid sequence alignment of the
cytoplasmic tails from Patr-AL and other human and chimpanzee MHC class I molecules. Shaded gray are positions 321, 326, 329, and 333 where Patr-AL
has a unique combination of amino acid residues. (B) 221 cells transfected with either Patr-AL (AL) or a mutant of Patr-AL (ALcytA2) having the cy-
toplasmic tail of HLA-A*02 were stained with anti–Patr-AL Ab (10A5) and analyzed by flow cytometry. (C) 221 cells transfected with HLA-A*02 (A*02)
or a mutant of HLA-A*02 (A*02cytAL) having the cytoplasmic tail of Patr-AL were stained with anti–HLA-A*02 Ab (BB7.2) and analyzed by flow
cytometry. For 10A5 binding (B) and BB7.2 binding (C) the average mfi value of cells is plotted. Error bars represent the SD between mfi for the data from
three replicate experiments. ***p # 0.0005.
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of Patr-AL and HLA-A. At position 295, Patr-AL has valine and
HLA-A*02 has glycine. Mutants were made, in which these res-
idues were swapped and analyzed using the same methods applied
to the cytoplasmic tail mutants (Fig. 8).
The substitution of valine for glycine at position 295 in Patr-AL
has no significant effect on cell-surface expression. Neither did
polymorphism at position 295 affect cell-surface expression of the
Patr-ALmutant that has the cytoplasmic tail of HLA-A*02 (Fig. 8).
In contrast, mutating residue 295 from glycine to valine in HLA-
A*02 increases the surface expression by 30%. This effect is not
seen in the HLA-A*02 mutant that has both the transmembrane
domain and the cytoplasmic tail of Patr-AL, and that gives iden-
tical cell-surface expression to HLA-A*02. However, the HLA-
A*02 mutant with just the Patr-AL cytoplasmic tail has expression
reduced by 32% (Fig. 8). These results demonstrate that in con-
trast with Patr-AL, in HLA-A, both the transmembrane and cy-
toplasmic tail residues play a role in surface expression. This
suggests that the cell-surface expression of Patr-AL and HLA-
A*02 is regulated by two different mechanisms and further
establishes how natural substitutions in the transmembrane do-
main and cytoplasmic tail can antagonize or synergize in deter-
mining the level of cell-surface expression of MHC class I
molecules (Fig. 9).
Discussion
To study the expression of Patr-AL, we made a specific mAb that
binds to Patr-AL with high specificity but does not react with other
human or chimpanzee MHC class I molecules. This Ab binds at
a low level to small numbers of PBMCs. Greater surface expression
of Patr-AL occurs when human class I–deficient 221 cells are
transfected with Patr-AL expressed under control of the CMV
promoter. For this reason, we used 221 transfectants to examine
the cell-surface expression and intracellular distribution of Patr-
AL. A minority of Patr-AL molecules are detected at the cell
FIGURE 7. The four residues that
distinguish the cytoplasmic tail of
Patr-AL all contribute to the intra-
cellular retention of Patr-AL. Patr-
AL, HLA-A*02:07, and mutants of
them that represent all 16 combina-
tions of the natural polymorphisms at
positions 321, 326, 329, and 333 were
transiently transfected into HeLa cells.
Each wild-type and mutant contained
3xFLAG epitopes at the N terminus
that enabled their surface expression to
be compared using the anti-3xFLAG
Ab and flow-cytometric analysis. Within
each panel, a subgroup of the mutants
are compared with the Patr-AL full tail
mutant (middle panels) and wild-type
HLA-A*02 (right panels). Shown in
the left panels are the sequence motifs
at positions 321, 326, 329, and 333
shared by the Patr-AL and HLA-A*02
paired in each row. Orange boxes de-
note residues naturally occurring in
Patr-AL; blue boxes denote residues
naturally occurring in HLA-A*02.
(A) Mutants have one residue shared
with Patr-AL and three with HLA-
A*02. (B) Mutants have two residues
shared with Patr-AL and two with
HLA-A*02. (C) Mutants have three
residues shared with Patr-AL and one
with HLA-A*02. In each panel, the
horizontal bars give the levels of cell-
surface expression as mfi. At least
three replicates were analyzed for
each mutant. Values that are statisti-
cally different from the HLA-A*02
cytoplasmic tail are: ***p , 0.0001,
**p , 0.0005, *p , 0.005. These
values were calculated by one-way
ANOVA for each pairwise comparison.
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surface (∼10%), the majority being retained inside the cell
within the ER and the cis-Golgi. This behavior contrasts with
HLA-A*02, which is predominantly expressed at the cell sur-
face. That a substantial majority of Patr-AL molecules are lo-
cated within cells could explain, at least in part, the small
amounts of Patr-AL detected on the surface of PBMCs. In ad-
dition, the Patr-AL promoter could limit the extent of tran-
scription in the cells in which Patr-AL is transcribed, but this has
yet to be investigated.
The retention of Patr-AL in early compartments of the secretory
pathway is likely to be an active process and one that could be
critical to its immunological function. Precedents for the intra-
cellular retention of MHC class I molecules are provided by human
MR1 and mouse Qa-1 (21–23). MR1 binds to the vitamin B
metabolites released by bacteria and yeast-infecting mucosal tis-
sue (24). On binding such Ags, MR1 moves to the cell surface
where it is recognized by mucosal-associated T cells. Qa-1 moni-
tors Ag processing in the ER by being sensitive to a self-peptide
FIGURE 8. Natural variation at position 295 of the transmembrane region affects expression of HLA-A*02, but not Patr-AL. Patr-AL and HLA-A*02:07
differ at position 295 in the transmembrane region, as well as at four positions in the cytoplasmic domain. For both Patr-AL and HLA-A*02, mutants were
made to give all combinations of the transmembrane region and cytoplasmic domain. Mutant construction, analysis of cell-surface expression, and calculation
of significance values were as described in the legend for Fig. 7. At least three replicates were analyzed for each mutant. ***p , 0.0001, **p , 0.0005.
FIGURE 9. The cytoplasmic tails of MHC class I molecules contain sorting motifs that contribute to their patterns of intracellular trafficking. The
cytoplasmic tail sequence and motif contents are compared among Patr-AL and human MHC class I molecules. Cytoplasmic tails of MHC class I molecules
differ in length and in their contents of intracellular sorting motifs. All sorting motifs are shaded gray, with the exception of the Patr-AL–specific motif,
which is shaded light orange. Functionally important residues within each motif are colored red. One motif is highlighted per tail sequence. Numbers on the
scale represent the position within the cytoplasmic tail of Patr-AL. References for each motif described are also noted (27, 28, 38–42).
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called FL9 that accumulates only when the ER-resident amino-
peptidase malfunctions (23). On binding to FL9, Qa-1 is released
from the ER and translocates to the cell surface where it is rec-
ognized by cytotoxic T cells that kill the defective cell (23). Both
the examples of MR1 and Qa-1 retention rely on the unavailability
of their ligands. Although peptides that can be presented by Patr-
AL are similar to those presented by HLA-A*02 (7), and are
therefore readily available, it is still possible that Patr-AL may
preferentially bind some type of modified peptide. To this end, the
unusually electropositive patch on the a2 domain of Patr-AL is
notable (7). We speculate that Patr-AL binds an electronegative
macromolecule that is normally not available in the ER.
Underlying the intracellular retention of Patr-AL are four amino
acid substitutions that distinguish the cytoplasmic tails of Patr-AL
and HLA-A*02. This was first appreciated by swapping the cy-
toplasmic tails of Patr-AL and HLA-A*02, and further dissected
by mutagenesis at the four positions (321, 326, 329, and 333) that
distinguish the two tails. In Patr-AL, each of the four residues acts
to decrease cell-surface expression, suggesting a stepwise evolu-
tion that was driven by a continued process of selection for in-
tracellular retention. The FNSE motif of Patr-AL is not shared
with any other known MHC class I molecule. In hominoid MHC
class I, N326 and E333 both occur, but not together. In Old World
Monkey MHC class I molecules (Supplemental Fig. 4), all four
residues occur, but no more than two in any particular MHC class
I variant. Residues F321, N326, and E333 occur in Old World
Monkey MHC-B, and S329 is present in MHC-E (Supplemental
Fig. 4). In fact, all four residues of the Patr-AL motif are dis-
tributed among the MHC-E molecules of the simian primates (Sup-
plemental Fig. 4). This observation and knowledge that HLA-E
is probably the oldest of the expressed MHC class I genes in
simian primates (25, 26) raise the possibility that the FNSE motif
first evolved at the MHC-E locus and was subsequently introduced
into Patr-AL by recombination or gene conversion.
A variety of motifs that determine the intracellular movements
and localization of MHC class I molecules have been identified
(18) (Fig. 9). For example, the cytoplasmic tail sequence of the
classical MHC class I HLA-C contains a dihydrophobic inter-
nalization and lysosomal targeting signal (27) that contributes to
its low cell-surface expression, when compared with HLA-A and
HLA-B. Cytoplasmic tails can also contain motifs essential for the
protein’s function and localization, such as the dihydrophobic
motif in the cytoplasmic tail of MIC-A that determines its baso-
lateral sorting (19, 28). The FNSE motif of Patr-AL involves
different residues and is nonoverlapping with other motifs (Fig. 9).
Thus, the cytoplasmic tail of Patr-AL is seen to contain a unique
sequence motif that is implicated in limiting cell-surface expres-
sion. It is also notable that a single amino acid difference in the
transmembrane domain has some contribution to the limitation of
Patr-AL expression, and that lowering the temperature of cells can
partially induce Patr-AL expression. Thus, in addition to the
strong retention motif defined, other features, such as interaction
with accessory molecules and/or peptide binding, could contribute
to Patr-AL expression.
The cytoplasmic tails of HLA class I molecules are targets for
viral proteins that subvert HLA class I function, and thus prevent
elimination of virus-infected cells by cytotoxic CD8 T cells (29).
For example, the BILF1 protein of EBV prevents Ag-presenting
HLA class I molecules from reaching the cell surface by direct-
ing them to lysosomes for degradation (30). Resistance to BILF1-
mediated downregulation is conferred by defined residues, C320,
N327, and/or E334, in the cytoplasmic tail of HLA class I (31).
N326 and E333 in the FNSE motif of Patr-AL are predicted to
prevent recognition by BILF1. Furthermore, F321 and N326 in
Patr-AL’s FNSE motif are predicted to prevent recognition by the
Nef proteins of human HIV and chimpanzee SIVcpz (32–35).
These Nef proteins bind to the cytoplasmic tail of MHC-A allo-
types, including HLA-A*02, and deliver them to lysosomes for
degradation (36). Being resistant to the subversive actions of viral
proteins would allow Patr-AL to potentially function as an Ag-
presenting molecule from where it localizes in the early secretory
pathway. For example, there are intracellular pathogens that ex-
ploit this part of the secretory pathway for replication, such as
Legionella pneumophila and related species (37), which infect
a wide variety of hosts, suggesting that Patr-AL may be well
placed to stimulate a cytotoxic T cell response against such
organisms.
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